<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6240620</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.02478</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dadar</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/399645/overview"/></contrib><contrib contrib-type="author"><name><surname>Chakraborty</surname><given-names>Sandip</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/462062/overview"/></contrib><contrib contrib-type="author"><name><surname>Dhama</surname><given-names>Kuldeep</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/369244/overview"/></contrib><contrib contrib-type="author"><name><surname>Prasad</surname><given-names>Minakshi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/399071/overview"/></contrib><contrib contrib-type="author"><name><surname>Khandia</surname><given-names>Rekha</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/403489/overview"/></contrib><contrib contrib-type="author"><name><surname>Hassan</surname><given-names>Sameer</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/614256/overview"/></contrib><contrib contrib-type="author"><name><surname>Munjal</surname><given-names>Ashok</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/399656/overview"/></contrib><contrib contrib-type="author"><name><surname>Tiwari</surname><given-names>Ruchi</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karthik</surname><given-names>Kumaragurubaran</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/403500/overview"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Deepak</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/403863/overview"/></contrib><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Hafiz M. N.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/550477/overview"/></contrib><contrib contrib-type="author"><name><surname>Chaicumpa</surname><given-names>Wanpen</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/329475/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization</institution>, <addr-line>Karaj</addr-line>, <country>Iran</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry</institution>, <addr-line>West Tripura</addr-line>, <country>India</country></aff><aff id="aff3"><sup>3</sup><institution>Division of Pathology, ICAR-Indian Veterinary Research Institute</institution>, <addr-line>Bareilly</addr-line>, <country>India</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Animal Biotechnology, LLR University of Veterinary and Animal Sciences</institution>, <addr-line>Hisar</addr-line>, <country>India</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Genetics, Barkatullah University</institution>, <addr-line>Bhopal</addr-line>, <country>India</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Biomedical Informatics, National Institute for Research in Tuberculosis, Indian Council of Medical Research</institution>, <addr-line>Chennai</addr-line>, <country>India</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, U P Pt. Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan</institution>, <addr-line>Mathura</addr-line>, <country>India</country></aff><aff id="aff8"><sup>8</sup><institution>Central University Laboratory, Tamil Nadu Veterinary and Animal Sciences University</institution>, <addr-line>Chennai</addr-line>, <country>India</country></aff><aff id="aff9"><sup>9</sup><institution>Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute</institution>, <addr-line>Bareilly</addr-line>, <country>India</country></aff><aff id="aff10"><sup>10</sup><institution>Tecnologico de Monterrey, School of Engineering and Sciences</institution>, <addr-line>Monterrey</addr-line>, <country>Mexico</country></aff><aff id="aff11"><sup>11</sup><institution>Department of Parasitology, Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Faculty of Medicine SIriraj Hospital, Mahidol University</institution>, <addr-line>Bangkok</addr-line>, <country>Thailand</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Rashika El Ridi, Cairo University, Egypt</p></fn><fn fn-type="edited-by"><p>Reviewed by: Nicola Luigi Bragazzi, Universit&#x000e0; di Genova, Italy; Ibrahim Rabia Bauiomy Aly, Theodor Bilharz Research Institute, Egypt</p></fn><corresp id="c001">*Correspondence: Maryam Dadar <email>dadar.m77@gmail.com</email></corresp><corresp id="c002">Kuldeep Dhama <email>kdhama@rediffmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2478</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>08</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Dadar, Chakraborty, Dhama, Prasad, Khandia, Hassan, Munjal, Tiwari, Karthik, Kumar, Iqbal and Chaicumpa.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Dadar, Chakraborty, Dhama, Prasad, Khandia, Hassan, Munjal, Tiwari, Karthik, Kumar, Iqbal and Chaicumpa</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Human papillomavirus (HPV) is a viral infection with skin-to-skin based transmission mode. HPV annually caused over 500,000 cancer cases including cervical, anogenital and oropharyngeal cancer among others. HPV vaccination has become a public-health concern, worldwide, to prevent the cases of HPV infections including precancerous lesions, cervical cancers, and genital warts especially in adolescent female and male population by launching national programs with international alliances. Currently, available prophylactic and therapeutic vaccines are expensive to be used in developing countries for vaccination programs. The recent progress in immunotherapy, biotechnology, recombinant DNA technology and molecular biology along with alternative and complementary medicinal systems have paved novel ways and valuable opportunities to design and develop effective prophylactic and therapeutic vaccines, drugs and treatment approach to counter HPV effectively. Exploration and more researches on such advances could result in the gradual reduction in the incidences of HPV cases across the world. The present review presents a current global scenario and futuristic prospects of the advanced prophylactic and therapeutic approaches against HPV along with recent patents coverage of the progress and advances in drugs, vaccines and therapeutic regimens to effectively combat HPV infections and its cancerous conditions.</p></abstract><kwd-group><kwd>human papilloma virus (HPV)</kwd><kwd>prophylaxis</kwd><kwd>vaccines</kwd><kwd>drugs</kwd><kwd>therapy</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><equation-count count="0"/><ref-count count="389"/><page-count count="32"/><word-count count="27758"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Human papilloma virus (HPV) infection is usually a commonly encountered infection (transient) which has attracted the attention of media in recent years due to the advancement in the field of vaccine development and changes in recommendations for screening of cancer (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). HPV is found to be the causative agent for dermatologic diseases and sexually transmitted diseases (<xref rid="B3" ref-type="bibr">3</xref>). Across the globe, HPV vaccination has become a public health priority, with many national programs with international alliances launched in several countries of the world. This vaccine can help prevent cases of HPV infection that may result in precancerous lesions, cervical cancers, and genital warts, especially in adolescent females and males. Universal HPV vaccination worldwide will result in a gradual reduction in the incidence of HPV cases (<xref rid="B4" ref-type="bibr">4</xref>). The <italic>Papillomaviridae</italic> family comprises more than 130 HPV genotypes that have been isolated from various human neoplasias such as warts, cancers, and cases of recurrent respiratory papillomatosis (RRP) (<xref rid="B5" ref-type="bibr">5</xref>). The prevalence and distribution of HPV types differ by geographic region. Moreover, HPV types in 30,848 invasive cervical cancers worldwide revealed differences by geographical region and histological type (<xref rid="B6" ref-type="bibr">6</xref>). This virus is a significant cause of mortality and morbidity in the developing countries (<xref rid="B7" ref-type="bibr">7</xref>). Globally, cervical cancer ranks as the second most common cancer in women and is responsible for a significant number of deaths (453 million). High-risk HPV, consisting of more than 100 types of HPV, is an important cause of cervical cancer (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Through the process of immunization along with other therapies, it is possible to control the HPV-associated cancers and such opportunity is created through the process of identifying HPV as a causative agent for malignancies. Against infectious diseases as a tradition use of vaccines have been done as a preventive measure. Success has been achieved in developing prophylactic vaccines against HPV types that cause disease by making the viral L1 (major capsid protein) as target (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). It is, however, to be kept in mind that there is not enough evidence for demonstrating the efficacy of the prophylactic vaccines for treatment of HPV infections and lesions associated with HPV (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>).</p><p>To control HPV infection, HPV vaccines have been introduced into national immunization programs (<xref rid="B14" ref-type="bibr">14</xref>). Since 2013, HPV vaccines (bivalent and quadrivalent) have been included in the national immunization programs of at least 66 nations, including NorthAmerica and Western Europe, primarily (<xref rid="B15" ref-type="bibr">15</xref>). Recombinant HPV virus-like particles (VLPs) are being produced at commercial level via heterologous expression of the major capsid protein L1 in yeast or insect cells (<xref rid="B16" ref-type="bibr">16</xref>). From the morphology viewpoint, VLPs are similar to natural HPV virions with considerable potentialities to induce animal and human type-specific antibody responses (<xref rid="B17" ref-type="bibr">17</xref>). A patent has been granted to (<xref rid="B18" ref-type="bibr">18</xref>) for developing a technique of disassembly and reassembly of VLPs to enhance the stability of VLPs. The present HPV vaccines are capable of preventing persistent HPV infections, as well as protecting against premalignant cervical lesions (<xref rid="B19" ref-type="bibr">19</xref>). Once HPV infection was established as the main cause of cervical and other types of cancer, our focus turned to typing of HPV by field testing with new diagnostics and applying effective HPV immunization strategies for cancer control (<xref rid="B20" ref-type="bibr">20</xref>). Licensed VLP-HPV vaccines should provide long-term safety and effective protection against targeted HPV types. Also, to determine the optimal ages for effective vaccination, their design should address the effects of vaccine modulators, mode of delivery, expandable coverage of HPV types, and effects on males and targeted pre-adolescents or adults (<xref rid="B21" ref-type="bibr">21</xref>). HPV vaccines are recommended for both adolescent males and females, and after these vaccines were introduced, a marked reduction in the prevalence of HPV-associated cancers has been observed (<xref rid="B22" ref-type="bibr">22</xref>). It is to be noted that no serious adverse events in relation to vaccine has been reported (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>).</p><p>Among effective prophylactic HPV vaccines, Cervarix (a bivalent vaccine) is protective against adenocarcinoma-causing types including HPV-16, 18, 31, 33 and 45 for a documented period of 6.4 years. Whereas, Gardasil (a quadrivalent vaccine) has been confirmed to protect against genital warts, respiratory papillomatosis, and certain types that cause squamous cell cancer, including HPV-6, 11, 16, 18, and 31, for 5 years (<xref rid="B10" ref-type="bibr">10</xref>). Despite these successes, vaccination against HPV has triggered much debate. Also, use of these vaccines in developing countries is essentially non-existent, mainly because of its high cost and the difficulty of introducing them into vaccination programs, as they both require three injections over a 6-month period for girls (<xref rid="B25" ref-type="bibr">25</xref>). Gardasil and Cervarix are effective vaccines against HPV, generally, but their coverage of HPV types is limited, and their use in pregnant women is not advised; hence, vaccines with a broader preventative and therapeutic spectrum and better safety profile are desired.</p><p>Chimeric vaccines, multivalent vaccines to address HPV types (broader spectrum) or to combine HPV with other pathogens, edible vaccines, biodegradable and mucoadhesive polymer-based vaccines, and various viral vectors harboring recombinant HPV DNA vaccines are being developed for greater immunogenicity than that of current vaccines. Similarly, for a more recipient-friendly vaccine, needleless immunization technologies, including the use of a jet gun, gene gun, and microneedles are being evaluated for HPV cancer prevention (<xref rid="B26" ref-type="bibr">26</xref>). Lyophilized HPV pseudovirions have been delivered to murine models using microneedles (<xref rid="B27" ref-type="bibr">27</xref>). Studies exploring PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov databases for published reports on immunogenicity and safety of bivalent and quadrivalent vaccines, specifically in Asian populations, have suggested strategies for developing vaccines that elicit enhanced HPV-16- and HPV-18- specific antibody levels (<xref rid="B28" ref-type="bibr">28</xref>). In light of the serious consequences of HPV-associated cancers and warts, HPV vaccination should be included in the standard childhood vaccination regimen (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>The present review presents a current global scenario and futuristic prospects of the advanced prophylactic and therapeutic approaches against HPV along with recent patents coverage of the progress and advances in drugs, vaccines and therapeutic regimens to effectively combat HPV infections and its induced- pathological sequels.</p></sec><sec id="s2"><title>HPV disease</title><p>HPVs belong to a large family of non-enveloped, small, approximately 7.9&#x02013;8 kbp circular dsDNA viruses that are surrounded by an icosahedral protein capsid composed primarily of a highly immunogenic L1 protein, with a minor contribution from the L2 protein (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). The virus is the cause of squamous epithelial cell proliferation, or common warts, on areas of the body such as the hands, feet, anus, cervix, scrotum, groin, thigh, or penis (<xref rid="B32" ref-type="bibr">32</xref>). The life cycle of the virus is divided into five phases. Infection and subsequent uncoating is the first phase wherein there is an affection of the basal cells. Genomic maintenance is the second phase during which there is an expression of the early proteins of the virus, viz., E1 and E2. This is followed by the proliferative phase wherein there is an expression of some other early proteins like E6 and E7. The cell cycle progresses after being stimulated by such proteins. Subsequently, there is a synthesis of the virus which is the fourth phase during which there is an expression of the late viral proteins, viz., L1 and L2. The virus is packaged in the epithelial layer under the influence of these late/structural proteins. During shedding of the dead cells at the stratified epithelial layer, there is the release of the virus (fifth phase) which can then cause infection of other cells (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>).</p><p>HPVs with different oncogenic potential have been assigned to three main groups: high-risk types, intermediate-risk types, and low-risk types. High-risk types include HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82; intermediate-risk types include HPV-26, 53, and 66; and low risk-types include HPV-6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 81. Among these types, 70% of cervical cancers result from type 16 and 18 infections, and if multiple HPV types infect women, persistent HPV infections can be established, and cervical cancer exacerbated (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B35" ref-type="bibr">35</xref>). There is also the involvement of HPV- 33 and 45 in causing squamous cell carcinoma and adenocarcinoma, respectively (<xref rid="B36" ref-type="bibr">36</xref>). It is to be mentioned in this regard that the low-risk HPV viruses and the oncogenic types are responsible for causing warts (anogenital) and cervical dysplasia, respectively (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>HPV is held responsible for the trends in the increase in the rate of oropharyngeal carcinoma as is revealed by molecular detection methods. The viral nucleic acid is detectable in a clinical specimen by polymerase chain reaction at a much greater frequency after the year 2000 as compared to before 1990 in the United States alone. The involvement of HPV in oropharyngeal carcinoma has greatly increased during a span of 20 years in the Netherlands from 1990 to 2010. Similar is the situation in another European country like Spain (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>).</p><p>Despite this, most HPV infections induce no or only mild cytological abnormalities; and few HPV infections lead to cervical cancer. HPV can also cause cervical and other cancers such as cancer of the vulva, vagina, penis, or anus. It can also cause cancer in the back of the throat, including the base of the tongue and tonsils (<xref rid="B39" ref-type="bibr">39</xref>). Usually HPV infections clear within 1&#x02013;2 years' time, but if multiple HPV types infect a person, the viruses may persist, leading to lethal cancers in various parts of the body. In one study by the U.S. Centers for Disease Control (CDC) conducted from 2004 to 2008, an average of 33,369 HPV-associated cancers was diagnosed annually. Therefore, CDC projected that every year roughly 26,000 new cancer cases occurred as a result of HPV infection, including 18,000 cases in females and 8,000 in males. In the U.S., cervical cancer prevention is based on two approaches: one primary and one secondary. The primary strategy is regular HPV immunizations, and the second strategy is screening of populations at risk or immunized to reduce HPV-related cancers (<xref rid="B40" ref-type="bibr">40</xref>).</p><p>Among oncogenic HPVs, genotypes 6 and 11 cause laryngeal papillomas and most of the genital warts, whereas types 16 and 18 are responsible for 70% of cervical cancers. To prevent infection with highly transmissible HPV, a quadrivalent (types 6, 11, 16, and 18) HPV vaccine has been evaluated and shown good results in clinical trials. Similarly, a bivalent vaccine (types 16 and 18) has shown greater than 90% protection against persistent HPV infections, even 5 years post-vaccination. In both, the vaccines were non-infectious, DNA-free VLPs, developed using recombinant technology, administered in conjunction with appropriate adjuvants, and three doses at 6-month intervals have been shown to elicit high-titer serum antibodies (<xref rid="B41" ref-type="bibr">41</xref>).</p><p>A study performed in young women 15&#x02013;25 years of age to assess the immunogenicity and efficacy of a human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical intraepithelial neoplasia (CIN) grade 1 or greater (CIN1+, CIN2+, or CIN3+) showed that vaccination of adolescent girls before their first sexual encounter resulted in better protection and prevention of HPV-associated cervical cancers and persistent infections (<xref rid="B42" ref-type="bibr">42</xref>). The HPV-16/18AS04-adjuvanted vaccine reduced the incidence of high-risk human papilloma viruses in a randomized cluster trial in adolescent girls and boys, irrespective of their lifestyles and sexual behavioral patterns (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>The clinical efficacy of bivalent (HPV-16 and 18), quadrivalent (HPV- 6, 11, 16, and 18), and nonavalent (9vHPV; HPV- 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccines against cervical cancer was tested. The bivalent and quadrivalent vaccines reduction in the rate of HPV-16 and 18 prevalences significantly compared to that of the 9vHPV vaccine and all three vaccines decreased the morbidity and mortality from cervical cancers resulting from oncogenic HPVs (<xref rid="B44" ref-type="bibr">44</xref>). The HPV-16/18-AS04-adjuvanted vaccine, when administered in a one-dose schedule to adolescent girls 9&#x02013;14 years of age and evaluated for immunogenicity and safety, showed clinically acceptable results compared to a three-dose vaccine schedule for women aged 15&#x02013;25 years (<xref rid="B45" ref-type="bibr">45</xref>). Another clinical trial (controlled phase II/III) that evaluated an HPV-16/18-AS04-adjuvanted vaccine in women showed that the vaccine efficiently reduced HPV-16/18 infection, provided cross-protection against some non-vaccine-type oncogenic HPVs that cause genital warts, and protected against oral, vulvar, and anal HPV infection regardless of the age, geographical location, or sexual practice of study participants (<xref rid="B46" ref-type="bibr">46</xref>). One 7-year follow-up study on phase III, double-blind, randomized controlled trial from 2006 to 2014 evaluated the efficacy, safety, and immunogenicity of the HPV-16/18-AS04-adjuvanted vaccine in women older than 25 years (in groups ranging 26&#x02013;35 years, 36&#x02013;45 years, and &#x02265;46 years). Control women received aluminum hydroxide, whereas vaccinated women were immunized with the HPV-16/18 vaccine. Results showed that the HPV-16/18 vaccine was effective in all age groups and protected against HPV-associated lesions (CIN1+), and corresponding cytological abnormalities, irrespective of the infecting HPV type. Hence, this vaccine was shown to be reliably effective against HPV infections (<xref rid="B47" ref-type="bibr">47</xref>). Studies have shown that immunizations with the HPV-16/18-AS04-adjuvanted vaccine do not promote autoimmune disease (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>Chronic local inflammation, alone or as a result of oral HPV infection, may play an important role in the etiology of head and neck squamous cell carcinomas (<xref rid="B49" ref-type="bibr">49</xref>). A study conducted in over 624 nursing students in Izmir, Turkey, revealed that the students had a very high level of knowledge as far as the risk factors and the transmission modes of the disease are concerned but such knowledge has not been used practically to make the vaccination against HPV successful (<xref rid="B50" ref-type="bibr">50</xref>). A mathematical model-based analysis has been utilized for systematic screening in women in the U.S. to protect the health benefits and harms; costs involved in vaccination with the bivalent, quadrivalent or nonavalent vaccine (<xref rid="B51" ref-type="bibr">51</xref>). Increased awareness of the health risks of HPV infection, such as cervical cancer and warts that results from education and self-testing is an important component in screening and diagnosing initial infections and advanced cases of HPV-associated cancers (<xref rid="B52" ref-type="bibr">52</xref>).</p><sec><title>Advances in developing prophylactic and therapeutic vaccines against HPV</title><p>Because the cultivation and propagation of HPV in cell/tissue culture are difficult, developing inactivated or live attenuated HPV vaccines is not a common practice. Therapeutic vaccines against HPV can be categorized into nanoparticle-, bacterial-, live vector- (bacterial and viral), nucleic acid- (DNA and RNA), protein-, peptide-, cell- (cytokine-transduced autologous tumor cells and dendritic cells [DCs]) based vaccines [reviewed in (<xref rid="B53" ref-type="bibr">53</xref>) and (<xref rid="B54" ref-type="bibr">54</xref>)]. Cytotoxic T lymphocyte (CTL) responses elicited by therapeutic vaccines against HPV early viral gene products E1, E2, E5, E6, and E7 (<xref rid="B53" ref-type="bibr">53</xref>). Therapeutic vaccines targeting E6 and E7 (early proteins encoded by HPV) are most common because these proteins are produced in all HPV-infected cells and are vital for cancer cells (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Therefore, researchers have focused on developing unconventional new-generation prophylactic and therapeutic HPV vaccines targeting capsid proteins or the genome by genetic engineering and recombinant DNA technology. The prophylactic vaccines are relatively safer (<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>). It is interesting to note that there is enhancement of cell mediated immunity by T cell based vaccines in contrast to prophylactic vaccines (that help in generating neutralizing antibodies) (<xref rid="B59" ref-type="bibr">59</xref>). At present, the questions that arise regarding vaccination against HPV is the protection period (specially, in relation to cross protection). Moreover the shortcomings of the VLP vaccines, viz., less thermal stability, lack of efficacy therapeutically, cost, etc., are also required to be overcome (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>Various new approaches are presented as below:</p><sec><title>Protein-based subunit vaccines</title><p>These include subunit or subvirion products that induce protective immunity. Fusion protein PD-E7 vaccines comprise a mutated HPV-16 E7 protein linked to the first 108 amino acids of <italic>Haemophilus influenzae</italic> protein D (PD), adjuvanted with AS02B. Vaccinated patients with oncogenic HPV-positive CINs mount significant E7- and PD-specific IgG responses (<xref rid="B61" ref-type="bibr">61</xref>). The therapeutic SGN-00101 vaccine (also known as HspE7, developed by StressGen), based on the fusion of the E7 protein of HPV16 and recombinant heat shock protein 65 (Hsp65) of <italic>Mycobacterium bovis</italic>, was evaluated for protection against anal neoplasia (<xref rid="B62" ref-type="bibr">62</xref>). Vaccination with SGN-00101 at a dose of 500 &#x003bc;g administered at 3-week intervals induced immune responses and lesion regression in women with high-grade CINs (<xref rid="B63" ref-type="bibr">63</xref>).</p><sec><title>SGN-00101</title><p>as a potential treatment for cervical tumors (<xref rid="B64" ref-type="bibr">64</xref>) and RRP (<xref rid="B65" ref-type="bibr">65</xref>) was evaluated. SGN-00101 induces the activity of CTLs in women having cervical intraepithelial lesions (CIN) (<xref rid="B66" ref-type="bibr">66</xref>). An HPV-6 L2/E7 fusion protein is another protein-based vaccine that induces antibodies against HPV-16 oncoproteins. ProCervix (GTL001) is adjuvanted with Aldara developed by Genticel; it consists of HPV-16 E7/HPV-18 E7 bivalent adenylate cyclase (CyaA)-based vaccine that targets HPV-16 and 18 infections (<xref rid="B67" ref-type="bibr">67</xref>). ProCervix has been proposed to clear HPV-16 infection while protecting against later infection with HPV-18. A phase 1 clinical trial for safety and immunogenicity of the ProCervix vaccine revealed that HPV clearance was several-fold higher in the group treated with ProCervix than in the placebo group (<xref rid="B68" ref-type="bibr">68</xref>).</p></sec></sec><sec><title>Peptide-based vaccines</title><p>As far as such type of vaccine is concerned, characterization of various specific epitopes has been done for the human MHC class I (HLA-A2) peptides. In mammalian models, the cell-mediated immune response is generated by immunizing with a peptide that carries E6 or E7 origin epitopes (<xref rid="B69" ref-type="bibr">69</xref>). Various peptide-based vaccines include extended epitope-specific peptides, synthetic long peptides (SLPs), or lipopeptides. SLPs consisting of peptides from HPV-16 (nine E6 and four E7) (HPV-16-SLP adjuvanted with Montanide ISA-51) were tested in phase II clinical trial (<xref rid="B70" ref-type="bibr">70</xref>) and interestingly in case of humans multiple clinical trials have been conducted for studying the HPV-16-SLP (long peptide vaccine) (<xref rid="B70" ref-type="bibr">70</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>). Examples of this kind of vaccine include those constructed with HPV-16 E7 12&#x02013;20, E7 86&#x02013;93, E7 86&#x02013;93, E7 11&#x02013;20, and E7 86&#x02013;93 lipopeptides (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>), HPV-16 E7 86&#x02013;93 (CIGB-228 vaccine) adjuvanted with very small-sized proteoliposomes (VSSPs) (<xref rid="B73" ref-type="bibr">73</xref>), as well as HPV-16 E7 49&#x02013;57 with a poly-IC (a Toll-like receptor [TLR]3 agonist) and anti-CD40 monoclonal antibody as the TriVax vaccine (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec><sec><title>Epitope-based vaccines</title><p>Vaccines designed using a traditional approach involve attenuation of a pathogen by sub-culturing, which is a long and tedious process that can take up to 15 years, and the safety of these vaccines is a matter of concern (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Bioinformatics is an important multidisciplinary tool that may allow optimization of the health benefits of vaccines.</p><p><italic>In silico</italic> tools, paired with improvements in recombinant DNA (rDNA) technology and knowledge of the host immune response and genetic background of the pathogen, will contribute to the future development of new vaccines (<xref rid="B78" ref-type="bibr">78</xref>). The first step toward applying bioinformatics to vaccine development consists of identifying epitopes that are potentially immunoprotective from those that are not (<xref rid="B76" ref-type="bibr">76</xref>). Prediction of T and B cell epitopes has been the main focus of immunoinformatics, and over the years many different tools have been developed (<xref rid="B79" ref-type="bibr">79</xref>). With the advent of bioinformatics and high-throughput technologies, vaccine research has entered a new era, and vaccine design has benefitted from the development of vaccine databases and <italic>in silico</italic> vaccine design tools (<xref rid="B80" ref-type="bibr">80</xref>).</p><p>A prediction for the 16 major epitope variants (V1&#x02013;V16) in the full-length L1 protein of HPV-16 and evaluation of the immunogenicity of these variants and reference DNA vaccine constructs was recently reported by Kumar et al. (<xref rid="B81" ref-type="bibr">81</xref>). The results of this study showed that the L500F (V16) and T379P (V8) variants induced a ~2.7-fold (<italic>p</italic> &#x0003c; 0.002) increase and ~0.4-fold (<italic>p</italic> &#x0003c; 0.328) decrease in antibody titer, respectively, after the final injection. This study offered a roadmap for the use of both <italic>in silico</italic> tools and experimental methods to develop DNA-based vaccines. The authors also suggested that multi-epitope DNA vaccines might induce more effective immune response against HPVs with different epitope variants than those constructed without a consideration of this variation (<xref rid="B81" ref-type="bibr">81</xref>).</p><p>In another study, <italic>in silico</italic> tools (B-cell and T-cell epitope prediction methods) were used to design a subunit vaccine against HPV (<xref rid="B82" ref-type="bibr">82</xref>). Using a conserved sequence in the L1 binding protein gene from 20 different sequences, the authors proposed a possible HPV vaccine target. Based on their analysis, the authors reported that the L1<sub>41</sub> protein of HPV was a promising candidate for vaccine design.</p><p>Yao et al. (<xref rid="B83" ref-type="bibr">83</xref>) identified E6 and E7 proteins as ideal candidates for therapeutic vaccines against HPV-16 infection. A total of 81 CTL epitopes in HPV-16 E6 (<italic>n</italic> = 59) and E7 (<italic>n</italic> = 22) were predicted using Immune Epitope Database Analysis Resource. Among the 20 clusters of epitopes in HPV-16 E6 generated, cluster 3 contained the most epitopes (10 epitopes), representing HLA-A<sup>*</sup>31:01 and -A<sup>*</sup>33:03. Of the 10 clusters of HPV-16 E7, cluster 3 contained the most epitopes (5 epitopes), representing HLA-A<sup>*</sup>01:01 and -A<sup>*</sup>26:01. Based on their observations, the authors suggested that a cocktail of E6 and E7 epitopes such as 52FAFRDLCIVYR62 of E6 (HLA-A<sup>*</sup>02:06, HLA-A<sup>*</sup>31:01, and HLA-A<sup>*</sup>33:03), 66PYAVCDKCLKF76 of E6 (HLA-A<sup>*</sup>11:01 and HLA-A<sup>*</sup>24:02), 2HGDTPTLHEY11 of E7 (HLA-A<sup>*</sup>01:01 and HLA-A<sup>*</sup>26:01), and 11YMLDLQPETT20 of E7 (HLA-A<sup>*</sup>02:01) could be used to vaccinate more than 50% of all individuals worldwide (<xref rid="B83" ref-type="bibr">83</xref>).</p><p>de Oliveira et al. (<xref rid="B84" ref-type="bibr">84</xref>) reported the designing of a multi-epitope recombinant protein. It contains the immunogenic epitopes of E6 and E7 proteins. This particular recombinant protein can protect against HPV-induced tumors in CD4<sup>+</sup> T cell-deficient mice but not in mice deficient in CD8<sup>+</sup> T cells. Moreover, the activities of the T cells that are E6/E7 specific are also enhanced. So the use of this multi-epitope protein is assumed to be a promising approach to design a potent vaccine therapeutically against HPV-induced tumors.</p><p>In another study, biopsies of nine cervical cancers (HPV-16-infected) in patients with HLA-A<sup>*</sup>02 were obtained. The E7 oncogene-coding region was reported to be conserved in all tumors. Of the nine samples, the E7<sub>11&#x02212;19</sub> peptide (11YMLDLQPET19) was detected by MS3 analysis of the HLA-A<sup>*</sup>02 immunoprecipitate from seven of them. However, of the 13 epitopes predicted using the <italic>in silico</italic> approach, only one was observed through an exquisitely sensitive physical detection method, suggesting that bioinformatic prediction should be used to identify probable epitopes for confirmation by physical detection. Because the conserved E7<sub>11&#x02212;19</sub> peptide is the dominant HLA-A<sup>*</sup>02 binding tumor antigen in HPV-16 transformed cervical squamous cells cancers and adenocarcinomas, it has the potential to be used for the development of therapeutic cancer vaccines (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>Sequence alignment studies have detected that the L2 proteins of HPV are having greater intertype variability than L1 which is responsible for the lower consistency of L2 protein as far as positioning in the variable region is concerned. There is the presence of greater number of epitopes in the region of L1 that is conserved and such regions are the prime targets for antibodies (neutralizing types). It can, therefore, be mentioned without a doubt that as far as designing vaccine is concerned a better target is L1 protein compared to L2 (<xref rid="B86" ref-type="bibr">86</xref>). <italic>In silico</italic> approaches to predict the epitopes are highly valuable compared to conventional procedures that are costly and time-consuming. The predicted peptides can then be tested both <italic>in vitro</italic> and <italic>in vivo</italic> to verify their effectiveness in triggering an immune response. Assays with short peptides (overlapping) covering the entire sequence of the targeted protein/antigen are used to define CTL epitopes (MHC Class I restricted). Determination of the epitopes of HPV-16 is also done in the same way (<xref rid="B53" ref-type="bibr">53</xref>).</p></sec><sec><title>Recombinant vaccines</title><sec><title>Recombinant adeno-associated virus (rAAV)</title><p>Intranasal immunization against HPV-16 with recombinant adeno-associated virus (rAAV) type 5 encoding the major capsid protein L1 of HPV-16 showed that a single-dose of this vaccine without an adjuvant was sufficient to elicit high titers of mucosal antibodies in vaginal washes and L1-specific serum antibodies (<xref rid="B87" ref-type="bibr">87</xref>). Immunization of mice with a single dose of AAV5-HPV-16 L1 intranasally results in the development of both cell-mediated as well as humoral immunity for a prolonged period (<xref rid="B88" ref-type="bibr">88</xref>). Another study showed that rAAV-type 9 administered intranasally to mice induced high-titer and long-lasting neutralizing antibodies against HPV-16 (<xref rid="B89" ref-type="bibr">89</xref>). A mutated HPV-16 E6/E7 gene, whose product is not oncogenic, was cloned into an adenoviral vector, and the vector elicited an immune response that increased the clearance of established HPV&#x02013;positive-cancer <italic>in vivo</italic> (<xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec><title>Recombinant measles virus (MV) vaccine</title><p>A vaccine expressing the L1 capsid protein of HPV-16 that was designed to protect against HPV-16 infection revealed measles virus for to be a valuable vehicle for the development of inexpensive and effective vaccines (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>). In another study, Gupta et al. (<xref rid="B93" ref-type="bibr">93</xref>) administered a recombinant live-attenuated MV Edmonston-Zagreb (rMVEZ) strain as a viral vector carrying heterologous genes that encoded the L1 major capsid proteins of HPV-16 and HPV-18 to rhesus monkeys (<xref rid="B93" ref-type="bibr">93</xref>). HPV-16L1/18L1-specific total IgG antibodies, neutralizing antibodies, and related cellular immune responses in non-human primates were comparable to those in response to the classical recombinant <italic>Pichia pastoris</italic> expressing HPV protein. A patent has been granted to Mendiretta et al. (<xref rid="B94" ref-type="bibr">94</xref>) for developing a dual vaccine applicable for treating measles and HPV by using measles vector and inserted genes coding for HPV antigens.</p></sec><sec><title>Vaccinia virus Ankara (MVA)-based vaccines</title><p>The growth of human tumors was effectively controlled by immunization with the recombinant vaccinia virus Ankara (MVA) expressing HPV E2 (MVA-E2). This vaccine showed potential to be used as a therapeutic vaccine (<xref rid="B95" ref-type="bibr">95</xref>). The viral vector-based MVA-E2 therapeutic vaccine inhibited HPV growth in high-grade lesions (CIN2 and CIN3) (<xref rid="B96" ref-type="bibr">96</xref>). Direct injection of the vaccine has been done in the uterine cervix (<xref rid="B97" ref-type="bibr">97</xref>). Immunization with this vaccine can eliminate precancerous lesions (CIN1, CIN2, and CIN3) associated with infection by oncogenic HPV types (<xref rid="B98" ref-type="bibr">98</xref>). A phase I/II study of the therapeutic MVA-E2 vaccine indicated that this vaccine is highly effective in inducing immune responses against human papilloma viruses and regression of flat condyloma lesions in men (<xref rid="B99" ref-type="bibr">99</xref>). The therapeutic antigen (TA)-HPV vaccine (improved by Celtic Pharmaca, previously Xenova or Cantab) is based on a live recombinant vaccinia virus strain (Wyeth) expressing a modified E6/E7 fusion protein of HPV-16 and HPV-18 (<xref rid="B100" ref-type="bibr">100</xref>). Safety and immunogenicity of the vaccine were confirmed in a proportion of those patients vaccinated (<xref rid="B101" ref-type="bibr">101</xref>). Injection of TA-HPV vaccine into the deltoid muscle has been done in a clinical study to patients having grade III vulvar intraepithelial neoplasia (VIN) and grade II vaginal intraepithelial neoplasia. After vaccination, identification of the enhancement of T-cell-based immunity (HPV E6 as well as E7 specific) has been done by employing interferon-gamma (IFN&#x003b3;) ELISPOT assay (<xref rid="B102" ref-type="bibr">102</xref>). A booster vaccine TA-CIN (HPV-16 L2/E6/E7) in combination with TA-HPV resulted in shrinkage of vulval intraepithelial neoplasias and symptom relief in some patients, with some showing an immune response (<xref rid="B103" ref-type="bibr">103</xref>). Multiple clinical trials have been conducted for evaluation of the efficacy as well as safety of MVA-based vaccine targeting the protein E2 (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B104" ref-type="bibr">104</xref>). For treating ano-genital lesions (intra-epithelial, including urethral condyloma or anal lesions) induced by HPV, phase III clinical study has been carried out (<xref rid="B105" ref-type="bibr">105</xref>). The sequences of attenuated MVA (recombinant) that encodes E6/E7 of HPV-16 (modified) are included in TG4001 vaccine. Further it is to be mentioned that this vaccine is nothing but MVATG8042 suspension (<xref rid="B106" ref-type="bibr">106</xref>).</p></sec></sec><sec><title>Bacteria-based vaccines</title><p>The reporting of Listeria-based vaccine for therapeutic purpose against HPV was done for the first time in the year 2009 (<xref rid="B107" ref-type="bibr">107</xref>). Two different vectors of a live-attenuated <italic>Listeria monocytogenes</italic> (Lm) were engineered by Gunn et al. (<xref rid="B108" ref-type="bibr">108</xref>). In one, the Lm vector was secreted with E7 as Lm-E7, and, in the other, E7 was fused to non-hemolytic listeriolysin O (LLO) protein of the bacteria (Lm-LLO-E7) (Figure <xref ref-type="fig" rid="F1">1</xref>). The most important vaccine with anti-cancer activities is ADXS 11-001 (or ADXS-HPV, formerly known as Lovaxin-C), a therapeutic <italic>Listeria</italic>-based vaccine targeting an HPV E7 antigen (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>) and resulting a TNF-alpha (TNF-&#x003b1;) response and IL-2 production by DCs (<xref rid="B110" ref-type="bibr">110</xref>). The phase II FAWCETT trial (NCT02399813) is assessing the safety of ADXS11-001 in patients with metastatic squamous cell carcinomas of the anal canal (SCCA) and will be testing for protection against cervical, oropharyngeal, and anal cancers (<xref rid="B111" ref-type="bibr">111</xref>). Another bacteria-based vaccine expressing the viral E7 protein has been designed utilizing <italic>Lactobacillus casei</italic> as a vector. The safety of the <italic>L. casei</italic>-based vaccine is relatively high and oral administration is found to be fruitful. For evaluation of the cellular immunity, this particular vaccine has been administered in patients having CIN3. Majority of the patients that have received the vaccine responded well with regression of the disease which is associated with E7 specific cellular immunity. Enzyme-linked immunospot (ELISPOT) assay has been employed for evaluation of the E7 specific-cellular immunity. When treatment with four-six capsules/day is done, there is exhibition of HPV E7 specific-cellular immunity in lymphocytes of the cervix (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Bacteria-based vaccines. <italic>Listeria monocytogenes</italic> can be used to secrete HPV E7 which activates CD4 helper T cells through MHC II antigen presentation mechanism. Another method of E7 delivery is to fuse E7 to non-hemolytic listeriolysin O (LLO) protein of the bacteria (Lm-LLO-E7) and thereby on delivery causes perforation of phagolysosome due to LLO and E7 protein made available to MHC I which activates cytotoxic T cells.</p></caption><graphic xlink:href="fimmu-09-02478-g0001"/></fig></sec><sec><title>Yeast-based vaccine</title><p>A recombinant HPV-16 L1-expressing <italic>Schizosaccharomyces pombe</italic> yeast strain (HPV-16L1 yeast) produced edible HPV vaccines that were administered to female BALB/c mice (<xref rid="B114" ref-type="bibr">114</xref>). A codon-optimized HPV-16 L1 gene cloned into a non-integrative expression vector was transformed in <italic>Pichia pastoris</italic> yeast cells. Heparin-Sepharose chromatography was employed to purify L1 protein from the yeast extract. The resulting protein contained native conformational epitopes, as evidenced by immuno-electron microscopy, and showed great potential for use as a low-cost vaccine (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>).</p></sec><sec><title>VLP-based vaccines</title><p>There has been the adoption of VLPs as platforms for developing various candidates of HPV second-generation vaccine. VLPs have close resemblance with HPV particles (native) and include conformational epitopes which help in induction of neutralizing antibodies (<xref rid="B26" ref-type="bibr">26</xref>). Vaccines based on VLPs are safer to use while offering a display of B-cell epitope at greater density and presentation of T-cell epitopes intracellularly (<xref rid="B117" ref-type="bibr">117</xref>). So VLPs are known to be highly immunogenic. Due to the lack of viral gene, the VLPs are fully non-infectious as well as non-oncogenic in nature forming structure resembling the HPV virus outer shell. They induce production of antibodies that react with the virus (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). Moreover, one interesting feature of VLP vaccine is that each of the vaccine has its adjuvant promoting durable immunity (<xref rid="B120" ref-type="bibr">120</xref>). But producing them on a large scale is expensive and difficult (<xref rid="B54" ref-type="bibr">54</xref>). Zhou et al. (<xref rid="B121" ref-type="bibr">121</xref>) explored VLP technology for the development of an HPV vaccine, which led to the most significant development in HPV vaccines and cervical cancer control (<xref rid="B121" ref-type="bibr">121</xref>). They expressed recombinant open reading frame (ORF) proteins L1 and L2 of HPV-16 in cells infected with a recombinant form of Vaccinia virus and explored the production of HPV-like particles, which is useful for biochemical studies and can provide a safe source of material for the development of vaccines. One promising alternative approach to producing recombinant VLP antigens is adding subdominant neutralizing epitope in the L2 protein of the HPV (<xref rid="B122" ref-type="bibr">122</xref>). In a 5-year study to assess the prophylactic efficacy of a quadrivalent HPV 6/11/16/18 L1 VLP vaccine in 552 adolescent and young adult females of 16&#x02013;23 years of age, vaccination reduced the incidence of cervical and genital cancers, precancerous dysplasias, and genital warts, and prevented infections with HPV-6, 11, 16, and 18 (<xref rid="B123" ref-type="bibr">123</xref>). When immunologic responses in 1106 young females against HPV types 6, 11, 16, and 18 L1 VLP vaccine were measured, 12- to 26-times higher levels of anti-HPV vaccine-type antibodies and an anamnestic protective immune response was observed, with no adverse side effects (<xref rid="B124" ref-type="bibr">124</xref>).</p><p>Mutant of <italic>Salmonella enterica</italic> serovar Typhi, i.e., Ty21a engineered to produce VLPs with HPV-16 L1 was administered as a potent live HPV vaccine to simultaneously induce protective immunity against cervical cancer and typhoid fever (<xref rid="B125" ref-type="bibr">125</xref>). Live bacteria-based HPV vaccines such as attenuated <italic>Shigella</italic> can be used to produce VLP (<xref rid="B126" ref-type="bibr">126</xref>) and to promote potent local and systemic immune responses (<xref rid="B127" ref-type="bibr">127</xref>). This is a prophylactic, efficient, and low-cost mucosal vaccine. Heterologous production of HPV-16 L1 protein in <italic>Lactococcus lactis</italic> was demonstrated using two vectors, pCYT, and pSEC, designed for intra- or extracellular expression, respectively (<xref rid="B128" ref-type="bibr">128</xref>). The results of a study by Cortes-Perez et al. (<xref rid="B128" ref-type="bibr">128</xref>) revealed that the use of recombinant food-grade lactic acid bacteria such as the <italic>L. lactis</italic> for the production of L1-based VLPs in a safe mucosal vector is a promising approach to creating HPV-16 prophylactic vaccines.</p><p>Abdoli et al. (<xref rid="B129" ref-type="bibr">129</xref>) designed HPV-16 VLPs with L1 protein in <italic>Spodoptera frugiperda</italic> 9 (Sf9) insect cells and suggested administration of recombinant baculovirus containing the HPV-16 L1 gene as a prophylactic vaccine and for diagnostic tests (<xref rid="B129" ref-type="bibr">129</xref>). Also, a modified baculovirus-based (MultiBac) approach to producing VLPs for heterologous expression of the HPV L1 protein in insect cells was used by Senger et al. (<xref rid="B130" ref-type="bibr">130</xref>). Self-assembly of the L1 protein of HPV-6a into VLPs was demonstrated in both L1- and L1+ L2- coexpressing <italic>Saccharomyces cerevisiae</italic> (<xref rid="B131" ref-type="bibr">131</xref>). An alternative HPV antigen to elicit an immune response against HPV is the L1 pentameric subunit or capsomere with conserved neutralizing epitopes (<xref rid="B132" ref-type="bibr">132</xref>). Expression of recombinant HPV capsomeres in <italic>Escherichia coli</italic> may substantially reduce manufacturing costs. Studies in animal models have shown that HPV capsomeres alone induce lower antibody titers than those in VLPs (<xref rid="B132" ref-type="bibr">132</xref>). Expression of the L1 gene of HPV types 6 and 11; 16 and 18 have been reported in <italic>S. cerevisiae</italic> for producing the HPV4 vaccine that is used for protection against persistent infection caused by HPV (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>). Another vaccine similar to HPV4 is HPV2, which is used for prevention of oncogenic HPV (<xref rid="B23" ref-type="bibr">23</xref>). In another study, a recombinant major capsid L1 protein of HPV-11 was produced intracellularly at high levels in an expression system based on galactose-inducible <italic>S. cerevisiae</italic> with an HPV-6/11 hybrid gene (<xref rid="B135" ref-type="bibr">135</xref>).</p><p>Moreover, VLPs of HPV-58 with the L1 protein produced in <italic>S. cerevisiae</italic> elicited antibodies and antigen-specific CD4+ and CD8+ T cell responses without the need for an adjuvant (<xref rid="B136" ref-type="bibr">136</xref>). Also, HPV-16 and -18 L1 protein expressed in <italic>E. coli</italic> to produce bivalent VLPs has been demonstrated safe and highly immunogenic as a vaccine candidate in preclinical studies (<xref rid="B137" ref-type="bibr">137</xref>). Fusion of HPV L1 to the surface of <italic>Shigella sonnei</italic> autotransporter, i.e., IcsA, introduced a new VLP strategy to improve live attenuated <italic>Shigella-</italic>HPV vaccines for better stability and more effective expression (<xref rid="B138" ref-type="bibr">138</xref>). Multivalent VLP vaccines for HPV were introduced by Xu et al. (<xref rid="B139" ref-type="bibr">139</xref>) and revealed that HPV-31 L1/L2 VLP-based vaccines induced strong type-specific and cross-reactive antibodies. Moreover, tobacco plant-based L1/L2 chimeras containing hybrid epitope sequences of HPV-16 L1/L2 induced anti-L1 and anti-L2 responses, and the antisera neutralized homologous HPV-16 and heterologous HPV-52 pseudovirions in mice (<xref rid="B140" ref-type="bibr">140</xref>). Vaccines targeting the L2 minor capsid antigen revealed particularly strong and long-lasting antibody responses in mice, with a Th2 to Th1 shift in response (<xref rid="B141" ref-type="bibr">141</xref>). VLPs displaying HPV L2 peptides for capsid display, adjuvant ability, and fusion with early HPV antigens or TLR agonists are in development to improve upon licensed HPV vaccines (<xref rid="B142" ref-type="bibr">142</xref>). These vaccines elicit neutralizing antibodies and can block infection with a wide range of HPV types (<xref rid="B143" ref-type="bibr">143</xref>).</p><p>Recently, the capacity of AS04-adjuvanted vaccines based on VLP chimeras of L1 and two L2 epitopes to protect against HPV was evaluated, and these chimeric vaccines induced immunity and protected against various types of HPV (HPV-6, 11, 16, 31, 35, 39, 45, 58, and 59 as pseudovirions or quasivirions) in both mouse and rabbit challenge models (<xref rid="B144" ref-type="bibr">144</xref>). Also, the use of different antigens such as oncogenic peptides, synthetic peptides, DNA, and bacterial antigens may allow the development of effective prophylactic and therapeutic vaccines that can address all of the issues associated with current vaccines.</p><p>Purified L1 capsomeres expressed in <italic>E. coli</italic> represent an economical alternative to (VLP)-based prophylactic vaccines against HPV-16 and 18 (<xref rid="B145" ref-type="bibr">145</xref>). Sch&#x000e4;dlich and colleagues reported that the L1&#x00394;N10 protein was particularly immunologic and that L1 constructs could be administered to produce potent immunogenic responses to capsomeres in bacteria as a potentially inexpensive alternative to VLP-based formulations. Furthermore, in another study, tobacco plants were used to express pentameric capsomeres of a modified HPV-16 L1 (L1-2xCysM) protein to induce immunity against HPV (<xref rid="B146" ref-type="bibr">146</xref>). Licensing of subunit vaccine (VLP-based) from the L1 protein (plus adjuvant) has been done already (<xref rid="B147" ref-type="bibr">147</xref>). A novel VLP with HPV-16 E5 based on a whole gene as well as long multi-epitope gene version of E5 was designed by Cordeiro and collaborators (<xref rid="B148" ref-type="bibr">148</xref>). It is interesting to note that for judgment of subunit vaccines in future, the benchmark should be the HPV VLP vaccines (<xref rid="B149" ref-type="bibr">149</xref>).</p></sec><sec><title>DNA vaccines</title><p>The safety of DNA (naked) is relatively higher. They are stable and lucrative due to ease of production and they have got application in sustaining expression of antigen in the cells at greater level (<xref rid="B150" ref-type="bibr">150</xref>&#x02013;<xref rid="B152" ref-type="bibr">152</xref>). Additionally the DNA vaccines do not evoke anti-DNA antibodies for which their repeated administration can be done (<xref rid="B153" ref-type="bibr">153</xref>). Moreover, DNA vaccines offer several other benefits such as having inherent adjuvant properties that are lacking in a traditional peptide or attenuated-virus vaccines, and they are highly effective in treating HPV infections. In this category, ZYC-101 (developed at Eisai, formerly MGI Pharma and previously known as Zycos Inc.), the precursor of amolimogene bepiplasmid, which was evaluated in phase I clinical trial, is based on a bacterial plasmid (BIOTOPE). It encodes 25-residues of a human MHC class I antigen (HLA-DR&#x003b1;) trafficking peptide (MAISGVPVLGFFIIAVLMSAQESWA) fused to an immunogenic peptide derived from the E7 protein of HPV-16 (82LLMGTLGIVCPIC94) (<xref rid="B154" ref-type="bibr">154</xref>). This vaccine is effective against anal and cervical dysplasias, with clinical outcomes consisting of regression of AINs (3/12 PRs), as well as regression of CINs (5/15 CRs) (<xref rid="B155" ref-type="bibr">155</xref>). Also, lesions showed the greatest regression in patients &#x0003c;25 years of age. In another study, DNA vaccine candidates with HPV-16 E6, E7, and L1 genes from an Iranian isolate inserted into the mammalian expression vector, pcDNA3 elicited therapeutic CTL responses to HPV-16 E6 and E7 proteins (<xref rid="B156" ref-type="bibr">156</xref>). In another study, a DNA vaccine expressing the E7 protein of HPV-16 with a mutation in the L-Y-C-Y-E pRb-binding motif at amino acids 23&#x02013;25 induced a potent CD8+ T cell immune response, as well as promoted significant anti-tumor effects in mice (<xref rid="B157" ref-type="bibr">157</xref>).</p><p>Moreover, the E7 oncoprotein of HPV linked to an interferon-inducing 17-kDa protein (ISG15) as an adjuvant elicited IFN-&#x003b3; responses and cytolytic effector CD8 T-cell responses (<xref rid="B158" ref-type="bibr">158</xref>). Recently, women with HPV-16 or 18 infections and normal cervical cytology showed potent immune responses to a GTL001 DNA vaccine with acceptable safety (<xref rid="B159" ref-type="bibr">159</xref>). Furthermore, Hsp70 can play a significant role in modified HPV-16 E7 and <italic>Mycobacterium tuberculosis</italic> Hsp70 fusion DNA vaccine and introduce as candidate therapeutic tumor vaccine (<xref rid="B160" ref-type="bibr">160</xref>). Another vectored DNA-based vaccine is VGX-3100 (IgE leader-E6/E7 DNA) developed by Inovio Pharmaceuticals, which is administered intramuscularly by electroporation and targets the E6 and E7 proteins of HPV-16 and 18 in CINs 2/3 (<xref rid="B161" ref-type="bibr">161</xref>). VGX-3100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and 18. Safety, immunogenicity, and efficacy of this vaccine were evaluated in phase I clinical trial that recruited 18 women who were previously treated for cervical lesions. The intramuscular route (into the deltoid muscle) was adopted for administration of the vaccine. This was followed by electroporation (<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Finally, these genotype-specific vaccines are in phase I clinical trials and in demand to resolve HPV infections and neoplasias (<xref rid="B54" ref-type="bibr">54</xref>).</p><p>However, it must be kept in mind that due to shortage of specificity (cell type) DNA vaccines show low immunogenicity. The DNA further lacks the capability (intrinsic) of amplification or nature of spreading to the cells (<italic>in vivo</italic>) in the surrounding. Nevertheless, there may be enhancement of potency of DNA vaccines (used against cervical cancer induced by HPV) by making DNA or the encoded antigen as the target to antigen presenting cells (APCs) and along with this, modification of the feature of APCs (antigen expressing) can boost immune response induced by the vaccine (<xref rid="B153" ref-type="bibr">153</xref>). Furthermore, it is also interesting to note that on employing as immunotherapeutic interventions (stand alone), the DNA-based anticancer vaccines are ineffective which can be explained by the establishment of immunosuppression (either systemic or local) (<xref rid="B161" ref-type="bibr">161</xref>, <xref rid="B164" ref-type="bibr">164</xref>&#x02013;<xref rid="B167" ref-type="bibr">167</xref>).</p></sec><sec><title>Plant-based vaccines</title><p>Production of candidate HPV vaccines in plant systems is a promising approach. These vaccines have been shown to be efficient and immunogenic, even though they are in the early stages of development (<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>). One such vaccine is produced in microalgae that have immunomodulatory properties (<xref rid="B170" ref-type="bibr">170</xref>, <xref rid="B171" ref-type="bibr">171</xref>). In one study, a plant codon-optimized version of the HPV-11 L1 major capsid protein coding sequence was synthesized and transformed into tobacco and potato plants, resulting in immunologically functional VLPs. The ingestion of this material activated anti-VLP immune responses in mice (<xref rid="B172" ref-type="bibr">172</xref>). Moreover, the L1 major capsid protein gene of HPV-16, with or without nuclear localization signals, was integrated into the <italic>Nicotiana tabacum</italic> cv. Xanthi genome and the proteins were assembled into capsomeres to produce VLPs. Rabbits immunized with small doses of the transgenic plants showed weak anti-HPV-16 L1 immune responses (<xref rid="B173" ref-type="bibr">173</xref>). Also, HPV-11 L1 major capsid protein in transgenic <italic>Arabidopsis thaliana</italic> ecotype Columbia and <italic>N. tabacum</italic> cv. Xanthi was evaluated as candidates for a low-cost subunit vaccine. Results indicated that immunization of New Zealand white rabbits with ~50 &#x003bc;g of plant-derived HPV-11 L1 induced a weak immune response to native HPV-11 L1 VLPs, as well as to HPV-11 pseudovirions (<xref rid="B174" ref-type="bibr">174</xref>).</p><p>Expression of an HPV-16 L2 epitope fused to the N- and C-terminus of the coat protein of potato virus X (PVX CP) in transgenic <italic>N. benthamiana</italic> plants was evaluated by Cerovska et al. (<xref rid="B175" ref-type="bibr">175</xref>) and reported immunogenic in mice. In mouse sera, antibodies titers against PVX CP and the L2 epitope (108&#x02013;120) were measured after vaccine delivery (<xref rid="B175" ref-type="bibr">175</xref>). Another study revealed that the HPV-16 L1 protein expressed in tobacco chloroplasts induced the self-assembly of VLPs that were highly immunogenic in mice after intraperitoneal injection (<xref rid="B176" ref-type="bibr">176</xref>). A circular dsDNA replicon was constructed by cloning a secreted embryonic alkaline phosphatase (SEAP) reporter gene and promoter into a geminivirus-derived plant expression vector that was co-transfected with vectors expressing L1 and L2 proteins into <italic>N. benthamiana</italic> plants, and an HPV-16 pseudovirus was purified. This pseudovirus was neutralized by antisera against current and candidate HPV vaccines and represents a potential plant-derived vaccine (<xref rid="B177" ref-type="bibr">177</xref>). A <italic>N. benthamiana</italic>-derived fusion protein with beta-1,3-1,4-glucanase (LicKM) of <italic>Clostridium thermocellum</italic> elicited a protective response with a yield of 100 mg/kg biomass with 99% purity after metal ion chelation and gel filtration purification (<xref rid="B178" ref-type="bibr">178</xref>). Transplastomic plants have been used for expression of mutated L1 gene of HPV. This results in the sole production of capsomeres that are pentameric in nature (<xref rid="B179" ref-type="bibr">179</xref>, <xref rid="B180" ref-type="bibr">180</xref>).</p></sec><sec><title>DC-based vaccines</title><p>This promising approach has been used to produce HPV therapeutic vaccines. For example, HPV-16 E6 18&#x02013;26 or HPV-16 E7 12&#x02013;20 peptides pulsed on immature DCs showed specific immune effects in women that were protective against advanced cervical cancer (<xref rid="B181" ref-type="bibr">181</xref>). In another study, a recombinant adenovirus encoding codon-optimized HPV-16 E6 and E7 proteins linked to DCs induced protective immunity against challenge by TC-1 cancer cells <italic>in vivo</italic> (<xref rid="B182" ref-type="bibr">182</xref>). For increasing the efficacy of DC-based vaccines not only antigens, but also novel strategies can also be incorporated into DCs. One classical example is the introduction of the small hairpin (sh) RNA-suppressor of cytokine signaling (SOCS1) into HPV-specific DC vaccine (E7 pulsed) (<xref rid="B183" ref-type="bibr">183</xref>). For evaluation of the immunogenicity as well as safety of such vaccines (DC-based), conduction of a dose escalation trial (phase I) has been done in cervical cancer (stage IIa or Ib) patients (<xref rid="B184" ref-type="bibr">184</xref>) In case of recurrency of cervical cancer also, phase I clinical trial has been conducted (<xref rid="B185" ref-type="bibr">185</xref>).</p><p>An overview of advanced vaccine technologies available for prevention and control of HPV is depicted in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Advanced vaccine technologies available for prevention and control of HPV.</p></caption><graphic xlink:href="fimmu-09-02478-g0002"/></fig></sec></sec><sec><title>Currently available prophylactic vaccines</title><p>Currently, there are several licensed prophylactic HPV vaccines, including Cervarix, Gardasil, and Gardasil 9. These vaccines are all based on L1 structural proteins and are designed to inhibit HPV infections on first exposure. Gardasil and Cervarix both contain aluminum-based adjuvants and trigger strong protective immune responses. These two vaccines are beneficial in case of recurrent cervical cancer. Both Gardasil and Cervarix have a similar efficiency against HPV-16 as well as HPV-18 (<xref rid="B186" ref-type="bibr">186</xref>&#x02013;<xref rid="B188" ref-type="bibr">188</xref>). They are also safe to used (<xref rid="B189" ref-type="bibr">189</xref>). However, case reports from the U.S. Vaccine Adverse Event Reporting System (VAERS) have shown that in spite of their efficacy and safety, a few autoimmune side effects have occurred. These vaccines do not induce sufficient cross-protection against non-vaccine types of HPV, as cross-protective immunity was shown to decline with the time (<xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B191" ref-type="bibr">191</xref>). To date, only bivalent and quadrivalent vaccines have shown efficacy; but a newer nonavalent vaccine is also under trial to evaluate its anti-HPV potential (<xref rid="B192" ref-type="bibr">192</xref>).</p><sec><title>Gardasil</title><p>A tetravalent vaccine targeting HPV known as Gardasil or Silgard (qHPV-6/11/16/18 vaccine; Kenilworth, NJ, USA) was licensed in 2006 and is composed of 120 &#x003bc;g of antigen per dose (VLP of recombinant L1 HPV-6 [20 &#x003bc;g], VLP of recombinant L1 HPV-11 [40 &#x003bc;g], VLP of recombinant L1 HPV-16 [40 &#x003bc;g], and VLP of recombinant L1 HPV-18 [20 &#x003bc;g]), adjuvanted with 225 &#x003bc;g of aluminum hydroxyphosphate sulfate (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B193" ref-type="bibr">193</xref>). This vaccine is licensed in many countries and has been shown to be immunogenic and safe and to inhibit infections with other HPV serotypes. Elevated HPV antibodies have been found in all vaccinated persons, ranging from 9 to 45 years of age. Gardasil is administered in 0.5 mL per dose to girls and women ages 9 to 26 years for the control of cervical, vulvar, vaginal, and anal cancers induced by HPV-16 and 18, genital warts (condyloma acuminata) induced by HPV-6 and 11, and dysplastic lesions induced by HPV-6, 11, 16, and 18, as well as grades 1, 2 and 3 CINs, cervical adenocarcinomas <italic>in situ</italic> (AISs), grades 2 and 3 vulvar intraepithelial neoplasias (VINs), grades 2 and 3 vaginal intraepithelial neoplasia (VaINs), and grades 1, 2, and 3 anal intraepithelial neoplasia (AINs). Gardasil is also administered to boys and men 9 to 26 years of age for the control of anal cancers induced by HPV-16 and 18, genital warts (condyloma acuminata) induced by HPV-6 and 11, dysplastic lesions induced by HPV-6, 11, 16, and 18, and grades 1, 2, and 3 AINs.</p><p>According to a FUTURE I and FUTURE II analysis, the efficacy of cervical and vulvar neoplasias and grade I VINs are 30, 75, and 48% respectively, and 83% for condyloma acuminate (<xref rid="B194" ref-type="bibr">194</xref>). Currently, the duration of protection by Gardasil is considered 9 years (<xref rid="B195" ref-type="bibr">195</xref>).</p></sec><sec><title>Cervarix</title><p>A bivalent HPV vaccine (HPV-2; Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) was licensed by the U.S. Food and Drug Administration (FDA) for administration to females 10&#x02013;25 years of age (<xref rid="B196" ref-type="bibr">196</xref>) and has been approved in Europe and Australia (<xref rid="B197" ref-type="bibr">197</xref>). This is an L1 VLP vaccine that is produced in a cabbage looper moth cell line (<italic>Trichoplusia ni</italic> [Hi 5]) infected with recombinant baculovirus HPV-16 and 18 L1 and adjuvanted with 500 &#x003bc;g of AS04, which consists of 50 &#x003bc;g of 3-O-deacetylated-4-monophosphoryl lipid A adsorbed into 500 &#x003bc;g of aluminum hydroxide (<xref rid="B198" ref-type="bibr">198</xref>). It consists of VLPs of HPV-16 and 18, which induce 70% of cervical cancers worldwide and play important roles in HPV-related vulvar, vaginal, penile, anal, and oropharyngeal cancers (<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B200" ref-type="bibr">200</xref>). The vaccine is composed of 20 &#x003bc;g of recombinant L1 from HPV-16 and 20 &#x003bc;g of recombinant L1 from HPV-18 and is administered intramuscularly in three doses (the second dose given at least 1 month after the initial dose and the third dose given at least 6 months after the initial dose). The AS04 adjuvant in the vaccine induced increased expression of phenotypic maturation markers along with production of pro-inflammatory cytokines as well as cytotoxicity against tumor cells that are positive for HPV when interleukin (IL)-15 dendritic cell (DC) are exposed to the vaccine (<xref rid="B201" ref-type="bibr">201</xref>). The vaccine exerted immunity againsy HPV via a novel mode, i.e., boosted innate immunity, including killing of HPV-infected cells by DC and NK cells. The PATRICIA clinical study revealed the efficacy of the vaccine against HPV-16 and 18-associated precancerous cervical lesions to be 92.9&#x02013;98.1 and 30.4%, respectively, and suggested cross-protection of other oncogenic HPV types such as HPV-31 and 45 (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B197" ref-type="bibr">197</xref>). The effectiveness of this vaccine against CIN2+ lesions with HPV-16 and 18 has also been reported. The vaccine is well tolerated, highly immunogenic, and capable of generating high titers of neutralizing antibody to HPV-16 and 18 (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B203" ref-type="bibr">203</xref>). A phase III double-blind, randomized controlled trial of the Cervarix vaccine showed an efficacy of 90.4% against CIN2+ lesions with HPV-16 and 18 (<xref rid="B203" ref-type="bibr">203</xref>). Cervarix induces high antibody titers in comparison to natural infection. In women, there has been demonstration of an enhanced humoral immune response (<xref rid="B204" ref-type="bibr">204</xref>). Currently, the duration of protection generated by Cervarix is estimated to be 9.4 years (<xref rid="B205" ref-type="bibr">205</xref>, <xref rid="B206" ref-type="bibr">206</xref>). One study showed that HPV universal mass vaccination of people in the UK with Cervarix prevented females from developing cervical cancer and protected males from HPV-16 and 18 infections (<xref rid="B207" ref-type="bibr">207</xref>).</p></sec><sec><title>Gardasil 9</title><p>Gardasil 9 (Merck and Co., Inc.), a 9vHPV (6/11/16/18/31/33/45/52/58) VLP-based vaccine provides protection against five additional oncogenic types (HPV-31, 33, 45, 52, and 58) and was approved by the FDA on December 10, 2014, for administration to females aged 9&#x02013;26 years and males aged 9&#x02013;15 years (<xref rid="B208" ref-type="bibr">208</xref>). Gardasil 9 targets up to 90% of genital warts (both Gardasil vaccines also target two HPV types responsible for ~90% of genital warts) (<xref rid="B209" ref-type="bibr">209</xref>). A phase III clinical trial in women aged 16&#x02013;26 years demonstrated the efficacy of the vaccine in inhibiting HPV infection (<xref rid="B210" ref-type="bibr">210</xref>). In another study, the safety and efficacy of the 9vHPV vaccine in males and females of 9&#x02013;26 years were assessed across seven phase III clinical trials. The results showed that this vaccine was well tolerated in subjects with a serious and non-serious adverse event profile similar to that of the Gardasil qHPV vaccine, although injection-site adverse events including pain, swelling, and erythema in both males and females and headache in felames were more common (&#x02265;10%) with the 9vHPV vaccine (<xref rid="B211" ref-type="bibr">211</xref>). Increased use of the Gardasil 9 vaccine offers the hope of reducing neonatal transmission of HPV and decreasing the incidence and morbidity of recurrent respiratory (laryngeal) pappillomatosis (RRP) (<xref rid="B212" ref-type="bibr">212</xref>). A study to estimate the public health effects and cost-effectiveness of vaccination with Gardasil 9 in Germany indicated that immunization of boys with the 9-valent vaccine reduced the incidence of cervical cancer by 24% and anal cancers in males and females of 30, and 14%, respectively, while over a million cases of genital warts would be prevented in 100 years (<xref rid="B213" ref-type="bibr">213</xref>). It is important to note that Gardasil-9 has not yet been approved for use in subjects who have received three doses of Gardasil or Cervarix (<xref rid="B214" ref-type="bibr">214</xref>). Moreover, Gardasil-9 is expected to be more cost-effective than HPV vaccines currently in use (<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B216" ref-type="bibr">216</xref>).</p></sec><sec><title>GTL001</title><p>For eradication of cells infected with HPV, a therapeutic vaccine (bivalent) known as GTL001 is available. It is a fusion of HPV-16 E7 as well as HPV-18 E7 and detoxified adenylate cyclase (CyaA) of <italic>Bordetella pertussis</italic> binding to specific CD11b+ antigen presenting cells (APC) (<xref rid="B217" ref-type="bibr">217</xref>). The interesting feature is there is induction of T cell responses (CD4+ and CD8+) in an antigen specific manner against the viral/tumor antigens. A recombinant CyaA that bears the HPV-16 E7 (antigen) when used for vaccination intradermally causes induction of a T cell response. This requires adjuvantation with a Toll-like receptor 9 agonist, i.e., CpG oligodeoxynucleotide (ODN1826). This ultimately results in elimination of tumors that express HPV-16 E7 (<xref rid="B218" ref-type="bibr">218</xref>, <xref rid="B219" ref-type="bibr">219</xref>). There are two GTL001 formulations, viz., a solution form and a powder form (which is more concentrated in nature) adjuvanted with imiquimod cream. The formulations have been tested in a clinical trial (phase I) and both are found to be safe and induced E7-specific CTL responses (<xref rid="B159" ref-type="bibr">159</xref>).</p></sec><sec><title>9-valent HPV vaccine</title><p>The safety as well as efficacy of the 9-valent vaccine providing protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 has been proven recently. This will help further in reducing the incidences of infection due to HPV along with the cancer related to the virus. Moreover, a herd immunity is generated for providing indirect protection to individuals that are unvaccinated (<xref rid="B220" ref-type="bibr">220</xref>). In boys as well as girls in the age group of 9&#x02013;15 years, geometric mean titer (GMT) (non-inferior) is generated by 9-valent vaccine (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B221" ref-type="bibr">221</xref>, <xref rid="B222" ref-type="bibr">222</xref>). The vaccine efficacy is proven also in 16&#x02013;26 years age group of males (<xref rid="B223" ref-type="bibr">223</xref>).</p></sec></sec><sec><title>Safety of the currentluy used HPV vaccines</title><p>Safety of HPV vaccines was studied in both clinical trials before they were licensed and through post-licensure surveillance programmes (<xref rid="B224" ref-type="bibr">224</xref>&#x02013;<xref rid="B233" ref-type="bibr">233</xref>). Like any other vaccines administered by intramuscular route, the HPV vaccinees may get inflammation (pain, erythema, swelling and pruritus) at the injection site. The other side effects include pyrexia, headache, chill, weakness, malaise, myalgia, and joint pain. These HPV vaccine-related adverse effects (AEs) usually occur from day 1 to day 15 after vaccination and mostly are mild; the vaccines are believed to be well tolerated in girls, boys and young women (<xref rid="B234" ref-type="bibr">234</xref>). Nevertheless, serious HPV vaccine related AEs that required hospitalization occurred in vaccinees of 9-valent HPV vaccine including asthmatic attack in a 10-year-old boy who had experienced seasonal allergy and bronchial asthma; high fever (&#x0003e;38&#x000b0;C), body pain, headache, and malaise in a 26-year-old woman; and occipital headache with photophobia, nausia and chill in a 23-year-old woman (<xref rid="B234" ref-type="bibr">234</xref>). In a large cohort study of &#x0003e;2 million young girls (aged 13&#x02013;16 years) between 2008 and 2012 in France of which 37% received HPV vaccine, autoimmune diseases (AID) occurred in 4,096 subjects during the follow-up time (mean of 33 months). The incidence of AID was not increased after HPV vaccination, except Guillain-Barre syndrome (GBS) which was found in 1.4 per 100,000 vaccinees <italic>versus</italic> 0.4 per 100,000 non-vaccinated subjects (<xref rid="B232" ref-type="bibr">232</xref>). No increase risk of GBS was observed following HPV vaccination in England (<xref rid="B235" ref-type="bibr">235</xref>). A systemic review and meta-analysis of 11 studies did not find any evidence of increased demyelinating diseases after HPV vaccination (<xref rid="B233" ref-type="bibr">233</xref>). However, at least 10 cases of neurological events were reported worldwide after HPV vaccination (<xref rid="B236" ref-type="bibr">236</xref>&#x02013;<xref rid="B241" ref-type="bibr">241</xref>). A case-control epidemiological study of the vaccine adverse event reporting system (VAERS) database was undertaken to evaluate the risk for reported autoimmune adverse events following quadrivalent HPV vaccination (<xref rid="B242" ref-type="bibr">242</xref>). Cases with gastroenteritis, rheumatoid artritis, thrombocytopenia, SLE, vasculitis, alopecia, CNS demyelinating conditions, ovarian damage, or irritable bowel syndrome were significantly more likely than control to have received quadrivalent HPV vaccine (<xref rid="B242" ref-type="bibr">242</xref>).</p><p>Safety of HPV vaccines in pregnancy or immediately pre-conceptually has been reviewed (<xref rid="B230" ref-type="bibr">230</xref>). The HPV vaccination concerns were not only the maternal safety, but also (and more) on the teratogenicity and other fetal adverse events (AEs) following HPV vaccination, including spontaneous miscarriage, preterm birth, congenital malformations, and fetal decease. Pooled results from 11 studies which compared 16,142 women who received at least one dose of either bivalent (2vHPV, Cervarix&#x000ae;) or quadrivalent (4vHPV, Gardasil&#x000ae;) vaccine, with 13,811 girls/women who received control vaccine (hepatitis A vaccine) indicated that the AEs in women who received the HPV vaccine were not greater than the controls, among the age groups 10&#x02013;14, 15&#x02013;25, and &#x0003e;25 years and the follow-up periods 0&#x02013;7, 7&#x02013;12, and &#x0003e;12 months. For the fetal safety, none of the studies reported a significant increased rate of spontaneous abortion and other fetal outcomes in overall subgroup analyses (e.g., age, interval of time of conception and nearest vaccination, number of vaccinations) compared with controls. The conclusion was the risk of AEs during pregnancy is unrelated to HPV vaccination before or during pregnancy (<xref rid="B230" ref-type="bibr">230</xref>).</p></sec></sec><sec id="s3"><title>Therapeutic approaches to HPV-induced disease</title><p>Currently, there are no HPV therapies available. Removal of the abnormal tissue by surgical operation is currently the recommended cure for cervical dysplasia. Removal of the affected tissue, e.g., cervical conizations, however, can lead to premature births. Thus, development of non-invasive treatment therapies for HPV-induced cancers is needed, and therapeutic HPV vaccines are a promising strategy (<xref rid="B243" ref-type="bibr">243</xref>, <xref rid="B244" ref-type="bibr">244</xref>).</p><p>One study demonstrated the therapeutic potential of curcumin in high-risk HPV-infected oral cancer cells. Curcumin down-regulated HPV transcription by suppressing the cellular transcription factors AP-1 and NF-&#x003ba;B and selectively inhibited E6 oncogene-mediated p53 degradation during carcinogenesis in HPV-16-positive oral cancer cells (<xref rid="B245" ref-type="bibr">245</xref>&#x02013;<xref rid="B248" ref-type="bibr">248</xref>). Another study showed that certain cervical cancers did not express HPV oncogenes E6 and E7, and these were considered HPV-inactive tumors because they showed increased WNT/&#x003b2;-catenin and sonic hedgehog signaling, decreased DNA methylation, enriched non-synonymous somatic mutations specifically targeting the TP53, ARID, WNT, and PI3K pathways. Hence, these tumors can be treated by therapies targeting WNT, PI3K, and/or TP53 mutations (<xref rid="B249" ref-type="bibr">249</xref>).</p><p>The regulatory activity of the immune system is influenced by either chemotherapy or radiotherapy and in tumor models of mice in combination with vaccination can increase the efficacy of T cell-based immunity against HPV infection (<xref rid="B250" ref-type="bibr">250</xref>). The lesions induced by HPV (that are of lesser risk and shows infestation with regulatory T cells) can be successfully treated by the use of cyclophosphamide at low dose thereby altering the local environment of the immune system. In recent past, properly planned randomized trial has been introduced in patients with cervical cancer that shows metastasis to compare solely chemotherapy versus chemotherapy combined with a long synthetic peptide of HPV-16. Adoptive cell therapy (ACT) or antibody based-therapeutic approaches have been proven to be successful for treatment of patients with melanoma (<xref rid="B251" ref-type="bibr">251</xref>, <xref rid="B252" ref-type="bibr">252</xref>). Earlier, it was evident from various sources that effector T cells that are specific to HPV can be obtained with consistency from cervical cancer patients. By the significance of local microenvironment of HPV-induced lesions, there may be a shift in the local balance of immune effectors through treatment. For example, uses of cyclooxygenase 2 (COX2) inhibitors (through inhibition of prostaglandin E2 production) or inhibitors of transforming growth factor beta (TGF&#x003b2;) receptor kinase (type I), anti-IL-6 or anti-IL-10 antibodies may prove to be efficacious. Ultimately, the main goal is a suppression of regulatory T cells and a generation of an effective effector T cell microenvironment by identifying the combination that is optimum in enhanced trafficking of the immune effector cells and their efficiency at the affected site. This ultimately provides scope to the immunity induced by vaccination for effective eradication of lesions that are persistent. In this regard, a good example is the use of imiquimod for priming the microenvironment to clear successfully HPV induced-vulvar lesions that are immune-mediated (<xref rid="B253" ref-type="bibr">253</xref>, <xref rid="B254" ref-type="bibr">254</xref>).</p><sec><title>Photodynamic therapy</title><p>For eliminating malignancies at an early Stage as well as for palliative treatment of cutaneous Tumors Along With Tumors of lungs and esophagus (at late stage), photodynamic therapy (PDT) is an option already approved by Food and Drug Administration (FDA) (<xref rid="B255" ref-type="bibr">255</xref>&#x02013;<xref rid="B258" ref-type="bibr">258</xref>). PDT is another approach used widely to treat various cancers. Topical administration of PDT is considered to be most appropriate for cervical and vulval intraepithelial lesions (<xref rid="B259" ref-type="bibr">259</xref>). 5-Aminolevulinic acid (ALA)-mediated PDT to treat HPV-associated cervical condyloma has been evaluated for HPV-6, 11, 16, and 18. Complete remission was observed after 1&#x02013;4 treatments in 98.2% of cases, resulting in an HPV clearance rate of 83.9%, with no evidence of cervical structural changes. This indicates the efficacy and safety of the PDT (<xref rid="B260" ref-type="bibr">260</xref>). Topical ALA-PDT has been found efficacious and well tolerated when used to treat high-risk HPV infections (<xref rid="B259" ref-type="bibr">259</xref>). A photosensitizer dye IR700 coupled with HPV VLPs, when exposed to cervical cancer cell lines and 690-nm light causes necrosis-like cell death by inducing the influx of CD8+ and CD4+ T-cells into the treated tumors (<xref rid="B261" ref-type="bibr">261</xref>).</p><p>Hexaminolevulinate-mediated PDT has been found to be safe for treating cervical intraepithelial neoplasia (CIN) (<xref rid="B262" ref-type="bibr">262</xref>, <xref rid="B263" ref-type="bibr">263</xref>). Immune cell infiltration is a striking feature of photodynamic therapy, and it forms the basis for treatment of neoplasms that are HPV-associated; especially in the case of vulvar intraepithelial neoplasia (VIN). In chronic VIN, there is an alteration of the immunological balance if photodynamic therapy is employed. This leads to clearance of virus as well as lesions (<xref rid="B258" ref-type="bibr">258</xref>). Nevertheless for treating HPV infection the effectiveness of antimicrobial photodynamic therapy (APDT) cannot be denied (<xref rid="B264" ref-type="bibr">264</xref>, <xref rid="B265" ref-type="bibr">265</xref>).</p></sec><sec><title>Cryotherapy</title><p>For treating cervical intraepithelial neoplasia, the efficacy along with safety and acceptability of cryotherapy is well documented. The cure rate with cryotherapy is very high (<xref rid="B266" ref-type="bibr">266</xref>). In low as well as middle income countries, cryotherapy seems to be suitable. But the shortage of refrigerant gas creates hindrance in the application of cryotherapy for treating HPV (<xref rid="B267" ref-type="bibr">267</xref>, <xref rid="B268" ref-type="bibr">268</xref>). It is interesting to note that within a period of 3 months one-fourth of the infection due to high risk HPV (hrHPV) can be cleared by cryotherapy (<xref rid="B269" ref-type="bibr">269</xref>).</p></sec><sec><title>Cytotoxic agents</title><p>A few cytotoxic agents, including podophyllin or trichloroacetic acid, have been used topically to remove genital warts (<xref rid="B270" ref-type="bibr">270</xref>), while 5-fluorouracil has been used to a lesser extent because it elicits a strong inflammatory reaction (<xref rid="B271" ref-type="bibr">271</xref>). Anti-cancer agents, i.e., arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and carboplatin target transcription factors AP-1 and NF-&#x003ba;B, play important roles in the expression of HPV oncoproteins E6 and E7 (<xref rid="B272" ref-type="bibr">272</xref>, <xref rid="B273" ref-type="bibr">273</xref>). Some immunomodulators like imiquimod have records of safety and efficacy in treating HPV-caused genital warts (<xref rid="B274" ref-type="bibr">274</xref>). <italic>Aspergillus, Gliocladium</italic>, and <italic>Penicillium</italic> species produce tricyclic alkaloid gliotoxin (<xref rid="B275" ref-type="bibr">275</xref>) and effectively reduce the proliferation of HPV-18 infected cells by inducing Bax, caspase-3, caspase-8, and caspase-9 and suppressing Bcl-2 (<xref rid="B276" ref-type="bibr">276</xref>).</p></sec><sec><title>Antiviral drugs</title><p>Cis-retinoic acid is used as adjunctive therapy for treating HPV-induced lesion of the larynx; but due to efficacy issues, the drug had been discontinued in patients suffering from recurrent respiratory papillomatosis (RRP) (<xref rid="B65" ref-type="bibr">65</xref>). At present, the most common drug used in adjuvant therapy of RRP is cidofovir. The drug is used at a concentration of 5 mg/mL with a dose up to the limit of 3 mg/kg. Such concentration and dose regimen can be followed both in children as well as adults (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B277" ref-type="bibr">277</xref>&#x02013;<xref rid="B279" ref-type="bibr">279</xref>). Cidofovir can also be administered through inhalation, and in the near future such inhalation therapy may provide scope further to perform research on the clinical ground (<xref rid="B280" ref-type="bibr">280</xref>). The expression of E6 as well as E7, has been reduced by cidofovir. This drug is also involved in the reduction of metastatic characteristics of tumor cells that are positive for HPV (<xref rid="B281" ref-type="bibr">281</xref>). Ribavirin and acyclovir have also been used from time to time, but their clinical efficacy is questionable (<xref rid="B65" ref-type="bibr">65</xref>). For reduction of the size of precancerous lesions of cervix (PLC), an essential oil (natural) containing drug known as anti-viral 2 (AV2) has been introduced. The drug contains various organic compounds, viz., geraniol, eugenol, nerolidol, and carvone which can confer a broad spectrum effect (both on oral administration or topical application). More than half of the size of lesion is reduced when AV2 is applied [(<xref rid="B282" ref-type="bibr">282</xref>), <ext-link ext-link-type="uri" xlink:href="http://www.cesa-alliance.com/webapp/index.html">http://www.cesa-alliance.com/webapp/index.html</ext-link>, (<xref rid="B268" ref-type="bibr">268</xref>)]. Xinfuning (a recombinant human interferon &#x003b1;-2b vaginal effervescent capsule), used to treat vaginal infections, enhances NK cell activity (<xref rid="B283" ref-type="bibr">283</xref>).</p><p>Both <italic>in vitro</italic> as well as <italic>in vivo</italic>, the activity of interferons (IFNs) against HPV is well proven. Due to the anti-viral activity, anti-proliferative nature and capability to generate host immune response, interferons are quiet noteworthy for treatment of HPV (<xref rid="B284" ref-type="bibr">284</xref>). For adjuvant therapy against papillomatosis of larynx, interferons are among the earliest agents to be adopted. Biphasic vesicles are used in recent time to deliver IFN-&#x003b1; topically that ensures its delivery locally for a prolonged period without much exposure systemically (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B286" ref-type="bibr">286</xref>). IFN-&#x003b1; co-administered with retinoids has shown promising results when used to treat cervical carcinomas (<xref rid="B287" ref-type="bibr">287</xref>). Combined therapy with IFN-&#x003b1; and ribavirin has been found to be effective against perianal and genital infection caused by HPV (<xref rid="B288" ref-type="bibr">288</xref>). Similarly, pegylated interferon along with ribavirin is useful for treating disseminated HPV infection (<xref rid="B289" ref-type="bibr">289</xref>). Treatment with IFN-&#x003b1; has been shown efficacious in reducing the rate of condyloma recurrence (<xref rid="B284" ref-type="bibr">284</xref>).</p></sec><sec><title>Herbal medicines</title><p>In the Chinese herbal medicine system, several plants with anti-HPV activity have been identified. The Chinese medicine named Paiteling, containing folium, sophora, cnidium, gall, and javanica oil, inhibits HPV by destroying mitochondrial and other membranes to cause necrosis (<xref rid="B290" ref-type="bibr">290</xref>). Carrageenan isolated from red algae, is known to bind HPV virions and inhibit post-attachment entry (<xref rid="B291" ref-type="bibr">291</xref>). Carrageenan gel as a sexual lubricant has shown efficacy in preventing infection with an HPV-16 pseudovirus (<xref rid="B292" ref-type="bibr">292</xref>).</p><p>Significant activities against HPV are shown by certain Chinese medicines (traditional) which are used for preventing as well as treating cancer in relation to HPV. The inhibitory effect of Chai Hu (from roots of <italic>Bupleurum chinense</italic>) on infection due to HPV is well known. This particular medicine has been found to interfere with DNA expression of HPV in genital warts. Youdujing is another medicine that is responsible for reversion of the cervical lesion function in patients having a greater risk of infection due to HPV (<xref rid="B293" ref-type="bibr">293</xref>&#x02013;<xref rid="B295" ref-type="bibr">295</xref>). Inhibition of the risk of infection due to HPV can be done by Paiteling consisting of folium as well as javanica oil as essential components. Moreover, this medicine also contains gall and cnidium as well as sophora all of which can ultimately cause the specific destruction of the mitochondria as well as other biological membranes ultimately resulting in degeneration of cells along with programmed cell death (<xref rid="B290" ref-type="bibr">290</xref>). Treating with fraction of <italic>Pinellia</italic> extract causes reduction of the expression of mRNA and level of protein of HPV E6 whereas there is increase in the protein level as well as mRNA of p53 in cancer cells of the cervix. The antitumor effect of the <italic>Pinellia</italic> extract fraction is thought to be due to the down-regulation of expression of HPV E6 gene and p53 gene upregulation (<xref rid="B296" ref-type="bibr">296</xref>, <xref rid="B297" ref-type="bibr">297</xref>). There is reduction of viral load along with improvement of cytological as well as pathological results in patients with infected cervix by application of Zibai gel (<xref rid="B298" ref-type="bibr">298</xref>). Youdujing cream is clinically effective and for condyloma acuminatum it is a popular choice. The amplification of HPV-DNA is inhibited as is evident by <italic>in vitro</italic> experiments to reveal the therapeutic efficacy of Youdujing in lesions of the genital tract (<xref rid="B299" ref-type="bibr">299</xref>&#x02013;<xref rid="B301" ref-type="bibr">301</xref>).</p></sec><sec><title>Ranpirnase RNAse</title><p>Ranpirnase RNAse is a peptide that cleaves double-stranded RNA (dsRNA). It can eradicate HPV from cultured cells. This drug has been used to treat several malignancies with few side effects, even with a transiently increased serum creatinine level. Three different formulations containing 1 mg/mL ranpirnase were applied topically to genital or anal warts of male volunteers, and it was moderately tolerated in these patients with a mean healing time 30 days (<xref rid="B302" ref-type="bibr">302</xref>). HPV-11 is the HPV type primarily responsible for genital warts, and ranpirnase is effective against this type, as well as HPV-16. In a patent application by Sulley and Squiquera (<xref rid="B303" ref-type="bibr">303</xref>), the enzyme is formulated with a vehicle that does not affect its activity and can be applied topically to genital warts for potential approval as a sexual lubricant. A close variant of ranpirnase has been granted with patent, which contained three mutations (I11V, D20B, and S103R) was found non-toxic and well-tolerated in humans (<xref rid="B304" ref-type="bibr">304</xref>).</p></sec><sec><title>RNA interference (RNAi)-based therapies</title><p>For cancer therapies based on RNAi, an ideal model system is the HPV-induced tumors because there is expression of E6 as well as E7 (the oncogenes responsible for causing cervical cancer) only on tumor cells (<xref rid="B305" ref-type="bibr">305</xref>). As far as the RNAi therapy is concerned, any of the non-structural (early genes) or structural genes (late genes) of HPV can be targeted (<xref rid="B306" ref-type="bibr">306</xref>). The two siRNAs targeting the E6/E7 promoter and E7 transcripts, and thereby knocking down E6 and E7 mRNAs elicit high levels of TP53 expression. Subsequently, apoptosis is induced in cell lines of cervical cancer origin which are positive for HPV-16 (<xref rid="B307" ref-type="bibr">307</xref>&#x02013;<xref rid="B309" ref-type="bibr">309</xref>). Nine siRNAs designed by Chang et al. (<xref rid="B310" ref-type="bibr">310</xref>) were found to target E6 or E6/E7 mRNA of HPV-16 and 18 specifically, and intratumoral administration of these siRNAs resulted in induction of cervical cancer cell apoptosis. In mice (immunocompetent), there is development of tumors (small sized) when HPV-16 E7 siRNAs are used for pre-treating tissue culture-1 cells of murine origin (<xref rid="B311" ref-type="bibr">311</xref>). In Caski cells, there may be suppression of tumors if siRNAs are injected intratumorally (<xref rid="B312" ref-type="bibr">312</xref>). HPV-siRNA plasmids were constructed using a pTOPO-U6 or pTOPO-U6II vector. HPV-16 and 18-type siRNA libraries have been screened for potent siRNAs, which will subsequently be validated in <italic>in vitro</italic> and <italic>in vivo</italic> experiments (<xref rid="B313" ref-type="bibr">313</xref>). However in the clinical setting, the success of RNAi-based therapies is limited (<xref rid="B314" ref-type="bibr">314</xref>). It is further interesting to note that the cisplastin sensitivity of cancerous cells is increased when siRNA is used to target oncogenes of HPV as it leads to reactivation of p53 pathway (<xref rid="B305" ref-type="bibr">305</xref>).</p></sec><sec><title>Localized immunomodulation</title><p>For clearance or suppression of infection due to HPV immunologically in a normal manner, the usefulness of localized immunomodulation has already been proven. The Aldara cream contains an active agent called imiquimod (a Toll like receptor-7 agonist) and this cream can be used topically. There is release of interferons (type I) along with proinflammatory cytokines due to activation of macrophages, dendritic cells along with keratinocytes by imiquimod (<xref rid="B315" ref-type="bibr">315</xref>, <xref rid="B316" ref-type="bibr">316</xref>). Imiquimod enhances immunity by activating a Th1 response (<xref rid="B317" ref-type="bibr">317</xref>). Imiquimod causes side effects that include irritation at the site of application. Green tea leaves contain an extract known as polyphenon E (sinecatechins) that causes immunomodulatory stimulation of the clearance of the virus (<xref rid="B318" ref-type="bibr">318</xref>).</p></sec><sec><title>Immunotherapy</title><p>Immunotherapy has emerged as an adjunctive treatment for standard cancer treatments (surgery, radiotherapy and/or chemotherapy). Substances used in the cancer immunotherapy include non-specific immune stimulators, cytokines, monoclonal antibodies and adoptive or engineered autologous immune cells, mainly T cells. The same strategies canbe applied for treatment of HPV-induced cancers. Bacillus Calmette-Guerin (BCG) given <italic>via</italic> catheter into bladder with tumor mass in several cycles over several months reduces the otherwise high recurence and progression rates of bladder cancer by causing stimulation of effective immune response against cancer cells (American Cancer Society). Cytokines (such as interferons) enhance immune system aganst cancers. Therapeutic antibodies, nakedly or conjugated (loaded) with radioisotope, toxin, or drug, kill directly the cancer cells. Some antibodies recognizes molecule which is highly expressed on cancer cells such that the cells are better seen by the effector immune system for antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-mediated cell lysis. Anitbody binding to cell surface receptor can also cause inhibition of downstream cell signaling and prevent cancer cell shading of decoy to increase effectiveness of the host immune system. Monoclonal antibodies in the form of bispecific T cell engager (BITE) bind to cancer cell and effector T cell simultaneously and bring them into vinicity for increasing the effector cell effectiveness. Antibodies to immune checkpoint molecules on effector T cells such as programmed cell death-1 (PD1) and cytotoxic lymphocyte antigen-4 (CTLA-4) restores the effector T cell activity which is suppressed by ligands highly expressed on the cancer cells leading consequently to not only cancer cell death, but also death of regulatory T cells in the tumor environment. Anti-PD-1/OX40 monoclonal antibody treatment increased CD4<sup>+</sup> and CD8<sup>+</sup> cells and decreased immunosuppressive CD4+FoxP3+ regulatory T (Treg) cells (<xref rid="B319" ref-type="bibr">319</xref>). Chimeric antigen receptor T cells (engineered patient's own T cells) (<xref rid="B320" ref-type="bibr">320</xref>) and cytokine activated adoptive/autologous tumor infiltrating lymphocytes (<xref rid="B321" ref-type="bibr">321</xref>) are effective in several cancer immunotherapy. These options canbe adopted for treatment of HPV-mediated cancers. Two monoclonal antibodies against the L1 protein of HPV-16 have been produced for diagnostic and therapeutic purposes (<xref rid="B322" ref-type="bibr">322</xref>). Anti-HPV 16/18 E6 (C1P5; Abcam) administered repeatedly induced apoptosis of HPV-related cervical cancer (<xref rid="B323" ref-type="bibr">323</xref>).</p></sec><sec><title>Miscellaneous therapies</title><p>Cimetidine has been found to be useful for papillomas of conjunctiva (in case of ocular surface infection due to HPV). It augments the immune system by inhibition of T suppressor cell function and enhances delayed-type hypersensitivity (DTH) (<xref rid="B324" ref-type="bibr">324</xref>). One interesting immunomodulator is dinitrochlorobenzene (DNCB) which may cause induction of DTH response; thereby causing regression of tumor. It has got direct application and is useful in case of surgical failure (<xref rid="B325" ref-type="bibr">325</xref>). There is reduction in the rate of recurrence of HPV-induced tumors by use of radiation therapy. Additionally chemotherapy eye drops are found to be efficacious in clinical various trials (<xref rid="B326" ref-type="bibr">326</xref>). It is also interesting to find that there is effective inhibition of the growth of tumors (expressing HPV E6 as well as E7) by cetuximab when grafting is done in severe combined immunodeficient (SCID) mice (<xref rid="B327" ref-type="bibr">327</xref>).</p><p>An overview on various therapeutic approaches available for treatment of HPV is depicted in Figure <xref ref-type="fig" rid="F3">3</xref>. Different patents recital to the HPV are provided in Table <xref rid="T1" ref-type="table">1</xref> and the <bold>v</bold>arious therapies available to treat HPV are summarized in Table <xref rid="T2" ref-type="table">2</xref>.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Various therapeutic approaches available for treatment of HPV.</p></caption><graphic xlink:href="fimmu-09-02478-g0003"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Different patents recital to the human papilloma virus (HPV).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>S. No</bold>.</th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Title of patent</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Patent No</bold>.</th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Inventors</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Description of patent</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Publication date</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Status</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">Compounds for the treatment of cancers associated with human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2012176163 A2</td><td valign="top" align="left" rowspan="1" colspan="1">Piramal SA, Padigaru M, Agarwal VR, Deshpande GA</td><td valign="top" align="left" rowspan="1" colspan="1">Pyrrolidine substituted with flavone derivatives</td><td valign="top" align="left" rowspan="1" colspan="1">December 27, 2012</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B328" ref-type="bibr">328</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">Compounds for the treatment of HPV-induced carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2016027005 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Rajendran SK, Paul P, Cheng YBF, Eklund P, Eriksson JE</td><td valign="top" align="left" rowspan="1" colspan="1">Mixture of pharmaceutically acceptable salts</td><td valign="top" align="left" rowspan="1" colspan="1">February 25, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B329" ref-type="bibr">329</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Methods of treating human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">US 8663964 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Saxena SK, Ardelt W</td><td valign="top" align="left" rowspan="1" colspan="1">Ranpirnase and 805 variant of ranpirnase have anti-viral activity against type 11 HPV</td><td valign="top" align="left" rowspan="1" colspan="1">March 4, 2014</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B304" ref-type="bibr">304</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Topical composition containing ranpirnase</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2016028634 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Sulley J, Squiquera L</td><td valign="top" align="left" rowspan="1" colspan="1">Enzymatically-active ranpirnase with liquid, gel, ointment, or serum as vehicle with no interference with enzymatic activity and to be applied externally</td><td valign="top" align="left" rowspan="1" colspan="1">February 25, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B303" ref-type="bibr">303</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus E7 antigen compositions and uses thereof</td><td valign="top" align="left" rowspan="1" colspan="1">US 20130209402 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Webb JR, Wick DA</td><td valign="top" align="left" rowspan="1" colspan="1">Use of E7 antigen from two or more HPV types in form of compound</td><td valign="top" align="left" rowspan="1" colspan="1">August 15, 2013</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B330" ref-type="bibr">330</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Method of vaccination against human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2013139744 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Colau BDA, Giannini S, Lockman L</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs with an adjuvant comprising TLR agonist</td><td valign="top" align="left" rowspan="1" colspan="1">September 26, 2013</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B331" ref-type="bibr">331</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein carrying human papilloma virus epitopes inserted in an adenylate cyclase protein or fragment</td><td valign="top" align="left" rowspan="1" colspan="1">US 8637039 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Preville XEE, Leclerc C, Ladant D, Timmerman B</td><td valign="top" align="left" rowspan="1" colspan="1">One or several epitopes inserted in permissive sites of an adenylate cyclase (CyaA) protein so as to target antigen presenting cells</td><td valign="top" align="left" rowspan="1" colspan="1">January 28, 2014</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B332" ref-type="bibr">332</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8.</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus treatment</td><td valign="top" align="left" rowspan="1" colspan="1">US 20080063661 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Neefe J, Goldstone S, Winnett M, Siegel M, Boux L</td><td valign="top" align="left" rowspan="1" colspan="1">A composition having a heat shock protein or an immunostimulatory fragment and human papilloma virus antigenic component</td><td valign="top" align="left" rowspan="1" colspan="1">March 13, 2008</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B333" ref-type="bibr">333</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9.</td><td valign="top" align="left" rowspan="1" colspan="1">Methods of treatment of HPV related diseases</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2015021155 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Wu TC, Hung CF, Roden R</td><td valign="top" align="left" rowspan="1" colspan="1">Mucosal tissue administration of therapeutic HPV vaccines, in a prime-boost regimen</td><td valign="top" align="left" rowspan="1" colspan="1">February 12, 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B334" ref-type="bibr">334</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10.</td><td valign="top" align="left" rowspan="1" colspan="1">Compositions and methods for cell targeted HPV treatment</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2016196282 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Quake SR, Wang J</td><td valign="top" align="left" rowspan="1" colspan="1">A targetable zinc-finger nuclease, selectively target HPV genome</td><td valign="top" align="left" rowspan="1" colspan="1">December 08, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B335" ref-type="bibr">335</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11.</td><td valign="top" align="left" rowspan="1" colspan="1">Use of new type of anti-HPV pharmaceutical preparation</td><td valign="top" align="left" rowspan="1" colspan="1">EP 3072512 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Liu T, Meng S, Zhao L, Hong G</td><td valign="top" align="left" rowspan="1" colspan="1">Combination of paracetamol and a pharmaceutical preparation for prevention and treatment of clinical symptoms caused by HPV infections, including warts, vulvar cancer, penile neoplasms, anal carcinoma, prostate cancer, bladder cancer, cervical cancer, rectal cancer, oral cancer and tonsil cancer</td><td valign="top" align="left" rowspan="1" colspan="1">September 28, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B336" ref-type="bibr">336</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.</td><td valign="top" align="left" rowspan="1" colspan="1">Multitype HPV peptide compositions and methods for treatment or prevention of human papilloma virus infections</td><td valign="top" align="left" rowspan="1" colspan="1">US 20100297144 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Roden R</td><td valign="top" align="left" rowspan="1" colspan="1">Embodiment contains L2 epitope from at least two HPV types</td><td valign="top" align="left" rowspan="1" colspan="1">November 25, 2010</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B337" ref-type="bibr">337</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.</td><td valign="top" align="left" rowspan="1" colspan="1">Compound podophyllotoxin gel for treating HPV virus and preparation method thereof</td><td valign="top" align="left" rowspan="1" colspan="1">CN 105287365 A</td><td valign="top" align="left" rowspan="1" colspan="1">Lide Y, Wensi Z, Qixiong X</td><td valign="top" align="left" rowspan="1" colspan="1">The gel includes salicylic acid, phenol, acetoxychavicol acetate and podophyllotoxin in ethanol and afterwords inclusion of glycerin, carbomer 940 and azone</td><td valign="top" align="left" rowspan="1" colspan="1">February 03, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B338" ref-type="bibr">338</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14.</td><td valign="top" align="left" rowspan="1" colspan="1">Pharmaceutical composition using <italic>Stryphnodendron</italic> extracts for treating HPV infections</td><td valign="top" align="left" rowspan="1" colspan="1">US 9023405 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Neto MADFL, Caetano LC, Neto PADSP, Silva ZPD</td><td valign="top" align="left" rowspan="1" colspan="1">Administration of an extract of <italic>Abarema cochliocarpos</italic></td><td valign="top" align="left" rowspan="1" colspan="1">May 05, 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B339" ref-type="bibr">339</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15.</td><td valign="top" align="left" rowspan="1" colspan="1">Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">US 9005889 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Huang RCC, Abd-Elazem IS</td><td valign="top" align="left" rowspan="1" colspan="1">A pharmaceutical composition containing triterpenoid saponin, lithospermic acid and nordihydroguaiaretic acid (NDGA) derivative</td><td valign="top" align="left" rowspan="1" colspan="1">April 14, 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B340" ref-type="bibr">340</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16.</td><td valign="top" align="left" rowspan="1" colspan="1">Vaginal cream for the treatment of human papilloma virus infection comprising docosanol, turmeric, amla and aloe</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2013171607 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Bertin W, Pecora T</td><td valign="top" align="left" rowspan="1" colspan="1">For topical treatment of skin lesions and of mucous membranes</td><td valign="top" align="left" rowspan="1" colspan="1">November 21, 2013</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B341" ref-type="bibr">341</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17.</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment of cancer and benign proliferative disorders</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2015059485 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Hampson I, Hampson L</td><td valign="top" align="left" rowspan="1" colspan="1">Methods to treat HPV associated dysplasia of the cervix</td><td valign="top" align="left" rowspan="1" colspan="1">April 30, 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B342" ref-type="bibr">342</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18.</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant human papilloma virus type 18 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">US 5820870 A</td><td valign="top" align="left" rowspan="1" colspan="1">Joyce JG, George HA, Hofman KJ, Jansen KU, Neeper MP</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccines for human papilloma virus type 18</td><td valign="top" align="left" rowspan="1" colspan="1">13 Oct 1998</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B343" ref-type="bibr">343</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">19.</td><td valign="top" align="left" rowspan="1" colspan="1">Composition for treatment and preventative of the human papilloma virus infection, ulcerations and boils</td><td valign="top" align="left" rowspan="1" colspan="1">CA 2967506 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Alessa NAA</td><td valign="top" align="left" rowspan="1" colspan="1">Based on herbal composition of a herbal combination, consists of <italic>Aloe vera, Citrullus colocynthis</italic>, hard sea salt, myrrh and garlic</td><td valign="top" align="left" rowspan="1" colspan="1">18 Jan 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B344" ref-type="bibr">344</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20.</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus vaccine with disassembled and reassembled virus-like particles</td><td valign="top" align="left" rowspan="1" colspan="1">US 6245568 B1</td><td valign="top" align="left" rowspan="1" colspan="1">Volkin DB, Heryk Mach H, Shi L</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine formulations containing virus-like particles (VLPs); those are made stable with enhanced shelf-life, by subjecting the VLPs to a disassembly and reassembly process</td><td valign="top" align="left" rowspan="1" colspan="1">12 Jun 2001</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B18" ref-type="bibr">18</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">21.</td><td valign="top" align="left" rowspan="1" colspan="1">Methods and materials for treating human papilloma virus infections</td><td valign="top" align="left" rowspan="1" colspan="1">US 7704965 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Clawson GA, Pa WH, Thiboutot D, Christensen N</td><td valign="top" align="left" rowspan="1" colspan="1">Antisense oligonucleotides designed to interact with HPV E6/E7 RNAs to reduce the number of HPV infected cells</td><td valign="top" align="left" rowspan="1" colspan="1">27 Apr 2010</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B345" ref-type="bibr">345</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">22.</td><td valign="top" align="left" rowspan="1" colspan="1">Topical treatment and prevention of human papilloma virus infection</td><td valign="top" align="left" rowspan="1" colspan="1">US 20050272700 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Buyuktimkin S, Buyuktimkin N, Yeager J</td><td valign="top" align="left" rowspan="1" colspan="1">Dietary indole compound-complexed with cyclodextrin to form a stable suspension for topical application</td><td valign="top" align="left" rowspan="1" colspan="1">8 Dec 2005</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B346" ref-type="bibr">346</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">23.</td><td valign="top" align="left" rowspan="1" colspan="1">Guanidinyl-substituted polyamides useful for treating human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">US 9133228 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Bashkin J, Edwards TG, Fisher C, Harris GD, Jr., Koeller KJ Jr</td><td valign="top" align="left" rowspan="1" colspan="1">Polyamide compositions containing guanidinyl radicals</td><td valign="top" align="left" rowspan="1" colspan="1">15 Sep 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B347" ref-type="bibr">347</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">24.</td><td valign="top" align="left" rowspan="1" colspan="1">Combined measles-human papilloma vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">US 9623098 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Mendiretta SK, Glueck R, Giannino V, Cantarella G, Scuderi F, Billeter M, Fazzio A</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant measles virus vectors containing heterologous nucleic acid encoding for one or more antigens derived from HPV</td><td valign="top" align="left" rowspan="1" colspan="1">18 Apr 2017</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B94" ref-type="bibr">94</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">25.</td><td valign="top" align="left" rowspan="1" colspan="1">Genes encoding major capsid protein L1 of human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">WO 2009076824 A1</td><td valign="top" align="left" rowspan="1" colspan="1">Zhang G, Shen Q, Lei J, Yuan J, Zhang M, Zhang Q, Xiong Y, Wei R, Wu K</td><td valign="top" align="left" rowspan="1" colspan="1">Codon-optimized genes encoding major capsid protein L1 of human papilloma virus is expressed in yeast cells and used as an immunogen</td><td valign="top" align="left" rowspan="1" colspan="1">25 Jun 2009</td><td valign="top" align="left" rowspan="1" colspan="1">Application</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B348" ref-type="bibr">348</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">26.</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccines for human papilloma virus and methods for using the same</td><td valign="top" align="left" rowspan="1" colspan="1">US 9050287 B2</td><td valign="top" align="left" rowspan="1" colspan="1">Weiner DB, Yan J</td><td valign="top" align="left" rowspan="1" colspan="1">A recombinant vaccine having consensus E6 and E7 genes</td><td valign="top" align="left" rowspan="1" colspan="1">9 Jun 2015</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B349" ref-type="bibr">349</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">27.</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus vectors</td><td valign="top" align="left" rowspan="1" colspan="1">US 6399383 b1</td><td valign="top" align="left" rowspan="1" colspan="1">Apt D, Khavari P, Stemmer W.P.C</td><td valign="top" align="left" rowspan="1" colspan="1">This particular invention provides with vectors that are useful in gene therapy against human papilloma virus.</td><td valign="top" align="left" rowspan="1" colspan="1">4 Jun 2002</td><td valign="top" align="left" rowspan="1" colspan="1">Grant</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B350" ref-type="bibr">350</xref>)</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Various therapies available to treat human papillomavirus (HPV).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>S. No</bold>.</th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Therapy available</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Chemical used</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Size of treatment group</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Application format/ Modality</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>HPV types surveyed for/ detected</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Reference(s)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">Photodynamic therapy</td><td valign="top" align="left" rowspan="1" colspan="1">5-Aminolevulinic acid</td><td valign="top" align="left" rowspan="1" colspan="1">39 patients</td><td valign="top" align="left" rowspan="1" colspan="1">10% thermogel</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B259" ref-type="bibr">259</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">30 women</td><td valign="top" align="left" rowspan="1" colspan="1">Topical 6% 5-ALA in gel form</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16 and 18</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B351" ref-type="bibr">351</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">41 patients</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 11, 6, 1, 56, 52, 45, 53, 16, 31, 35, 39, 59, 51, 58, and 81</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B352" ref-type="bibr">352</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Hexaminolevulinate (higher bioavailablity than 5-ALA)</td><td valign="top" align="left" rowspan="1" colspan="1">24 non-pregnant women</td><td valign="top" align="left" rowspan="1" colspan="1">(10 mM) thermogel</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B353" ref-type="bibr">353</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">262 women of childbearing age</td><td valign="top" align="left" rowspan="1" colspan="1">5%, 1%, 0.2% ointment</td><td valign="top" align="left" rowspan="1" colspan="1">HPVtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B263" ref-type="bibr">263</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">Cryotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">89 (&#x02265;18 years, HIV-1positive)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">HPVtypes 45, 16,18,51, and 58</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">269</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carbon dioxide as the refrigerant</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0201c;Double-freeze&#x0201d; procedure of two 3-minute freezes with a thawing interval of 5 min</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, and 71</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B354" ref-type="bibr">354</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">79 (HIV-positive women)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B355" ref-type="bibr">355</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Liquid nitrogen</td><td valign="top" align="left" rowspan="1" colspan="1">3 months old child</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B356" ref-type="bibr">356</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carbon dioxide as the refrigerant</td><td valign="top" align="left" rowspan="1" colspan="1">34</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0201c;Double-freeze&#x0201d; procedure of two 3-minute freezes with a thawing interval of 5 min</td><td valign="top" align="left" rowspan="1" colspan="1">Pap smear test irrespective of HPV type</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Loop Electrosurgical Excision Procedure (LEEP)</td><td valign="top" align="left" rowspan="1" colspan="1">Electric current is passed through a loop of wire, that is used as scalpel to remove the tissue</td><td valign="top" align="left" rowspan="1" colspan="1">195</td><td valign="top" align="left" rowspan="1" colspan="1">Removal of epithelium and a small amount of underlying stroma from the entire cervical transformation zone</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B357" ref-type="bibr">357</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">354</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B358" ref-type="bibr">358</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Cytotoxic agents</td><td valign="top" align="left" rowspan="1" colspan="1">Imiquimod (3.75% or 5% crea</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Topical application</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B359" ref-type="bibr">359</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Podofilox 0.5% solution or gel</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Sinecatechins 15% ointment</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Bichloracetic acid 80%&#x02212;90%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Trichloroacetic acid 80%&#x02212;90%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vidarabine/ 5-fluorouracil (5%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B360" ref-type="bibr">360</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B361" ref-type="bibr">361</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">5-Fluorouracil (5%)</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">Topical application</td><td valign="top" align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TN3"><sup>***</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B362" ref-type="bibr">362</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Arsenic trioxide</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Cell culture</td><td valign="top" align="left" rowspan="1" colspan="1">HPVpositive HeLa cancer cell line</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B363" ref-type="bibr">363</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">HeLa cells (HPV18 positive)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B364" ref-type="bibr">364</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin, carboplatin, and oxaliplatin</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SiHa (HPV 16+) CaSki (HPV 16+), HeLa (HPV 18+), and UT-DEC-1 (HPV 33+) cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B365" ref-type="bibr">365</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Imiquimod (5%)</td><td valign="top" align="left" rowspan="1" colspan="1">76</td><td valign="top" align="left" rowspan="1" colspan="1">Topical application in cream form</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 6, 11, 42, 44, 16, 18, 31, 33, 35, 45, 51, 52, and 56</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B274" ref-type="bibr">274</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">250 mg cream</td><td valign="top" align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TN4"><sup>****</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B366" ref-type="bibr">366</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Antiviral drugs</td><td valign="top" align="left" rowspan="1" colspan="1">Cidofovir<break/>Cidofovir</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Local intratumor injections</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16 and 18</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B367" ref-type="bibr">367</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SiHa, Caski, SCC-147, UM-SCC-47, UD-SCC-2 and UM-SCC-104 cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">HPV type 16</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B368" ref-type="bibr">368</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">Adjuvant therapy (7.5 mg/ml)</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 6, 11, and 16</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B369" ref-type="bibr">369</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin+pegylated interferon- alfa-2b</td><td valign="top" align="left" rowspan="1" colspan="1">1 (HIV negative male)</td><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin -oral form (400 mg twice / day)interferon- (120 &#x003bc;g subcutaneously once per week)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B289" ref-type="bibr">289</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1 (with acquired aplastic anemia)</td><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin -oral form (400 mg twice/ day) interferon- (10 million IU subcutaneously once per week)</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 31, 52, and 6</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B288" ref-type="bibr">288</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1 (Human immunodeficiency virus and hepatitis C virus positive)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B370" ref-type="bibr">370</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cidofovir</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">Topical application</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B258" ref-type="bibr">258</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Acyclovir</td><td valign="top" align="left" rowspan="1" colspan="1">1 (Herpes Simplex Virus and Human Papillomavirus coinfection)</td><td valign="top" align="left" rowspan="1" colspan="1">Intravenous (600 mg/three times a day)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B371" ref-type="bibr">371</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">AV2&#x000ae; (a combination of carvone, eugenol, geraniol, nerolidol in equal volumes diluted 50% in olive oil</td><td valign="top" align="left" rowspan="1" colspan="1">400</td><td valign="top" align="left" rowspan="1" colspan="1">Topical application</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Herpes simplex virus type 1 thymidine kinase expression</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">HPV positive CaSki and SiHa cells</td><td valign="top" align="left" rowspan="1" colspan="1">HPV type 16</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B372" ref-type="bibr">372</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">Herbal therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Smoke of burned dried fruit of the pine tree</td><td valign="top" align="left" rowspan="1" colspan="1">03</td><td valign="top" align="left" rowspan="1" colspan="1">Twice a day</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B373" ref-type="bibr">373</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Paiteling</td><td valign="top" align="left" rowspan="1" colspan="1">239</td><td valign="top" align="left" rowspan="1" colspan="1">Applied 3 days after the end of menstruation (on days 1&#x02013;4, 8&#x02013;11 and 15&#x02013;18)- a total of 12 such applications</td><td valign="top" align="left" rowspan="1" colspan="1">HPV16, 18, 31, 33, 35, 45, 51, 52, 53, 56, 58, 59, 66, 68 and CP8304</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B374" ref-type="bibr">374</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carrageenan</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Crosslinked 3% carrageenan beads</td><td valign="top" align="left" rowspan="1" colspan="1">high-titer HPV16 pseudo-viruses into HeLa cells</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B291" ref-type="bibr">291</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">141</td><td valign="top" align="left" rowspan="1" colspan="1">Carrageenan-based gel</td><td valign="top" align="left" rowspan="1" colspan="1">HPV types 6, 11, 40, 42, 44,54, 16, 18, 26, 31, 33, 34, 35, 39, 45,51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 61,62, 71, 72, 81, 83, 84, and 89</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B375" ref-type="bibr">375</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Youdujing preparation</td><td valign="top" align="left" rowspan="1" colspan="1">35</td><td valign="top" align="left" rowspan="1" colspan="1">YDJ external lotion</td><td valign="top" align="left" rowspan="1" colspan="1">HPV16 and 18</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B294" ref-type="bibr">294</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Podophyllotoxin (resin mixture from <italic>Podophyllum peltatum</italic> resin mixture from <italic>Podophyllum peltatum</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">27 Women</td><td valign="top" align="left" rowspan="1" colspan="1">20% solution</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B376" ref-type="bibr">376</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>Pinelliapedatisecta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">15 mice</td><td valign="top" align="left" rowspan="1" colspan="1">Dried rhizome extract (10 mg/kg/day)</td><td valign="top" align="left" rowspan="1" colspan="1">CaSkicell line containing HPV16</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B377" ref-type="bibr">377</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8.</td><td valign="top" align="left" rowspan="1" colspan="1">Ranpirnase RNase</td><td valign="top" align="left" rowspan="1" colspan="1">Obtained from Leopard frog <italic>Rana pipiens</italic></td><td valign="top" align="left" rowspan="1" colspan="1">42 male volunteers</td><td valign="top" align="left" rowspan="1" colspan="1">1 mg/ml ranpirnase formulation for topical application</td><td valign="top" align="left" rowspan="1" colspan="1">HPV-11 infected A431 human epidermoid carcinoma cells</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B302" ref-type="bibr">302</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9.</td><td valign="top" align="left" rowspan="1" colspan="1">RNAi-based therapies</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">HPV 18 positive HeLa and C4I</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B378" ref-type="bibr">378</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">9 siRNAs against E6/ E7 genes of HPV-16 /18</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">17~22 sense and antisense hairpin oligonucleotide</td><td valign="top" align="left" rowspan="1" colspan="1">HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B310" ref-type="bibr">310</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">HPV16 E7 siRNA</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan/HPV16 &#x02013;E7 siRNA complex</td><td valign="top" align="left" rowspan="1" colspan="1">CaSki cells constitutively expressing HPV16 E6 and E7</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B311" ref-type="bibr">311</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan/HPV16 E7 siRNA nanoparticle complex</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B379" ref-type="bibr">379</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10.</td><td valign="top" align="left" rowspan="1" colspan="1">Miscellaneous therapies</td><td valign="top" align="left" rowspan="1" colspan="1">Oral cimetidine</td><td valign="top" align="left" rowspan="1" colspan="1">4 children</td><td valign="top" align="left" rowspan="1" colspan="1">30&#x02013;40 mg/kg daily divided into 3 doses</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B380" ref-type="bibr">380</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Levamisole</td><td valign="top" align="left" rowspan="1" colspan="1">40 patients</td><td valign="top" align="left" rowspan="1" colspan="1">5 mg/kg on 3 consecutive days fortnightly for 5 months</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B381" ref-type="bibr">381</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>Propionibacterium acnes</italic> or <italic>Coryneobacterium parvum</italic></td><td valign="top" align="left" rowspan="1" colspan="1">28 volunteers</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal application of 0.1 ml culture in one wart, at 30&#x02013;40 days intervals for a total of up to five times</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B382" ref-type="bibr">382</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Oral zinc sulfate</td><td valign="top" align="left" rowspan="1" colspan="1">20 patients</td><td valign="top" align="left" rowspan="1" colspan="1">10 mg/kg</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B383" ref-type="bibr">383</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Bacillus Calmette-Gu&#x000e9;rin Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">50 patients</td><td valign="top" align="left" rowspan="1" colspan="1">Local application of BCG mixweekly for 6 consecutive weeks</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B384" ref-type="bibr">384</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cantharidin (Isolated from blister beetle, <italic>Cantharis vesicatoria</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">12 patients</td><td valign="top" align="left" rowspan="1" colspan="1">0.7% solution</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B385" ref-type="bibr">385</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Formic acid application</td><td valign="top" align="left" rowspan="1" colspan="1">100 patients</td><td valign="top" align="left" rowspan="1" colspan="1">85%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B386" ref-type="bibr">386</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Bleomycin</td><td valign="top" align="left" rowspan="1" colspan="1">Forty patients</td><td valign="top" align="left" rowspan="1" colspan="1">1 U/mlat 2-week intervals.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B387" ref-type="bibr">387</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p><italic>Diagnosed by histopathological methods</italic>.</p></fn><fn id="TN2"><label>**</label><p><italic>HPV typing by RFLP</italic>.</p></fn><fn id="TN3"><label>***</label><p><italic>Biopsy confirmed case</italic>.</p></fn><fn id="TN4"><label>****</label><p><italic>PCR based positive or negative detection</italic>.</p></fn></table-wrap-foot></table-wrap><p>Last but not the least this review is a unique/comprehensive review which highlights the various advances in developing vaccines (both prophylactic and therapeutic) and therapeutic regimens along with recent patents coverage on drugs, vaccines and therapeutics against HPV that will help the scientists and medical practitioners to prevent, treat and facilitate the eradication of the malignancies in relation to HPV in an effective and more promising manner. Moreover, the mind of researchers will be more innovative to combine therapeutic vaccines against HPV with radiation and chemotherapy for designing better control measures along with adopting advanced therapeutic approaches to counter HPV infections and the associated cancerous conditions. The advanced information on HPV vaccines and therapeutics presented in this review compilation along with carrying out more researches in futuristic prospects in the right directions would pave way to design and develop suitable prophylactic and therapeutic vaccines, drugs and treatment modalities delivering clinical outcomes in an improved manner and to combat HPV and its cancerous conditions effectively at global level.</p></sec></sec><sec id="s4"><title>Conclusion and future prospects</title><p>This review highlights the advances in designing prophylactic and therapeutic vaccines as well as treatment regimens against human papilloma virus (HPV) to encourage the development of effective vaccines and therapies against this important disease. For prevention of HPV infection, the use of topical microbicides has been explored widely. For instance, like the use of carrageenan to prevent genital infection due to HPV, several patent applications for formulations are pending which comprise several natural components, such as <italic>Aloe vera</italic>, turmeric, <italic>Citrullus colocynthis</italic>, hard sea salt, myrrh, and garlic to treat HPV. More clinical trials are needed to be conducted to explore the utility of topical microbicides. Studies through mathematical modeling have predicted that vaccination can maintain the antibody levels (especially against HPV-16 and 18) at a much higher level than the level reached due to natural infection for a period of minimum two decades after vaccination. So it can eliminate the requirement of booster dose for a long period. Derivation of the consensus sequence for E6 and E7 genes, followed by codon optimization of these genes and their use as immunogen will pave the way for effective prophylactics. Three commercially available prophylactic vaccines show sufficient efficacy; however, attempts to develop next-generation vaccines that are inexpensive, effective, stable, and that show broad cross-neutralizing immunity are in progress. Recombinant vaccine immunogens based on transgenic plants are an attractive and potentially affordable alternative to vaccines by injection. For example, edible plants can be grown locally and distributed easily without special training or equipment. Approved HPV vaccines based on recombinant VLPs of important high-risk HPV L1 major capsid antigen are effective in controlling HPV infections, but do not have therapeutic applications or protect against cutaneous infections. There are studies to evaluate alternative approaches to deliver current vaccine in a safer and affordable way. For example, microneedle deliveries of lyophilized HPV pseudovirions are thermostable and have been tested in a murine model. Also, acceptance of HPV vaccines has been hindered by many factors associated with place of residence, culture, and economics. Administration of these vaccines has been virtually non-existent in developing countries, mainly because of their extremely high costs and the technical challenges of vaccination, which require multiple doses over a 6-month period (<xref rid="B388" ref-type="bibr">388</xref>). Also, refrigeration is needed during shipping and storage, introducing logistical difficulties in areas that lack adequate infrastructure. HPV vaccines cost approximately US $450 (Gardasil) and US $495 (Gardasil 9) in the U.S. for the complete course of three injections. Therefore, second-generation HPV vaccines are needed to reduce the costs of vaccine production and increase immunization schedule feasibility.</p><p>A subdominant neutralizing epitope in the HPV L2 protein is an alternative approach to produce recombinant VLP antigens. This well-conserved linear neutralizing HPV epitope, which is located at the amino terminus of the L2 protein, may be exposed while the virus is on the basement membrane during infection. Attempts are being made to formulate more stable VLPs for immunization, and in fact, VLPs which are subjected to a disassembly and reassembly process have been found to be more stable, and the patent has been granted to the technology. Another alternative antigen for use in HPV vaccines is the pentameric subunit or capsomere of the L1 protein that has essential neutralizing epitopes to induce an immune response to protect against HPV. Recombinant capsomeres expressed in <italic>E. coli</italic> represent one important approach to reducing manufacturing costs. Studies in animal models have reported that HPV capsomeres alone induce lower antibody titers than VLPs. Therefore, this approach will require further optimization for increased antibody titers. However, the pentamers can be lyophilized for greater thermostability, suggesting the potential for formulations that can be shipped and stored without refrigeration (<xref rid="B389" ref-type="bibr">389</xref>). Thus, use of capsomeres is an attractive and affordable option for developing second-generation HPV vaccines (<xref rid="B389" ref-type="bibr">389</xref>).</p><p>On the other hand, production of combined preventive-therapeutic antigens, focusing on fusions of L2 with E7, or both E6 and E7, is in the early stages, and their therapeutic effectiveness has not been demonstrated. However, these therapeutic vaccines have shown some promise in some early clinical trials. Curcumin has also shown the potential to prevent HPV-associated oral cancers by selectively inhibiting E6 oncogene-mediated p53 degradation. Apart from vaccination, several therapeutic approaches are also becoming popular nowadays to counter HPV, and if given in conjugation with vaccines, the disease may be combated in a better way. Among some treatment strategies, a photodynamic therapy which uses 5-aminolevulinic acid has been tested against HPV-6, 11, 16, and 18 and a higher clearance rate (83.9%) has been observed, without affecting the cervical tissue morphology. Topical application of few cytotoxic compounds including podophyllin, arsenic trioxide, carboplatin or trichloroacetic acid also has been suggested to remove genital warts. Interferons and immunomodulators like imiquimod also have been tested for their efficacy in removing genital warts and found useful. Antivirals like cidofovir, ribavirin, and acyclovir have been tested against HPV, but cidofovir has been used widely, and since it can be administered through inhalation, additional benefits are present for using it in clinical applications. Ranpirnase RNase enzyme cleaves dsRNAs, and in the form of a topically applicable ointment, it has proved effective in treating anal warts. The treatment modules encompassing the use of antisense RNA are still in infancy but have shown some promise in therapeutic efficacy.</p><p>For HPV vaccines, pre-adolescent girls are the primary target but evaluation of the cost effectiveness of vaccination of other groups needs to be done. For certain candidate vaccines entering phase III trial, a viable vaccine (prophylactic) against a few types of HPV may become available in a less period of five years. For complementing conventional therapy designing of the therapeutic vaccines (under investigation) are done mostly. However, the extent of benefit or the cost at which such benefits can be offered to the women are not yet clear. Clearing of the earliest stage of infection due to HPV by therapeutic vaccines is possible but is less developed. Certainly such vaccines hold promises to reduce the suffering as well as cost of treatment associated with disease of the cervix. For precancerous lesions, it is, however, crucial to continue the process of development of accurate screening as well as treatment plans and programs as there is forward movement of the process of vaccine development.</p><p>No one can deny the fact that vaccination against HPV has proven to be a landmark in the history of prevention of cancer. The incidence of HPV-induced cervical cancer will reduce drastically if adolescent girls are immunized, and this must be the priority not only in the industrialized world, but also in developing nations where it is sometimes impossible to detect the precancerous lesions at an early stage. It is however unfortunate that even in the developed nations of the Western world, the screening to detect cervical HPV-induced cancer is not performed on a regular basis. In this context, implementation of immunization of girls in every nation universally is of immense benefit. To succeed in such aspect of prevention of HPV infection especially in women, convincing the parents as well as their daughters is a top priority. Similarly, vaccination in homosexual males is of utmost relevance concerning prevention of HPV in the community. But to assess the sexual orientation in every male is somewhat difficult for which universal male vaccination is essential. With the usage of efficient vaccination and application of potent therapeutics, the effective elimination of the disease is expected and in fact combinations of several therapies have helped people in getting rid of this ailment. For all these reasons, it is necessary for the public health authorities to remain proactive and at the same time innovative methods will also be required for financing introduction of HPV vaccine and advancing the development of potent therapeutics.</p></sec><sec id="s5"><title>Author contributions</title><p>All the authors substantially contributed to the conception, design, analysis, and interpretation of data, checking and approving the final version of the manuscript, and agree to be accountable for its contents. MD, KD, SH, and RT initiated this review compilation. SC, RK, AM, MP, and DK updated different vaccines and therapies. RK designed table. KK designed the figures. KD, HI, MD and WC reviewed, analyzed and edited.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>All the authors acknowledge and thank their respective Institutes and Universities.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This compilation is a review article written, analyzed and designed by its authors and required no substantial funding to be stated.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forcier</surname><given-names>M</given-names></name><name><surname>Musacchio</surname><given-names>N</given-names></name></person-group>. <article-title>An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention</article-title>. <source>Dermatol Ther</source>. (<year>2010</year>) <volume>23</volume>:<fpage>458</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/j.1529-8019.2010.01350.x</pub-id><?supplied-pmid 20868401?><pub-id pub-id-type="pmid">20868401</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brianti</surname><given-names>P</given-names></name><name><surname>De Flammineis</surname><given-names>E</given-names></name><name><surname>Mercuri</surname><given-names>SR</given-names></name></person-group>. <article-title>Review of HPV-related diseases and cancers</article-title>. <source>New Microbiologica</source>. (<year>2017</year>) <volume>40</volume>:<fpage>80</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 28368072?><pub-id pub-id-type="pmid">28368072</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Palefsky</surname><given-names>JM</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Bloom</surname><given-names>A</given-names></name></person-group>
<source>Human Papillomavirus Infections: Epidemiology and Disease Associations</source>. <publisher-loc>Waltham</publisher-loc>: <publisher-name>UpToDate</publisher-name> (<year>2018</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations">https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations</ext-link> (Accessed June 16, 2018).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonanni</surname><given-names>P</given-names></name><name><surname>Bechini</surname><given-names>A</given-names></name><name><surname>Donato</surname><given-names>R</given-names></name><name><surname>Capei</surname><given-names>R</given-names></name><name><surname>Sacco</surname><given-names>C</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human papilloma virus vaccination: impact and recommendations across the world</article-title>. <source>Ther Adv Vaccines</source> (<year>2014</year>) <volume>3</volume>:<fpage>3</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1177/2051013614557476</pub-id><?supplied-pmid 25553242?><pub-id pub-id-type="pmid">25553242</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>M</given-names></name></person-group>. <article-title>Immunobiology of HPV and HPV vaccines</article-title>. <source>Gynecol Oncol</source>. (<year>2008</year>) <volume>109</volume>:<fpage>S15</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2008.02.003</pub-id><?supplied-pmid 18474288?><pub-id pub-id-type="pmid">18474288</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Howell-Jones</surname><given-names>R</given-names></name><name><surname>Snijders</surname><given-names>PJ</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name></person-group>. <article-title>Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication</article-title>. <source>Int J Cancer</source>. (<year>2011</year>) <volume>128</volume>:<fpage>927</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25396</pub-id><?supplied-pmid 20473886?><pub-id pub-id-type="pmid">20473886</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fardows</surname><given-names>J</given-names></name><name><surname>Nehar</surname><given-names>N</given-names></name><name><surname>Laskar</surname><given-names>N</given-names></name><name><surname>Joly</surname><given-names>SN</given-names></name></person-group>
<article-title>Human Papilloma virus vaccine: future of cervical cancer prevention</article-title>. <source>J Enam Med Coll.</source> (<year>2016</year>) <volume>6</volume>:<fpage>157</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.3329/jemc.v6i3.29683</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zur Hausen</surname><given-names>H</given-names></name></person-group>. <article-title>Papillomaviruses and cancer: from basic studies to clinical application</article-title>. <source>Nat Rev Cancer</source>. (<year>2002</year>) <volume>2</volume>:<fpage>342</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrc798</pub-id><?supplied-pmid 12044010?><pub-id pub-id-type="pmid">12044010</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Bruni</surname><given-names>L</given-names></name><name><surname>Barrionuevo-Rosas</surname><given-names>L</given-names></name><name><surname>Albero</surname><given-names>G</given-names></name><name><surname>Serrano</surname><given-names>B</given-names></name><name><surname>Mena</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>D</given-names></name><etal/></person-group>
<source>ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in India</source>. Summary Rep. (<year>2016</year>).</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>DM</given-names></name></person-group>. <article-title>Currently approved prophylactic HPV vaccines</article-title>. <source>Expert Rev. Vaccine</source> (<year>2009</year>) <volume>8</volume>:<fpage>1663</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.123</pub-id><?supplied-pmid 19943762?><pub-id pub-id-type="pmid">19943762</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kash</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Kollipara</surname><given-names>R</given-names></name><name><surname>Downing</surname><given-names>C</given-names></name><name><surname>Guidry</surname><given-names>J</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name></person-group>. <article-title>Safety and efficacy data on vaccines and immunization to human papillomavirus</article-title>. <source>J Clin Med</source>. (<year>2015</year>) <volume>4</volume>:<fpage>614</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.3390/jcm4040614</pub-id><?supplied-pmid 26239350?><pub-id pub-id-type="pmid">26239350</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>KB</given-names></name></person-group>. <article-title>Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies</article-title>. <source>Discov Med</source>. (<year>2010</year>) <volume>10</volume>:<fpage>7</fpage>&#x02013;<lpage>17</lpage>. <?supplied-pmid 20670593?><pub-id pub-id-type="pmid">20670593</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Maraj</surname><given-names>B</given-names></name><name><surname>Tran</surname><given-names>NP</given-names></name><name><surname>Knoff</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>Emerging human papilloma virus vaccines</article-title>. <source>Expert Opin Emerg Drugs</source>. (<year>2012</year>) <volume>17</volume>:<fpage>469</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1517/14728214.2012.744393</pub-id><pub-id pub-id-type="pmid">23163511</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>KT</given-names></name></person-group>. <article-title>&#x0201c;Saving lives&#x0201d;: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria</article-title>. <source>Soc Sci Med</source>. (<year>2016</year>) <volume>153</volume>:<fpage>193</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.socscimed.2016.02.006</pub-id><?supplied-pmid 26921834?><pub-id pub-id-type="pmid">26921834</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stillo</surname><given-names>M</given-names></name><name><surname>Santisteve</surname><given-names>PC</given-names></name><name><surname>Lopalco</surname><given-names>PL</given-names></name></person-group>. <article-title>Safety of human papillomavirus vaccines: a review</article-title>. <source>Expert Opin Drug Saf</source>. (<year>2015</year>) <volume>14</volume>:<fpage>697</fpage>&#x02013;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.2015.1013532</pub-id><?supplied-pmid 25689872?><pub-id pub-id-type="pmid">25689872</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>LL</given-names></name></person-group>. <article-title>Prophylactic HPV vaccines: reducing the burden of HPV-related diseases</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>S23</fpage>&#x02013;<lpage>S28</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.001</pub-id><?supplied-pmid 16194583?><pub-id pub-id-type="pmid">16194583</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>ND</given-names></name><name><surname>Reed</surname><given-names>CA</given-names></name><name><surname>Cladel</surname><given-names>NM</given-names></name><name><surname>Han</surname><given-names>R</given-names></name><name><surname>Kreider</surname><given-names>JW</given-names></name></person-group>. <article-title>Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus</article-title>. <source>J Virol</source>. (<year>1996</year>) <volume>70</volume>:<fpage>960</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 8551636?><pub-id pub-id-type="pmid">8551636</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkin</surname><given-names>DB</given-names></name><name><surname>Heryk Mach</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name></person-group>
<article-title>Human papilloma virus vaccine with disassembled and reassembled virus-like particles</article-title>. US 6245568 B1 (<year>2001</year>).</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>TB</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name></person-group>. <article-title>HPV vaccines: translating immunogenicity into efficacy</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>1403</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1103936</pub-id><?supplied-pmid 26512762?><pub-id pub-id-type="pmid">26512762</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>EL</given-names></name><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Garnett</surname><given-names>GP</given-names></name><name><surname>Meheus</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>242</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.038</pub-id><?supplied-pmid 16950013?><pub-id pub-id-type="pmid">16950013</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Markowitz</surname><given-names>L</given-names></name><name><surname>Avila</surname><given-names>MH</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name></person-group>. <article-title>Research needs following initial licensure of virus-like particle HPV vaccines</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>227</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.102</pub-id><?supplied-pmid 16950011?><pub-id pub-id-type="pmid">16950011</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariri</surname><given-names>S</given-names></name><name><surname>Markowitz</surname><given-names>L</given-names></name><name><surname>Dunne</surname><given-names>E</given-names></name><name><surname>Unger</surname><given-names>E</given-names></name></person-group>. <article-title>Population impact of HPV vaccines: summary of early evidence</article-title>. <source>J Adolesc Health</source> (<year>2013</year>) <volume>53</volume>:<fpage>679</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.jadohealth.2013.09.018</pub-id><?supplied-pmid 24263069?><pub-id pub-id-type="pmid">24263069</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>LE</given-names></name><name><surname>Dunne</surname><given-names>EF</given-names></name><name><surname>Saraiya</surname><given-names>M</given-names></name><name><surname>Lawson</surname><given-names>HW</given-names></name><name><surname>Chesson</surname><given-names>H</given-names></name><name><surname>Unger</surname><given-names>ER</given-names></name></person-group>. <article-title>Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>Morb. Mort. Wkly. Rep. Recomm. Rep.</source> (<year>2007</year>) <volume>56</volume>, <fpage>1</fpage>&#x02013;<lpage>24</lpage>. <?supplied-pmid 17380109?><pub-id pub-id-type="pmid">17380109</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaarthigeyan</surname><given-names>K</given-names></name></person-group>. <article-title>Cervical cancer in India and HPV vaccination</article-title>. <source>Ind J Med Paediatr Oncol</source>. (<year>2012</year>) <volume>33</volume>:<fpage>7</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4103/0971-5851.96961</pub-id><?supplied-pmid 22754202?><pub-id pub-id-type="pmid">22754202</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogoda</surname><given-names>CS</given-names></name><name><surname>Roden</surname><given-names>RB</given-names></name><name><surname>Garcea</surname><given-names>RL</given-names></name></person-group>. <article-title>Immunizing against anogenital cancer: HPV vaccines</article-title>. <source>PLoS Pathog</source>. (<year>2016</year>) <volume>12</volume>:<fpage>e1005587</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005587</pub-id><?supplied-pmid 27196109?><pub-id pub-id-type="pmid">27196109</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomar</surname><given-names>A</given-names></name><name><surname>Kushwah</surname><given-names>A</given-names></name></person-group>
<article-title>Advances in human papilloma virus vaccines: a review</article-title>. <source>Int J Basic Clin Pharmacol</source>. (<year>2014</year>) <volume>3</volume>:<fpage>37</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.2011.551114</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kines</surname><given-names>RC</given-names></name><name><surname>Zarnitsyn</surname><given-names>V</given-names></name><name><surname>Johnson</surname><given-names>TR</given-names></name><name><surname>Pang</surname><given-names>YYS</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Nicewonger</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles</article-title>. <source>PLoS ONE</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0120797</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0120797</pub-id><?supplied-pmid 25785935?><pub-id pub-id-type="pmid">25785935</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setiawan</surname><given-names>D</given-names></name><name><surname>Luttjeboer</surname><given-names>J</given-names></name><name><surname>Pouwels</surname><given-names>KB</given-names></name><name><surname>Wilschut</surname><given-names>JC</given-names></name><name><surname>Postma</surname><given-names>MJ</given-names></name></person-group>. <article-title>Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis</article-title>. <source>Jpn J Clin Oncol</source>. (<year>2017</year>) <volume>47</volume>:<fpage>265</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyw192</pub-id><?supplied-pmid 28042137?><pub-id pub-id-type="pmid">28042137</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>L</given-names></name></person-group>. <article-title>Human papillomavirus and the HPV vaccine: where are we today?</article-title>
<source>Pediatr Ann</source>. (<year>2017</year>) <volume>46</volume>:<fpage>e2</fpage>&#x02013;<lpage>e5</lpage>. <pub-id pub-id-type="doi">10.3928/19382359-20161216-01</pub-id><?supplied-pmid 28079910?><pub-id pub-id-type="pmid">28079910</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazer</surname><given-names>IH</given-names></name></person-group>. <article-title>Prevention of cervical cancer through papillomavirus vaccination</article-title>. <source>Nat Rev Immunol</source>. (<year>2004</year>) <volume>4</volume>:<fpage>46</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/nri1260</pub-id><?supplied-pmid 14704767?><pub-id pub-id-type="pmid">14704767</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leggatt</surname><given-names>GR</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name></person-group>. <article-title>HPV vaccines: the beginning of the end for cervical cancer</article-title>. <source>Curr Opinion Immunol</source>. (<year>2007</year>) <volume>19</volume>:<fpage>232</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2007.01.004</pub-id><?supplied-pmid 17293100?><pub-id pub-id-type="pmid">17293100</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>MA</given-names></name></person-group>. <article-title>Epithelial cell responses to infection with human papillomavirus</article-title>. <source>Clin Microbiol Rev</source>. (<year>2012</year>) <volume>25</volume>:<fpage>215</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.05028-11</pub-id><?supplied-pmid 22491770?><pub-id pub-id-type="pmid">22491770</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>M</given-names></name></person-group>. <article-title>Pathology and epidemiology of HPV infection in females</article-title>. <source>Gynecol. Oncol</source>. (<year>2010</year>) <volume>117</volume>:<fpage>S5</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2010.01.024</pub-id><?supplied-pmid 20304221?><pub-id pub-id-type="pmid">20304221</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaCour</surname><given-names>DE</given-names></name></person-group>. <article-title>Human papillomavirus in infants: transmission, prevalence, and persistence</article-title>. <source>J Pediatr Adolesc Gynecol</source>. (<year>2012</year>) <volume>25</volume>:<fpage>93</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpag.2011.03.001</pub-id><?supplied-pmid 21600804?><pub-id pub-id-type="pmid">21600804</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>N</given-names></name><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>de Sanjos</surname><given-names>&#x000e9;S</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Castellsagu</surname><given-names>&#x000e9;X</given-names></name><name><surname>Shah</surname><given-names>KV</given-names></name><etal/></person-group>. <article-title>Epidemiologic classification of human papillomavirus types associated with cervical cancer</article-title>. <source>N Engl J Med</source>. (<year>2003</year>) <volume>348</volume>:<fpage>518</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa021641</pub-id><?supplied-pmid 12571259?><pub-id pub-id-type="pmid">12571259</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjalma</surname><given-names>WAA</given-names></name><name><surname>Fiander</surname><given-names>A</given-names></name><name><surname>Reich</surname><given-names>O</given-names></name><name><surname>Powell</surname><given-names>N</given-names></name><name><surname>Nowakowski</surname><given-names>AM</given-names></name><name><surname>Kirschner</surname><given-names>B</given-names></name><name><surname>Koiss</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>132</volume>:<fpage>854</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.27713</pub-id><?supplied-pmid 22752992?><pub-id pub-id-type="pmid">22752992</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>AP</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Kimple</surname><given-names>RJ</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name></person-group>. <article-title>Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time</article-title>. <source>Chem Res Toxicol</source>. (<year>2014</year>) <volume>27</volume>:<fpage>462</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/tx500034c</pub-id><?supplied-pmid 24641254?><pub-id pub-id-type="pmid">24641254</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillison</surname><given-names>ML</given-names></name><name><surname>Chaturvedi</surname><given-names>AK</given-names></name><name><surname>Anderson</surname><given-names>WF</given-names></name><name><surname>Fakhry</surname><given-names>C</given-names></name></person-group>
<article-title>Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma</article-title>. <source>J Clin Oncol</source>. (<year>2015</year>) <volume>29</volume>:<fpage>3235</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2015.61.6995</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillison</surname><given-names>ML</given-names></name><name><surname>Castellsagu&#x000e9;</surname><given-names>X</given-names></name><name><surname>Chaturvedi</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>MT</given-names></name><name><surname>Snijders</surname><given-names>P</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix</article-title>. <source>Int J Cancer</source> (<year>2014</year>) <volume>134</volume>:<fpage>497</fpage>&#x02013;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.28201</pub-id><?supplied-pmid 23568556?><pub-id pub-id-type="pmid">23568556</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centers</surname><given-names>for disease control and prevention I</given-names></name></person-group>
<article-title>(CDC) Human papillomavirus-associated cancers &#x02013; United States, 2004&#x02013;2008</article-title>. <source>MMWR Morb Mortal Wkly. Rep</source>. (<year>2012</year>) <volume>61</volume>:<fpage>258</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="pmid">22513527</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutts</surname><given-names>F</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Goldie</surname><given-names>S</given-names></name><name><surname>Castellsague</surname><given-names>X</given-names></name><name><surname>de Sanjose</surname><given-names>S</given-names></name><name><surname>Garnett</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Human papillomavirus and HPV vaccines: a review</article-title>. <source>Bull. WHO</source> (<year>2007</year>) <volume>85</volume>:<fpage>719</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.06.038414</pub-id><?supplied-pmid 18026629?><pub-id pub-id-type="pmid">18026629</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apter</surname><given-names>D</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Castellsague</surname><given-names>X</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Skinner</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial</article-title>. <source>HPV PATRICIA Study Group Clin Vaccine Immunol</source>. (<year>2015</year>) <volume>22</volume>:<fpage>361</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00591-14</pub-id><?supplied-pmid 25651922?><pub-id pub-id-type="pmid">25651922</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtinen</surname><given-names>M</given-names></name><name><surname>Apter</surname><given-names>D</given-names></name><name><surname>Baussano</surname><given-names>I</given-names></name><name><surname>Eriksson</surname><given-names>T</given-names></name><name><surname>Natunen</surname><given-names>K</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<fpage>1284</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.12.019</pub-id><?supplied-pmid 25593103?><pub-id pub-id-type="pmid">25593103</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luckett</surname><given-names>R</given-names></name><name><surname>Feldman</surname><given-names>S</given-names></name></person-group>. <article-title>Impact of 2, 4 and 9-valent HPV vaccines on morbidity and mortality from cervical cancer</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>1332</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1108500</pub-id><?supplied-pmid 26588179?><pub-id pub-id-type="pmid">26588179</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romanowski</surname><given-names>B</given-names></name><name><surname>Schwarz</surname><given-names>TF</given-names></name><name><surname>Ferguson</surname><given-names>L</given-names></name><name><surname>Peters</surname><given-names>K</given-names></name><name><surname>Dionne</surname><given-names>M</given-names></name><name><surname>Behre</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>20</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1065363</pub-id><?supplied-pmid 26176261?><pub-id pub-id-type="pmid">26176261</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinner</surname><given-names>SR</given-names></name><name><surname>Apter</surname><given-names>D</given-names></name><name><surname>Carvalho</surname><given-names>ND</given-names></name><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Konno</surname><given-names>R</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases</article-title>. <source>Expert Rev Vaccines</source> (<year>2016</year>) <volume>15</volume>:<fpage>367</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2016.1124763</pub-id><?supplied-pmid 26902666?><pub-id pub-id-type="pmid">26902666</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Skinner</surname><given-names>SR</given-names></name><name><surname>Rosario-Raymundo</surname><given-names>MRD</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Lazcano-Ponce</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomized controlled VIVIANE study</article-title>. <source>Lancet Infect Dis</source>. (<year>2016</year>) <volume>16</volume>:<fpage>1154</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30120-7</pub-id><pub-id pub-id-type="pmid">27373900</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willame</surname><given-names>C</given-names></name><name><surname>Rosillon</surname><given-names>D</given-names></name><name><surname>Zima</surname><given-names>J</given-names></name><name><surname>Angelo</surname><given-names>M-G</given-names></name><name><surname>Stuurman</surname><given-names>AL</given-names></name><name><surname>Vroling</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>2862</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2016.1199308</pub-id><?supplied-pmid 27428517?><pub-id pub-id-type="pmid">27428517</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tezal</surname><given-names>M</given-names></name></person-group>. <article-title>Interaction between chronic inflammation and oral HPV infection in the etiology of head and neck cancers</article-title>. <source>Int J Otolaryngol.</source> (<year>2012</year>) <volume>2012</volume>:<fpage>575242</fpage>. <pub-id pub-id-type="doi">10.1155/2012/575242</pub-id><?supplied-pmid 22518158?><pub-id pub-id-type="pmid">22518158</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bal-Yilmaz</surname><given-names>H</given-names></name><name><surname>Koniak-Griffin</surname><given-names>D</given-names></name></person-group>. <article-title>Knowledge, behaviors, and attitudes about human papilloma virus among nursing students in izmir, Turkey</article-title>. <source>J. Cancer Educ.</source> (<year>2017</year>) <volume>33</volume>:<fpage>814</fpage>&#x02013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1007/s13187-017-1163-1</pub-id><?supplied-pmid 28074443?><pub-id pub-id-type="pmid">28074443</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Burger</surname><given-names>EA</given-names></name><name><surname>Sy</surname><given-names>S</given-names></name><name><surname>Campos</surname><given-names>NG</given-names></name></person-group>. <article-title>Optimal cervical cancer screening in women vaccinated against human papillomavirus</article-title>. <source>J Natl Cancer Inst</source>. (<year>2017</year>) <volume>109</volume>:<fpage>djw216</fpage>. <pub-id pub-id-type="doi">10.1093/jnci/djw216</pub-id><?supplied-pmid 27754955?><pub-id pub-id-type="pmid">27754955</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presser</surname><given-names>BE</given-names></name><name><surname>Katz</surname><given-names>ML</given-names></name><name><surname>Shoben</surname><given-names>AB</given-names></name><name><surname>Moore</surname><given-names>D</given-names></name><name><surname>Ruffin</surname><given-names>MT</given-names></name><name><surname>Paskett</surname><given-names>ED</given-names></name><etal/></person-group>. <article-title>Effects of an education intervention about HPV self-testing for healthcare providers and staff</article-title>. <source>J Cancer Educ</source>. (<year>2017</year>) <pub-id pub-id-type="doi">10.1007/s13187-017-1164-0</pub-id>. [Epub ahead of print].<?supplied-pmid 28074444?><pub-id pub-id-type="pmid">28074444</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khallouf</surname><given-names>H</given-names></name><name><surname>Grabowska</surname><given-names>AK</given-names></name><name><surname>Riemer</surname><given-names>AB</given-names></name></person-group>. <article-title>Therapeutic vaccine strategies against human papillomavirus</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>2</volume>:<fpage>422</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines2020422</pub-id><?supplied-pmid 26344626?><pub-id pub-id-type="pmid">26344626</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panatto</surname><given-names>D</given-names></name><name><surname>Amicizia</surname><given-names>D</given-names></name><name><surname>Bragazzi</surname><given-names>NL</given-names></name><name><surname>Rizzitelli</surname><given-names>E</given-names></name><name><surname>Tramalloni</surname><given-names>D</given-names></name><name><surname>Valle</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Chapter eight-human papillomavirus vaccine: state of the art and future perspectives</article-title>. <source>Adv Protein Chem Struct Biol</source>. (<year>2015</year>) <volume>101</volume>:<fpage>231</fpage>&#x02013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apcsb.2015.08.004</pub-id><pub-id pub-id-type="pmid">26572981</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Jeang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Current state in the development of candidate therapeutic HPV vaccines</article-title>. <source>Expert Rev Vaccines</source> (<year>2016</year>) <volume>15</volume>:<fpage>989</fpage>&#x02013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2016.1157477</pub-id><?supplied-pmid 26901118?><pub-id pub-id-type="pmid">26901118</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtinen</surname><given-names>M</given-names></name><name><surname>Paavonem</surname><given-names>J</given-names></name></person-group>
<article-title>Vaccination against human papilloma viruses shows great promise</article-title>. <source>Lancet</source> (<year>2004</year>) <volume>364</volume>:<fpage>1731</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17410-2</pub-id><pub-id pub-id-type="pmid">15541429</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>AK</given-names></name><name><surname>Cobucci</surname><given-names>RN</given-names></name><name><surname>Rodrigues</surname><given-names>HM</given-names></name><name><surname>de Melo</surname><given-names>AG</given-names></name><name><surname>Giraldo</surname><given-names>PC</given-names></name></person-group>. <article-title>Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review</article-title>. <source>Braz J Infect Dis</source>. (<year>2014</year>) <volume>18</volume>:<fpage>651</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjid.2014.02.005</pub-id><?supplied-pmid 24780368?><pub-id pub-id-type="pmid">24780368</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Chattopadhyay</surname><given-names>A</given-names></name><name><surname>Samanta</surname><given-names>L</given-names></name><name><surname>Panigrahi</surname><given-names>P</given-names></name></person-group>. <article-title>HPV and cervical cancer epidemiology- Current status of HPV vaccination in India</article-title>. <source>Asian Pac J Cancer Prev</source>. (<year>2016</year>) <volume>17</volume>:<fpage>3663</fpage>&#x02013;<lpage>73</lpage>. <?supplied-pmid 27644600?><pub-id pub-id-type="pmid">27644600</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Farmer</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Hung</surname><given-names>CF</given-names></name></person-group>
<article-title>The current state of therapeutic and T-cell based vaccines against human papilloma viruses</article-title>. <source>Virus Res</source>. (<year>2017</year>) <volume>231</volume>:<fpage>148</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2016.12.002</pub-id><pub-id pub-id-type="pmid">27932207</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouyanfard</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name></person-group>
<article-title>Human papilloma virus first and second generation vaccines- current status and future directions</article-title>. <source>Biol Chem</source>. (<year>2017</year>) <volume>398</volume>:<fpage>871</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2017-0105</pub-id><pub-id pub-id-type="pmid">28328521</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallez</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>P</given-names></name><name><surname>Maudoux</surname><given-names>F</given-names></name><name><surname>Doyen</surname><given-names>J</given-names></name><name><surname>No&#x000eb;l</surname><given-names>JC</given-names></name><name><surname>Beliard</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein&#x02013;based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia</article-title>. <source>Cancer Immunol Immunother.</source> (<year>2004</year>) <volume>53</volume>:<fpage>642</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-004-0501-4</pub-id><?supplied-pmid 14985860?><pub-id pub-id-type="pmid">14985860</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palefsky</surname><given-names>JM</given-names></name><name><surname>Berry</surname><given-names>JM</given-names></name><name><surname>Jay</surname><given-names>N</given-names></name><name><surname>Krogstad</surname><given-names>M</given-names></name><name><surname>Da Costa</surname><given-names>M</given-names></name><name><surname>Darragh</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals</article-title>. <source>AIDS</source> (<year>2006</year>) <volume>20</volume>, <fpage>1151</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 16691066?><pub-id pub-id-type="pmid">16691066</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>LD</given-names></name><name><surname>Wilczynski</surname><given-names>S</given-names></name><name><surname>Muderspach</surname><given-names>LI</given-names></name><name><surname>Burnett</surname><given-names>AF</given-names></name><name><surname>O'meara</surname><given-names>A</given-names></name><name><surname>Brinkman</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia</article-title>. <source>Gynecol Oncol.</source> (<year>2007</year>) <volume>106</volume>:<fpage>558</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.05.038</pub-id><?supplied-pmid 17631950?><pub-id pub-id-type="pmid">17631950</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einstein</surname><given-names>MH</given-names></name><name><surname>Kadish</surname><given-names>AS</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Wadler</surname><given-names>S</given-names></name><name><surname>Streicher</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III</article-title>. <source>Gynecol Oncol</source>. (<year>2007</year>) <volume>106</volume>:<fpage>453</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.04.038</pub-id><?supplied-pmid 17586030?><pub-id pub-id-type="pmid">17586030</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carifi</surname><given-names>M</given-names></name><name><surname>Napolitano</surname><given-names>D</given-names></name><name><surname>Morandi</surname><given-names>M</given-names></name><name><surname>Dall'Olio</surname><given-names>D</given-names></name></person-group>. <article-title>Recurrent respiratory papillomatosis: current and future perspectives</article-title>. <source>Ther. Clin. RiskManag.</source> (<year>2015</year>) <volume>11</volume>:<fpage>731</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S81825</pub-id><?supplied-pmid 25999724?><pub-id pub-id-type="pmid">25999724</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawana</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Kozuma</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name></person-group>. <article-title>Therapeutic human papillomavirus (HPV) vaccines: a novel approach</article-title>. <source>Open Virol J</source>. (<year>2012</year>) <volume>6</volume>:<fpage>264</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2174/1874357901206010264</pub-id><?supplied-pmid 23341862?><pub-id pub-id-type="pmid">23341862</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquerr&#x000e9;</surname><given-names>M</given-names></name><name><surname>Momot</surname><given-names>M</given-names></name><name><surname>Goubier</surname><given-names>A</given-names></name><name><surname>Misseri</surname><given-names>Y</given-names></name><name><surname>Bissery</surname><given-names>MC</given-names></name></person-group>
<article-title>Bivalent adenylate cyclase (CYA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time</article-title>. <source>Cancer Res.</source> (<year>2015</year>) <volume>75</volume>(<issue>15 Supplement</issue>), <fpage>2507</fpage>&#x02013;<lpage>07</lpage>. <pub-id pub-id-type="doi">10.1158/1538-7445.AM2015-2507</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedmann</surname><given-names>EM</given-names></name></person-group>. <article-title>Two therapeutic HPV vaccine candidates successful in phase 1</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2012</year>) <volume>8</volume>:<fpage>1741</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.4161/hv.23373</pub-id><?supplied-pmid 23817319?><pub-id pub-id-type="pmid">23817319</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TY</given-names></name><name><surname>Hussein</surname><given-names>WM</given-names></name><name><surname>Toth</surname><given-names>I</given-names></name><name><surname>Skwarczynski</surname><given-names>M</given-names></name></person-group>. <article-title>Advances in peptide-based human papillomavirus therapeutic vaccines</article-title>. <source>Curr Top Med Chem</source>. (<year>2012</year>) <volume>12</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.2174/156802612802652402</pub-id><?supplied-pmid 22827526?><pub-id pub-id-type="pmid">22393562</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vos van Steenwijk</surname><given-names>PJ</given-names></name><name><surname>Ramwadhdoebe</surname><given-names>TH</given-names></name><name><surname>L&#x000f6;wik</surname><given-names>MJ</given-names></name><name><surname>van der Minne</surname><given-names>CE</given-names></name><name><surname>Berends-van der Meer</surname><given-names>DM</given-names></name><name><surname>Fathers</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions</article-title>. <source>Cancer Immunol Immunotherapy</source> (<year>2012</year>) <volume>61</volume>:<fpage>1485</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-012-1292-7</pub-id><?supplied-pmid 22684521?><pub-id pub-id-type="pmid">22684521</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenter</surname><given-names>GG</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><name><surname>Valentijn</surname><given-names>AR</given-names></name><name><surname>Lowik</surname><given-names>MJ</given-names></name><name><surname>Berends-van der Meer</surname><given-names>DM</given-names></name><name><surname>Vloon</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia</article-title>. <source>N.Engl.J. Med</source>. (<year>2009</year>) <volume>361</volume>:<fpage>1838</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0810097</pub-id><?supplied-pmid 19890126?><pub-id pub-id-type="pmid">19890126</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Poelgeest</surname><given-names>MI</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><name><surname>van Esch</surname><given-names>EM</given-names></name><name><surname>Stynenbosch</surname><given-names>LFM</given-names></name><name><surname>Kerpershoek</surname><given-names>G</given-names></name><name><surname>van Persijn van Meerten</surname><given-names>EL</given-names></name><etal/></person-group>. <article-title>HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial</article-title>. <source>J. Transl.Med</source>. (<year>2013</year>) <volume>11</volume>:<fpage>88</fpage>. <pub-id pub-id-type="doi">10.1186/1479-5876-11-88</pub-id><?supplied-pmid 23557172?><pub-id pub-id-type="pmid">23557172</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solares</surname><given-names>AM</given-names></name><name><surname>Baladron</surname><given-names>I</given-names></name><name><surname>Ramos</surname><given-names>T</given-names></name><name><surname>Valenzuela</surname><given-names>C</given-names></name><name><surname>Borbon</surname><given-names>Z</given-names></name><name><surname>Fanjull</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial</article-title>. <source>ISRN Obstet. Gynecol.</source> (<year>2011</year>) <volume>2011</volume>:<fpage>292951</fpage>. <pub-id pub-id-type="doi">10.5402/2011/292951</pub-id><?supplied-pmid 21748025?><pub-id pub-id-type="pmid">21748025</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nezafat</surname><given-names>N</given-names></name><name><surname>Ghasemi</surname><given-names>Y</given-names></name><name><surname>Javadi</surname><given-names>G</given-names></name><name><surname>Khoshnoud</surname><given-names>MJ</given-names></name><name><surname>Omidinia</surname><given-names>E</given-names></name></person-group>. <article-title>A novel multi-epitope peptide vaccine against cancer: an <italic>in silico</italic> approach</article-title>. <source>J Theor Biol</source>. (<year>2014</year>) <volume>349</volume>:<fpage>121</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2014.01.018</pub-id><?supplied-pmid 24512916?><pub-id pub-id-type="pmid">24512916</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrios</surname><given-names>K</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name></person-group>. <article-title>TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers</article-title>. <source>Cancer Immunol Immunother.</source> (<year>2012</year>) <volume>61</volume>:<fpage>1307</fpage>&#x02013;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-012-1259-8</pub-id><?supplied-pmid 22527249?><pub-id pub-id-type="pmid">22527249</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria-Guerra</surname><given-names>RE</given-names></name><name><surname>Nieto-Gomez</surname><given-names>R</given-names></name><name><surname>Govea-Alonso</surname><given-names>DO</given-names></name><name><surname>Rosales-Mendoza</surname><given-names>S</given-names></name></person-group>. <article-title>An overview of bioinformatics tools for epitope prediction: implications on vaccine development</article-title>. <source>J Biomed Inform</source>. (<year>2015</year>) <volume>53</volume>:<fpage>405</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbi.2014.11.003</pub-id><?supplied-pmid 25464113?><pub-id pub-id-type="pmid">25464113</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanda</surname><given-names>SK</given-names></name><name><surname>Usmani</surname><given-names>SS</given-names></name><name><surname>Agrawal</surname><given-names>P</given-names></name><name><surname>Nagpal</surname><given-names>G</given-names></name><name><surname>Gautam</surname><given-names>A</given-names></name><name><surname>Raghava</surname><given-names>GP</given-names></name></person-group>. <article-title>Novel <italic>in silico</italic> tools for designing peptide-based subunit vaccines and immunotherapeutics</article-title>. <source>Brief Bioinform</source>. (<year>2016</year>) <volume>18</volume>:<fpage>467</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbw025</pub-id><?supplied-pmid 27016393?><pub-id pub-id-type="pmid">27016393</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackwood</surname><given-names>MW</given-names></name><name><surname>Hickle</surname><given-names>L</given-names></name><name><surname>Kapil</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name></person-group>
<article-title>Vaccine development using recombinant DNA technology</article-title>. <source>Council Agric Sci Technol</source>. (<year>2008</year>) <volume>38</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backert</surname><given-names>L</given-names></name><name><surname>Kohlbacher</surname><given-names>O</given-names></name></person-group>. <article-title>Immunoinformatics and epitope prediction in the age of genomic medicine</article-title>. <source>Genome Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>119</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-015-0245-0</pub-id><?supplied-pmid 26589500?><pub-id pub-id-type="pmid">26589500</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name></person-group>. <article-title>Databases and <italic>in silico</italic> tools for vaccine design</article-title>. In: <person-group person-group-type="editor"><name><surname>Kortagere</surname><given-names>S</given-names></name></person-group>, editor. <source>In Silico Models for Drug Discovery. Methods in Molecular Biology (Methods and Protocols), Vol. 993</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana Press</publisher-name> (<year>2013</year>). p. <fpage>115</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-342-8_8</pub-id><?supplied-pmid 23568467?></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>Das</surname><given-names>BC</given-names></name><etal/></person-group>. <article-title>Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: <italic>in-silico</italic> and <italic>in-vivo</italic> insight to vaccine development</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>15751</fpage>. <pub-id pub-id-type="doi">10.1038/srep15751</pub-id><?supplied-pmid 26507515?><pub-id pub-id-type="pmid">26507515</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>S</given-names></name><name><surname>Shrivastav</surname><given-names>VK</given-names></name><name><surname>Shrivastav</surname><given-names>A</given-names></name><name><surname>Jana</surname><given-names>AM</given-names></name></person-group>
<article-title><italic>In silico</italic> vaccine design against the target L1 binding protein of human papillomavirus, an etiological agent of cervical cancer, using bioinformatics tools</article-title>. <source>Int J Pharm Sci Res</source>. (<year>2013</year>) <volume>42</volume>:<fpage>4758</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.13040/IJPSR.0975-8232.4(10).4758-62</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cun</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an <italic>in silico</italic> approach</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<fpage>2289</fpage>&#x02013;<lpage>2294</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.02.065</pub-id><?supplied-pmid 23499609?><pub-id pub-id-type="pmid">23499609</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>LMF</given-names></name><name><surname>Morale</surname><given-names>MG</given-names></name><name><surname>Chaves</surname><given-names>AAM</given-names></name><name><surname>Cavalher</surname><given-names>AM</given-names></name><name><surname>Lopes</surname><given-names>AS</given-names></name><name><surname>de Oliveira Diniz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine</article-title>. <source>PLoS ONE</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0138686</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0138686</pub-id><?supplied-pmid 26390407?><pub-id pub-id-type="pmid">26390407</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keskin</surname><given-names>DB</given-names></name><name><surname>Reinhold</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Lank</surname><given-names>S</given-names></name><name><surname>O'Connor</surname><given-names>D</given-names></name><etal/></person-group> (<year>2011</year>). Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. <source>Front Immunol.</source>
<volume>13</volume>:<fpage>75</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2011.00075</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baidya</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Kabir</surname><given-names>MG</given-names></name><name><surname>Arifuzzaman</surname><given-names>M</given-names></name></person-group>. <article-title>Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18</article-title>. <source>Bioinformation</source> (<year>2017</year>) <volume>13</volume>:<fpage>86</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.6026/97320630013086</pub-id><?supplied-pmid 28584449?><pub-id pub-id-type="pmid">28584449</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuck</surname><given-names>D</given-names></name><name><surname>Lau</surname><given-names>T</given-names></name><name><surname>Leuchs</surname><given-names>B</given-names></name><name><surname>Kern</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1</article-title>. <source>J Virol</source>. (<year>2006</year>) <volume>80</volume>:<fpage>2621</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.80.6.2621-2630.2006</pub-id><?supplied-pmid 16501072?><pub-id pub-id-type="pmid">16501072</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>K</given-names></name><name><surname>Salvetti</surname><given-names>A</given-names></name></person-group>
<article-title>AAV vector vaccines against infectious diseases</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<fpage>5</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00005</pub-id><pub-id pub-id-type="pmid">24478774</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>K</given-names></name><name><surname>Stahl-Hennig</surname><given-names>C</given-names></name><name><surname>Leuchs</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>Kleinschmidt</surname><given-names>JA</given-names></name></person-group>. <article-title>Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques</article-title>. Hum. <source>Gene Ther.</source> (<year>2012</year>) <volume>23</volume>:<fpage>733</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2011.202</pub-id><?supplied-pmid 22401308?><pub-id pub-id-type="pmid">22401308</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieking</surname><given-names>BG</given-names></name><name><surname>Vermeer</surname><given-names>DW</given-names></name><name><surname>Spanos</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Vermeer</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>WT</given-names></name><etal/></person-group>. <article-title>A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors</article-title>. <source>Cancer Gene Ther</source>. (<year>2012</year>) <volume>19</volume>:<fpage>667</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/cgt.2012.55</pub-id><?supplied-pmid 22918471?><pub-id pub-id-type="pmid">22918471</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuniga</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liniger</surname><given-names>M</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name><name><surname>Caballero</surname><given-names>M</given-names></name><name><surname>Pavlovic</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Attenuated measles virus as a vaccine vector</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<fpage>2974</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.064</pub-id><?supplied-pmid 17303293?><pub-id pub-id-type="pmid">17303293</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantarella</surname><given-names>G</given-names></name><name><surname>Liniger</surname><given-names>M</given-names></name><name><surname>Zuniga</surname><given-names>A</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Billeter</surname><given-names>M</given-names></name><name><surname>Naim</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<fpage>3385</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.061</pub-id><?supplied-pmid 19200837?><pub-id pub-id-type="pmid">19200837</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Giannino</surname><given-names>V</given-names></name><name><surname>Rishi</surname><given-names>N</given-names></name><name><surname>Glueck</surname><given-names>R</given-names></name></person-group>. <article-title>Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus <italic>Pichia pastoris</italic> recombinant protein vaccine</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<fpage>4724</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.07.051</pub-id><?supplied-pmid 27523740?><pub-id pub-id-type="pmid">27523740</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendiretta</surname><given-names>SK</given-names></name><name><surname>Glueck</surname><given-names>R</given-names></name><name><surname>Giannino</surname><given-names>V</given-names></name><name><surname>Cantarella</surname><given-names>G</given-names></name><name><surname>Scuderi</surname><given-names>F</given-names></name><name><surname>Billeter</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Combined measles-human papilloma vaccine</article-title>. US 9623098 B2 (<year>2017</year>).</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>VV</given-names></name><name><surname>Sutter</surname><given-names>G</given-names></name><name><surname>Jos</surname><given-names>&#x000e9;MV</given-names></name><name><surname>Garc&#x000ed;a-Carranca</surname><given-names>A</given-names></name><name><surname>Erfle</surname><given-names>V</given-names></name><name><surname>Mendoza</surname><given-names>NM</given-names></name><etal/></person-group>
<article-title>Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus</article-title>. <source>Cancer</source> (<year>2000</year>) <volume>88</volume>:<fpage>1650</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(20000401)88:7&#x0003c;1650::AID-CNCR20&#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">10738224</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Hernandez</surname><given-names>E</given-names></name><name><surname>Gonzalez-Sanchez</surname><given-names>JL</given-names></name><name><surname>Andrade-Manzano</surname><given-names>A</given-names></name><name><surname>Contreras</surname><given-names>ML</given-names></name><name><surname>Padilla</surname><given-names>S</given-names></name><name><surname>Guzman</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine</article-title>. <source>Cancer Gene Ther.</source> (<year>2006</year>) <volume>13</volume>:<fpage>592</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cgt.7700937</pub-id><?supplied-pmid 16456551?><pub-id pub-id-type="pmid">16456551</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayereh</surname><given-names>KG</given-names></name><name><surname>Khadem</surname><given-names>G</given-names></name></person-group>. <article-title>Preventive and therapeutic vaccines against human papillomaviruses associated cervical cancers</article-title>. <source>Iran J Basic Med Sci</source>. (<year>2012</year>) <volume>15</volume>:<fpage>585</fpage>&#x02013;<lpage>601</lpage>. <?supplied-pmid 23493151?><pub-id pub-id-type="pmid">23493151</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corona Gutierrez</surname><given-names>CM</given-names></name><name><surname>Tinoco</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>T</given-names></name><name><surname>Contreras</surname><given-names>ML</given-names></name><name><surname>Cortes</surname><given-names>RR</given-names></name><name><surname>Calzado</surname><given-names>P</given-names></name><etal/></person-group> (<year>2004</year>). Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. <source>Hum Gene Ther.</source>
<volume>15</volume>:<fpage>421</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1089/10430340460745757</pub-id><pub-id pub-id-type="pmid">15144573</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albarran</surname><given-names>AC</given-names></name><name><surname>de la Garza</surname><given-names>A</given-names></name><name><surname>Quiroz</surname><given-names>BJCC</given-names></name><name><surname>Zea</surname><given-names>EV</given-names></name><name><surname>Estrada</surname><given-names>ID</given-names></name><name><surname>Fuentez</surname><given-names>EM</given-names></name><etal/></person-group>
<article-title>MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study</article-title>. <source>Bio. Drugs</source> (<year>2007</year>) <volume>21</volume>:<fpage>47</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.2165/00063030-200721010-00006</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Borysiewicz</surname><given-names>L</given-names></name><name><surname>Fiander</surname><given-names>A</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Jasani</surname><given-names>B</given-names></name><name><surname>Navabi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer</article-title>. <source>Vaccine</source> (<year>2001</year>) <volume>19</volume>:<fpage>2549</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(00)00488-6</pub-id><?supplied-pmid 11257391?><pub-id pub-id-type="pmid">11257391</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>AM</given-names></name><name><surname>Stern</surname><given-names>PL</given-names></name><name><surname>Rankin</surname><given-names>EM</given-names></name><name><surname>Sommer</surname><given-names>H</given-names></name><name><surname>Nuessler</surname><given-names>V</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer</article-title>. <source>Clin Cancer Res.</source> (<year>2002</year>) <volume>8</volume>:<fpage>3676</fpage>&#x02013;<lpage>85</lpage>. <?supplied-pmid 12473576?><pub-id pub-id-type="pmid">12473576</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>PJ</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Boswell</surname><given-names>CM</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Hickling</surname><given-names>JK</given-names></name><name><surname>Dobson</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia</article-title>. <source>Clin Cancer Res</source>. (<year>2003</year>) <volume>9</volume>:<fpage>5205</fpage>&#x02013;<lpage>13</lpage>. <?supplied-pmid 14614000?><pub-id pub-id-type="pmid">14614000</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>EJ</given-names></name><name><surname>Faulkner</surname><given-names>RL</given-names></name><name><surname>Sehr</surname><given-names>P</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>LJ</given-names></name><name><surname>Burt</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Effect of TA-CIN (HPV 16 L2E6E7) booster immunization in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)</article-title>. <source>Vaccine</source> (<year>2004</year>) <volume>22</volume>:<fpage>2722</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.049</pub-id><pub-id pub-id-type="pmid">15246603</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosales</surname><given-names>C</given-names></name><name><surname>Graham</surname><given-names>VV</given-names></name><name><surname>Rosas</surname><given-names>GA</given-names></name><name><surname>Merchant</surname><given-names>H</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name></person-group>. <article-title>A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2000</year>) <volume>49</volume>:<fpage>347</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s002620000125</pub-id><?supplied-pmid 10999461?><pub-id pub-id-type="pmid">10999461</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Lopez-Contreras</surname><given-names>M</given-names></name><name><surname>Rosales</surname><given-names>C</given-names></name><name><surname>Magallanes-Molina</surname><given-names>JR</given-names></name><name><surname>Gonzalez-Vergara</surname><given-names>R</given-names></name><name><surname>Arroyo-Cazarez</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine</article-title>. <source>HumGene Ther</source>. (<year>2014</year>) <volume>25</volume>:<fpage>1035</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2014.024</pub-id><?supplied-pmid 25275724?><pub-id pub-id-type="pmid">25275724</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>JL</given-names></name><name><surname>Dalstein</surname><given-names>V</given-names></name><name><surname>Leveque</surname><given-names>J</given-names></name><name><surname>Mathevet</surname><given-names>P</given-names></name><name><surname>Raulic</surname><given-names>P</given-names></name><name><surname>Baldauf</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy</article-title>. <source>Am J Obstetr Gynecol.</source> (<year>2011</year>) <volume>204</volume>:<fpage>169e161</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2010.09.020</pub-id><?supplied-pmid 21284968?><pub-id pub-id-type="pmid">21284968</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciag</surname><given-names>PC</given-names></name><name><surname>Radulovic</surname><given-names>S</given-names></name><name><surname>Rothman</surname><given-names>J</given-names></name></person-group>. <article-title>The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<fpage>3975</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.041</pub-id><?supplied-pmid 19389451?><pub-id pub-id-type="pmid">19389451</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>GR</given-names></name><name><surname>Zubair</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>ZK</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Paterson</surname><given-names>Y</given-names></name></person-group>. <article-title>Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16</article-title>. <source>J Immunol.</source> (<year>2001</year>) <volume>167</volume>:<fpage>6471</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.167.11.6471</pub-id><?supplied-pmid 11714814?><pub-id pub-id-type="pmid">11714814</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cory</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>C</given-names></name></person-group>. <article-title>ADXS-HPV: a therapeutic <italic>Listeria</italic> vaccination targeting cervical cancers expressing the HPV E7 antigen</article-title>. <source>Hum. Vaccin. Immunother.</source> (<year>2014</year>) <volume>10</volume>:<fpage>3190</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4161/hv.34378</pub-id><?supplied-pmid 25483687?><pub-id pub-id-type="pmid">25483687</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Trimble</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Yeatermeyer</surname><given-names>J</given-names></name><etal/></person-group> (<year>2004</year>). Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. <source>J Virol.</source>
<volume>78</volume>:<fpage>8468</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.78.16.8468-8476.2004</pub-id><pub-id pub-id-type="pmid">15280455</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>V</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group>. <article-title>Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach</article-title>. <source>J Gastrointest Cancer.</source> (<year>2016</year>) <volume>7</volume>:<fpage>721</fpage>. <pub-id pub-id-type="doi">10.21037/jgo.2016.08.03</pub-id><?supplied-pmid 27747086?><pub-id pub-id-type="pmid">27747086</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawana</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Tomio</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><etal/></person-group> (<year>2014</year>). Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. <source>Vaccine</source>
<volume>32</volume>:<fpage>6233</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.09.020</pub-id><pub-id pub-id-type="pmid">25258102</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Hung</surname><given-names>CF</given-names></name></person-group>. <article-title>Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research</article-title>. <source>Gynecol Oncol</source>. (<year>2016</year>) <volume>27</volume>:<fpage>e51</fpage>. <pub-id pub-id-type="doi">10.3802/jgo.2016.27.e51</pub-id><?supplied-pmid 27329199?><pub-id pub-id-type="pmid">27329199</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasagawa</surname><given-names>T</given-names></name><name><surname>Tani</surname><given-names>M</given-names></name><name><surname>Basha</surname><given-names>W</given-names></name><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>Tohda</surname><given-names>H</given-names></name><name><surname>Giga-Hama</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A human papillomavirus type 16 vaccine by oral delivery of L1 protein</article-title>. <source>Virus Res</source>. (<year>2005</year>) <volume>110</volume>:<fpage>81</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2005.02.001</pub-id><?supplied-pmid 15845258?><pub-id pub-id-type="pmid">15845258</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirnbauer</surname><given-names>R</given-names></name><name><surname>Booy</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name></person-group>. <article-title>Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic</article-title>. <source>Proc Natl Acad Sci. USA</source>. (<year>1992</year>) <volume>89</volume>:<fpage>12180</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.24.12180</pub-id><?supplied-pmid 1334560?><pub-id pub-id-type="pmid">1334560</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname><given-names>SB</given-names></name><name><surname>de Alencar Muniz Chaves</surname><given-names>A</given-names></name><name><surname>Aires</surname><given-names>KA</given-names></name><name><surname>Cianciarullo</surname><given-names>AM</given-names></name><name><surname>Garcea</surname><given-names>RL</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name></person-group>. <article-title>Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris</article-title>. <source>Arch Virol</source>. (<year>2009</year>) <volume>154</volume>:<fpage>1609</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-009-0484-8</pub-id><?supplied-pmid 19756360?><pub-id pub-id-type="pmid">19756360</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JW</given-names></name><name><surname>Roden</surname><given-names>RB</given-names></name></person-group>. <article-title>Virus-like particles for the prevention of human papillomavirus-associated malignancies</article-title>. <source>Expert Rev Vaccine</source>. (<year>2013</year>) <volume>12</volume>:<fpage>129</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1586/erv.12.151</pub-id><?supplied-pmid 23414405?><pub-id pub-id-type="pmid">23414405</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>M</given-names></name></person-group>. <article-title>HPV &#x02013; immune response to infection and vaccination</article-title>. <source>Infect Agent Cancer</source>. (<year>2010</year>) <volume>5</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/1750-9378-5-19</pub-id><?supplied-pmid 20961432?><pub-id pub-id-type="pmid">20961432</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dochez</surname><given-names>C</given-names></name><name><surname>Bogers</surname><given-names>JJ</given-names></name><name><surname>Verhelst</surname><given-names>R</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name></person-group>. <article-title>HPV vaccines to prevent cervical cancer and genital warts: an update</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>:<fpage>1595</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.081</pub-id><?supplied-pmid 24606637?><pub-id pub-id-type="pmid">24606637</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Demars</surname><given-names>LR</given-names></name></person-group>. <article-title>Primary strategies for HPV infection and cervical cancer prevention</article-title>. <source>Clin Obstet Gynecol</source>. (<year>2014</year>) <volume>57</volume>:<fpage>256</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1097/GRF.0000000000000027</pub-id><?supplied-pmid 24686336?><pub-id pub-id-type="pmid">24686336</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>XY</given-names></name><name><surname>Stenzel</surname><given-names>DJ</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name></person-group>. <article-title>Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles</article-title>. <source>Virology</source> (<year>1991</year>) <volume>185</volume>:<fpage>251</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 1656586?><pub-id pub-id-type="pmid">1656586</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagu</surname><given-names>S</given-names></name><name><surname>Karanam</surname><given-names>B</given-names></name><name><surname>Gambhira</surname><given-names>R</given-names></name><name><surname>Chivukula</surname><given-names>SV</given-names></name><name><surname>Chaganti</surname><given-names>RJ</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines</article-title>. <source>J Natl Cancer Inst</source>. (<year>2009</year>) <volume>101</volume>:<fpage>782</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djp106</pub-id><?supplied-pmid 19470949?><pub-id pub-id-type="pmid">19470949</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Ault</surname><given-names>KA</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><name><surname>Costa</surname><given-names>RL</given-names></name><name><surname>Petta</surname><given-names>CA</given-names></name><name><surname>Andrade</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>5571</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.068</pub-id><?supplied-pmid 16753240?><pub-id pub-id-type="pmid">16753240</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Costa</surname><given-names>RL</given-names></name><name><surname>Petta</surname><given-names>CA</given-names></name><name><surname>Andrade</surname><given-names>RP</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Iversen</surname><given-names>OE</given-names></name><etal/></person-group>. <article-title>High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up</article-title>. <source>Br J Cancer</source> (<year>2006</year>) <volume>95</volume>:<fpage>1459</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6603469</pub-id><?supplied-pmid 17117182?><pub-id pub-id-type="pmid">17117182</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraillery</surname><given-names>D</given-names></name><name><surname>Baud</surname><given-names>D</given-names></name><name><surname>Pang</surname><given-names>SYY</given-names></name><name><surname>Schiller</surname><given-names>J</given-names></name><name><surname>Bobst</surname><given-names>M</given-names></name><name><surname>Zosso</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever</article-title>. <source>Clin Vaccine Immunol</source>. (<year>2007</year>) <volume>14</volume>:<fpage>1285</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00164-07</pub-id><?supplied-pmid 17687110?><pub-id pub-id-type="pmid">17687110</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>L</given-names></name></person-group>. <article-title>Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model</article-title>. <source>Acta Biochim Biophys Sin.</source> (<year>2009</year>) <volume>41</volume>:<fpage>137</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmn016</pub-id><?supplied-pmid 19204831?><pub-id pub-id-type="pmid">19204831</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name></person-group>. <article-title>HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2014</year>) <volume>10</volume>:<fpage>3491</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4161/hv.36084</pub-id><?supplied-pmid 25483698?><pub-id pub-id-type="pmid">25483698</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes-Perez</surname><given-names>NG</given-names></name><name><surname>Kharrat</surname><given-names>P</given-names></name><name><surname>Langella</surname><given-names>P</given-names></name><name><surname>Berm&#x000fa;dez-Humar&#x000e1;n</surname><given-names>LG</given-names></name></person-group>. <article-title>Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium</article-title>. <source>BMC Res Notes</source> (<year>2009</year>) <volume>2</volume>:<fpage>1</fpage>. <pub-id pub-id-type="doi">10.1186/1756-0500-2-167</pub-id><?supplied-pmid 19703307?><pub-id pub-id-type="pmid">19121226</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdoli</surname><given-names>A</given-names></name><name><surname>Soleimanjahi</surname><given-names>H</given-names></name><name><surname>Fotouhi</surname><given-names>F</given-names></name><name><surname>Pour Beiranvand</surname><given-names>S</given-names></name><name><surname>Kianmehr</surname><given-names>Z</given-names></name></person-group>. <article-title>Human papillomavirus type16-L1 VLP production in insect cells</article-title>. <source>Iran J Basic Med Sci</source>. (<year>2013</year>) <volume>16</volume>:<fpage>891</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 24106591?><pub-id pub-id-type="pmid">24106591</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senger</surname><given-names>T</given-names></name><name><surname>Sch&#x000e4;dlich</surname><given-names>L</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name></person-group>. <article-title>Enhanced papillomavirus-like particle production in insect cells</article-title>. <source>Virology</source> (<year>2009</year>) <volume>388</volume>:<fpage>344</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.04.004</pub-id><?supplied-pmid 19409593?><pub-id pub-id-type="pmid">19409593</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>KJ</given-names></name><name><surname>Cook</surname><given-names>JC</given-names></name><name><surname>Joyce</surname><given-names>JG</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Schultz</surname><given-names>LD</given-names></name><name><surname>George</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae</article-title>. <source>Virology</source> (<year>1995</year>) <volume>209</volume>:<fpage>506</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1995.1283</pub-id><?supplied-pmid 7778283?><pub-id pub-id-type="pmid">7778283</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>White</surname><given-names>WI</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Suzich</surname><given-names>JA</given-names></name><name><surname>Lane</surname><given-names>C</given-names></name><name><surname>Garcea</surname><given-names>RL</given-names></name></person-group>. <article-title>Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies</article-title>. <source>J Virol</source>. (<year>1998</year>) <volume>72</volume>:<fpage>6151</fpage>&#x02013;<lpage>4</lpage>. <?supplied-pmid 9621080?><pub-id pub-id-type="pmid">9621080</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaer</surname><given-names>SK</given-names></name><name><surname>Sigurdsson</surname><given-names>K</given-names></name><name><surname>Iversen</surname><given-names>OE</given-names></name><name><surname>Hernandez-Avila</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Perez</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions</article-title>. <source>Cancer Prev Res (Phila.)</source> (<year>2009</year>) <volume>2</volume>:<fpage>868</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-09-0031</pub-id><?supplied-pmid 19789295?><pub-id pub-id-type="pmid">19789295</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mello</surname><given-names>CF</given-names></name></person-group>. <article-title>Vaccination against human papillomavirus</article-title>. <source>Einstein (Sau Paulo)</source> (<year>2013</year>) <volume>11</volume>:<fpage>547</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1590/S1679-45082013000400027</pub-id><?supplied-pmid 24488402?><pub-id pub-id-type="pmid">24488402</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>JC</given-names></name><name><surname>Joyce</surname><given-names>JG</given-names></name><name><surname>George</surname><given-names>HA</given-names></name><name><surname>Schultz</surname><given-names>LD</given-names></name><name><surname>Hurni</surname><given-names>WM</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><etal/></person-group>. <article-title>Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from <italic>Saccharomyces cerevisiae</italic></article-title>. <source>Protein Expr Purif</source>. (<year>1999</year>) <volume>17</volume>:<fpage>477</fpage>&#x02013;<lpage>84</lpage>. <?supplied-pmid 10600468?><pub-id pub-id-type="pmid">10600468</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwag</surname><given-names>HL</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Chang</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group>. <article-title>The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae</article-title>. <source>J Microbiol</source>. (<year>2012</year>) <volume>50</volume>:<fpage>813</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-012-2292-1</pub-id><?supplied-pmid 23124750?><pub-id pub-id-type="pmid">23124750</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2014</year>) <volume>10</volume>:<fpage>469</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.4161/hv.26846</pub-id><?supplied-pmid 24161937?><pub-id pub-id-type="pmid">24161937</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>. <article-title>Fusion of HPV L1 into <italic>Shigella</italic> surface IcsA: a new approach in developing live attenuated <italic>Shigella</italic>-HPV vaccine</article-title>. <source>Antivir Res</source>. (<year>2014</year>) <volume>102</volume>:<fpage>61</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.12.003</pub-id><?supplied-pmid 24333518?><pub-id pub-id-type="pmid">24333518</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group>. <article-title>Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles</article-title>. <source>J Med. Microbiol</source>. (<year>2007</year>) <volume>56</volume>:<fpage>907</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.47073-0</pub-id><?supplied-pmid 17577054?><pub-id pub-id-type="pmid">17577054</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineo</surname><given-names>CB</given-names></name><name><surname>Hitzeroth</surname><given-names>II</given-names></name><name><surname>Rybicki</surname><given-names>EP</given-names></name></person-group>. <article-title>Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras</article-title>. <source>Plant Biotechnol J</source>. (<year>2013</year>) <volume>11</volume>:<fpage>964</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/pbi.12089</pub-id><?supplied-pmid 23924054?><pub-id pub-id-type="pmid">23924054</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumban</surname><given-names>E</given-names></name><name><surname>Peabody</surname><given-names>J</given-names></name><name><surname>Peabody</surname><given-names>DS</given-names></name><name><surname>Chackerian</surname><given-names>B</given-names></name></person-group>. <article-title>A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<fpage>4647</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.052</pub-id><?supplied-pmid 23933337?><pub-id pub-id-type="pmid">23933337</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>RT</given-names></name><name><surname>Schellenbacher</surname><given-names>C</given-names></name><name><surname>Chackerian</surname><given-names>B</given-names></name><name><surname>Roden</surname><given-names>RB</given-names></name></person-group>. <article-title>Progress and prospects for L2-based human papillomavirus vaccines</article-title>. <source>Expert Rev. Vaccines</source> (<year>2016</year>) <volume>15</volume>:<fpage>853</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2016.1157479</pub-id><?supplied-pmid 26901354?><pub-id pub-id-type="pmid">26901354</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyler</surname><given-names>M</given-names></name><name><surname>Tumban</surname><given-names>E</given-names></name><name><surname>Chackerian</surname><given-names>B</given-names></name></person-group>. <article-title>Second-generation prophylactic HPV vaccines: successes and challenges</article-title>. <source>Expert Rev Vaccine</source>. (<year>2014</year>) <volume>13</volume>:<fpage>247</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2014.865523</pub-id><?supplied-pmid 24350614?><pub-id pub-id-type="pmid">24350614</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boxus</surname><given-names>M</given-names></name><name><surname>Fochesato</surname><given-names>M</given-names></name><name><surname>Miseur</surname><given-names>A</given-names></name><name><surname>Mertens</surname><given-names>E</given-names></name><name><surname>Dendouga</surname><given-names>N</given-names></name><name><surname>Brendle</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Broad cross protection is induced by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles in preclinical models</article-title>. <source>J Virol</source>. (<year>2016</year>) <volume>90</volume>:<fpage>6314</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00449-16</pub-id><?supplied-pmid 27147749?><pub-id pub-id-type="pmid">27147749</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000e4;dlich</surname><given-names>L</given-names></name><name><surname>Senger</surname><given-names>T</given-names></name><name><surname>Gerlach</surname><given-names>B</given-names></name><name><surname>M&#x000fc;cke</surname><given-names>N</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Bravo</surname><given-names>IG</given-names></name><etal/></person-group>. <article-title>Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity</article-title>. <source>J Virol</source>. (<year>2009</year>) <volume>83</volume>:<fpage>7690</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02588-08</pub-id><?supplied-pmid 19457985?><pub-id pub-id-type="pmid">19457985</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>SW</given-names></name><name><surname>Waheed</surname><given-names>MT</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>JL</given-names></name><name><surname>Shinwari</surname><given-names>ZK</given-names></name><name><surname>L&#x000f6;ssl</surname><given-names>AG</given-names></name></person-group>. <article-title>Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2014</year>) <volume>10</volume>:<fpage>2975</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.4161/21645515.2014.970973</pub-id><?supplied-pmid 25483463?><pub-id pub-id-type="pmid">25483463</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schellenbacher</surname><given-names>C</given-names></name><name><surname>Roden</surname><given-names>RBS</given-names></name><name><surname>Kirnbauer</surname><given-names>R</given-names></name></person-group>
<article-title>Developments in L2-based human papilloma virus (HPV) vaccines</article-title>. <source>Virus Res</source>. (<year>2017</year>) <volume>231</volume>:<fpage>166</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.020</pub-id><pub-id pub-id-type="pmid">27889616</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro</surname><given-names>MN</given-names></name><name><surname>Paolini</surname><given-names>F</given-names></name><name><surname>Massa</surname><given-names>S</given-names></name><name><surname>Curzio</surname><given-names>G</given-names></name><name><surname>Illiano</surname><given-names>E</given-names></name><name><surname>Duarte Silva</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Anti-tumor effects of genetic vaccines against HPV major oncogenes</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2015</year>) <volume>11</volume>:<fpage>45</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.4161/hv.34303</pub-id><?supplied-pmid 25483514?><pub-id pub-id-type="pmid">25483514</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name></person-group>. <article-title>Raising expectations for subunit vaccine</article-title>. <source>J Infect Dis</source>. (<year>2015</year>) <volume>211</volume>:<fpage>1373</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu648</pub-id><?supplied-pmid 25420478?><pub-id pub-id-type="pmid">25420478</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>JJ</given-names></name><name><surname>Ulmer</surname><given-names>JB</given-names></name><name><surname>Shiver</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>MA</given-names></name></person-group>
<article-title>DNA vaccines</article-title>. <source>Annu Rev Immunol</source>. (<year>1997</year>) <volume>15</volume>:<fpage>617</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.15.1.617</pub-id><pub-id pub-id-type="pmid">9143702</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurunathan</surname><given-names>S</given-names></name><name><surname>Klinman</surname><given-names>DM</given-names></name><name><surname>Seder</surname><given-names>RA</given-names></name></person-group>. <article-title>DNA vaccines: immunology, application, and optimization</article-title>. <source>Annu Rev Immunol</source>. (<year>2000</year>) <volume>18</volume>:<fpage>927</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.927</pub-id><?supplied-pmid 10837079?><pub-id pub-id-type="pmid">10837079</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Mahendran</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>PK</given-names></name><name><surname>Rai</surname><given-names>A</given-names></name></person-group>. <article-title>DNA vaccines and their applications in veterinary practice: Current perspectives</article-title>. <source>Vet Res Commun</source>. (<year>2008</year>) <volume>32</volume>:<fpage>341</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s11259-008-9040-3</pub-id><?supplied-pmid 18425596?><pub-id pub-id-type="pmid">18425596</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>CF</given-names></name><name><surname>Monie</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name></person-group>
<article-title>DNA vaccines for cervical cancer: from bench to bed side</article-title>. <source>Exp Mol Med</source>. (<year>2007</year>) <volume>39</volume>:<fpage>679</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/emm.2007.74</pub-id><pub-id pub-id-type="pmid">18160838</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Salas</surname><given-names>LM</given-names></name></person-group>. <article-title>Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia</article-title>. <source>Curr Opin Mol Ther</source>. (<year>2008</year>) <volume>10</volume>:<fpage>622</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 19051140?><pub-id pub-id-type="pmid">19051140</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname><given-names>CL</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name></person-group>. <article-title>Development of therapeutic HPV vaccines</article-title>. <source>Lancet Oncol</source>. (<year>2009</year>) <volume>10</volume>:<fpage>975</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70227-X</pub-id><?supplied-pmid 19796749?><pub-id pub-id-type="pmid">19796749</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazeli</surname><given-names>M</given-names></name><name><surname>Soleimanjahi</surname><given-names>H</given-names></name><name><surname>Dadashzadeh</surname><given-names>S</given-names></name></person-group>. <article-title>Further stimulation of cellular immune responses through association of HPV-16 E6, E7 and L1 genes in order to produce more effective therapeutic DNA vaccines in cervical cancer model</article-title>. <source>Iran J Cancer Prev</source>. (<year>2015</year>) <volume>8</volume>:<fpage>18</fpage>. <?supplied-pmid 25821567?><pub-id pub-id-type="pmid">25821567</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrami</surname><given-names>AA</given-names></name><name><surname>Ghaemi</surname><given-names>A</given-names></name><name><surname>Tabarraei</surname><given-names>A</given-names></name><name><surname>Sajadian</surname><given-names>A</given-names></name><name><surname>Gorji</surname><given-names>A</given-names></name><name><surname>Soleimanjahi</surname><given-names>H</given-names></name></person-group>. <article-title>DNA vaccine encoding HPV-16 E7 with mutation in LYCYE pRb-binding motif induces potent anti-tumor responses in mice</article-title>. <source>J Virol Methods</source> (<year>2014</year>) <volume>206</volume>:<fpage>12</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2014.05.013</pub-id><?supplied-pmid 24880067?><pub-id pub-id-type="pmid">24880067</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarreal</surname><given-names>DO</given-names></name><name><surname>Wise</surname><given-names>MC</given-names></name><name><surname>Siefert</surname><given-names>RJ</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>LM</given-names></name><name><surname>Weiner</surname><given-names>DB</given-names></name></person-group>. <article-title>Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity</article-title>. <source>Mol Ther</source>. (<year>2015</year>) <volume>23</volume>:<fpage>1653</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2015.120</pub-id><?supplied-pmid 26122932?><pub-id pub-id-type="pmid">26122932</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Bouillette-Marussig</surname><given-names>M</given-names></name><name><surname>Hens</surname><given-names>A</given-names></name><name><surname>De Coster</surname><given-names>I</given-names></name><name><surname>Depuydt</surname><given-names>C</given-names></name><name><surname>Goubier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>GTL001, A therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: results of a phase I clinical trial</article-title>. <source>Clin Cancer Res</source>. (<year>2016</year>) <volume>22</volume>:<fpage>3238</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0085</pub-id><?supplied-pmid 27252412?><pub-id pub-id-type="pmid">27252412</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine</article-title>. <source>Oncol Rep</source>. (<year>2013</year>) <volume>30</volume>:<fpage>3020</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3892/or.2013.2742</pub-id><?supplied-pmid 24065282?><pub-id pub-id-type="pmid">24065282</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloy</surname><given-names>N</given-names></name><name><surname>Buqu&#x000e9;</surname><given-names>A</given-names></name><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Castoldi</surname><given-names>F</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Cremer</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Trial watch: naked and vectored DNA-based anticancer vaccines</article-title>. <source>Oncoimmunology</source> (<year>2015</year>) <volume>4</volume>:<fpage>e1026531</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2015.1026531</pub-id><?supplied-pmid 26155408?><pub-id pub-id-type="pmid">26155408</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagarazzi</surname><given-names>ML</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Morrow</surname><given-names>MP</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Parker</surname><given-names>RL</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses</article-title>. <source>Sci Transl Med</source>. (<year>2012</year>) <volume>4</volume>:<fpage>155ra138</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3004414</pub-id><?supplied-pmid 23052295?><pub-id pub-id-type="pmid">23052295</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname><given-names>CL</given-names></name><name><surname>Morrow</surname><given-names>MP</given-names></name><name><surname>Kraynyak</surname><given-names>KA</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Dallas</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial</article-title>. <source>Lancet</source> (<year>2015</year>) <volume>386</volume>:<fpage>2078</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00239-1</pub-id><?supplied-pmid 26386540?><pub-id pub-id-type="pmid">26386540</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Garcia</surname><given-names>P</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Trial watch: DNA vaccines for cancer therapy</article-title>. <source>Oncoimmunology</source> (<year>2013</year>) <volume>2</volume>:<fpage>e23803</fpage>. <pub-id pub-id-type="doi">10.4161/onci.23803</pub-id><?supplied-pmid 23734328?><pub-id pub-id-type="pmid">23734328</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fioretti</surname><given-names>D</given-names></name><name><surname>Iurescia</surname><given-names>S</given-names></name><name><surname>Rinaldi</surname><given-names>M</given-names></name></person-group>. <article-title>Recent advances in design of immunogenic and effective naked DNA vaccines against cancer</article-title>. <source>Recent Pat. Anticancer Drug Discov</source>. (<year>2014</year>) <volume>9</volume>:<fpage>66</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.2174/1574891X113089990037</pub-id><?supplied-pmid 23444943?><pub-id pub-id-type="pmid">23444943</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pol</surname><given-names>J</given-names></name><name><surname>Bloy</surname><given-names>N</given-names></name><name><surname>Obrist</surname><given-names>F</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Herve Fridman</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Trial watch: DNA vaccines for cancer therapy</article-title>. <source>Oncoimmunology</source> (<year>2014</year>) <volume>3</volume>:<fpage>e28185</fpage>. <pub-id pub-id-type="doi">10.4161/onci.28185</pub-id><?supplied-pmid 24800178?><pub-id pub-id-type="pmid">24800178</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colluru</surname><given-names>VT</given-names></name><name><surname>Johnson</surname><given-names>LE</given-names></name><name><surname>Olson</surname><given-names>BM</given-names></name><name><surname>McNeel</surname><given-names>DG</given-names></name></person-group>. <article-title>Preclinical and clinical development of DNA vaccines for prostate cancer</article-title>. <source>Urol Oncol</source>. (<year>2016</year>) <volume>34</volume>:<fpage>193</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.urolonc.2013.09.014</pub-id><?supplied-pmid 24332642?><pub-id pub-id-type="pmid">24332642</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Wani</surname><given-names>MY</given-names></name><name><surname>Deb</surname><given-names>R</given-names></name><name><surname>Karthik</surname><given-names>K</given-names></name><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Barathidasan</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Plant based oral vaccines for human and animal pathogens &#x02013; a new era of prophylaxis: current and future perspectives</article-title>. <source>J Exp Biol Agri Sci</source>. (<year>2013</year>) <volume>1</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>K</given-names></name></person-group>. <article-title>Expression of recombinant vaccines and antibodies in plants</article-title>. <source>Monoclon Antib Immunodiag Immunother</source>. (<year>2014</year>) <volume>33</volume>:<fpage>192</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/mab.2014.0049</pub-id><?supplied-pmid 24937251?><pub-id pub-id-type="pmid">24937251</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagchi</surname><given-names>S</given-names></name></person-group>. <article-title>Red-algae derivative could be useful adjunct to HPV vaccine</article-title>. <source>Lancet Oncol</source>. (<year>2006</year>) 7<source>:</source>623. <pub-id pub-id-type="doi">10.1016/S1470-2045(06)70781-1</pub-id><?supplied-pmid 16903009?><pub-id pub-id-type="pmid">16903009</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demurtas</surname><given-names>OC</given-names></name><name><surname>Massa</surname><given-names>S</given-names></name><name><surname>Ferrante</surname><given-names>P</given-names></name><name><surname>Venuti</surname><given-names>A</given-names></name><name><surname>Franconi</surname><given-names>R</given-names></name><name><surname>Giuliano</surname><given-names>G</given-names></name></person-group>. <article-title>A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection</article-title>. <source>PLoS ONE</source> (<year>2013</year>) <volume>8</volume>:<fpage>e61473</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061473</pub-id><?supplied-pmid 23626690?><pub-id pub-id-type="pmid">23626690</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HL</given-names></name><name><surname>LI</surname><given-names>WS</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>YAN</surname><given-names>XF</given-names></name><etal/></person-group>. <article-title>Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants</article-title>. <source>Acta Biochim Biophys Sin</source>. (<year>2005</year>) <volume>37</volume>:<fpage>153</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/37.3.153</pub-id><?supplied-pmid 15756416?><pub-id pub-id-type="pmid">15756416</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varsani</surname><given-names>A</given-names></name><name><surname>Williamson</surname><given-names>AL</given-names></name><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>Jaffer</surname><given-names>M</given-names></name><name><surname>Rybicki</surname><given-names>EP</given-names></name></person-group>. <article-title>Expression of Human papillomavirus type 16 major capsid protein in transgenic <italic>Nicotiana tabacum</italic> cv</article-title>. Xanthi. <source>Arch Virol</source>. (<year>2003</year>) <volume>148</volume>:<fpage>1771</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-003-0119-4</pub-id><?supplied-pmid 14505089?><pub-id pub-id-type="pmid">14505089</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>TO</given-names></name><name><surname>Hitzeroth</surname><given-names>II</given-names></name><name><surname>Christensen</surname><given-names>ND</given-names></name><name><surname>Rybicki</surname><given-names>EP</given-names></name></person-group>. <article-title>Expression of HPV-11 L1 protein in transgenic <italic>Arabidopsis thaliana</italic> and <italic>Nicotiana tabacum</italic></article-title>. <source>BMC Biotechnol</source>. (<year>2007</year>) <volume>7</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6750-7-56</pub-id><?supplied-pmid 17850660?><pub-id pub-id-type="pmid">17850660</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerovska</surname><given-names>N</given-names></name><name><surname>Hoffmeisterova</surname><given-names>H</given-names></name><name><surname>Moravec</surname><given-names>T</given-names></name><name><surname>Plchova</surname><given-names>H</given-names></name><name><surname>Folwarczna</surname><given-names>J</given-names></name><name><surname>Synkova</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Transient expression of Human papillomavirus type 16 L2 epitope fused to N-and C-terminus of coat protein of Potato virus X in plants</article-title>. <source>J Biosci</source>. (<year>2012</year>) <volume>37</volume>:<fpage>125</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s12038-011-9177-z</pub-id><?supplied-pmid 22357210?><pub-id pub-id-type="pmid">22357210</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mill&#x000e1;n</surname><given-names>FS</given-names></name><name><surname>Ortigosa</surname><given-names>SM</given-names></name><name><surname>Herv&#x000e1;s-Stubbs</surname><given-names>S</given-names></name><name><surname>Corral-Mart&#x000ed;nez</surname><given-names>P</given-names></name><name><surname>Segu&#x000ed;-Simarro</surname><given-names>JM</given-names></name><name><surname>Ga&#x000e9;tan</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic</article-title>. <source>Plant Biotechnol J</source>. (<year>2008</year>) <volume>6</volume>:<fpage>427</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-7652.2008.00338.x</pub-id><pub-id pub-id-type="pmid">18422886</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamprecht</surname><given-names>RL</given-names></name><name><surname>Kennedy</surname><given-names>P</given-names></name><name><surname>Huddy</surname><given-names>SM</given-names></name><name><surname>Bethke</surname><given-names>S</given-names></name><name><surname>Hendrikse</surname><given-names>M</given-names></name><name><surname>Hitzeroth</surname><given-names>II</given-names></name><etal/></person-group>. <article-title>Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>20431</fpage>. <pub-id pub-id-type="doi">10.1038/srep20431</pub-id><?supplied-pmid 26853456?><pub-id pub-id-type="pmid">26853456</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venuti</surname><given-names>A</given-names></name><name><surname>Massa</surname><given-names>S</given-names></name><name><surname>Mett</surname><given-names>V</given-names></name><name><surname>Vedova</surname><given-names>LD</given-names></name><name><surname>Paolini</surname><given-names>F</given-names></name><name><surname>Franconi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>An E7-based therapeutic vaccine protects mice against HPV16 associated cancer</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<fpage>3395</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.068</pub-id><?supplied-pmid 19200826?><pub-id pub-id-type="pmid">19200826</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waheed</surname><given-names>MT</given-names></name><name><surname>Thones</surname><given-names>N</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Hassan</surname><given-names>SW</given-names></name><name><surname>Gottschamel</surname><given-names>J</given-names></name><name><surname>Lossl</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes</article-title>. <source>Plant Biotechnol J</source>. (<year>2011</year>) <volume>9</volume>, <fpage>651</fpage>&#x02013;<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-7652.2011.00612.x</pub-id><?supplied-pmid 21447051?><pub-id pub-id-type="pmid">21447051</pub-id></mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybicki</surname><given-names>EP</given-names></name></person-group>
<article-title>Plant-based vaccine against viruses</article-title>. <source>Virol. J</source>. (<year>2014</year>) <volume>11</volume>:<fpage>205</fpage>
<pub-id pub-id-type="doi">10.1186/s12985-014-0205-0</pub-id><pub-id pub-id-type="pmid">25465382</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahma</surname><given-names>OE</given-names></name><name><surname>Herrin</surname><given-names>VE</given-names></name><name><surname>Ibrahim</surname><given-names>RA</given-names></name><name><surname>Toubaji</surname><given-names>A</given-names></name><name><surname>Bernstein</surname><given-names>S</given-names></name><name><surname>Dakheel</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer</article-title>. <source>J Transl Med</source>. (<year>2014</year>) <volume>12</volume>:<fpage>353</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-014-0353-4</pub-id><?supplied-pmid 25510844?><pub-id pub-id-type="pmid">25510844</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>ZX</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Guan</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>ZL</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group>
<article-title>Immunotherapeutic effects of dendritic cells pulsed with a codon-optimized HPV 16 E6 and E7 fusion gene <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source>Asian Pac. J Cancer Prev.</source> (<year>2014</year>) <volume>16</volume>:<fpage>3843</fpage>&#x02013;<lpage>3847</lpage>. <pub-id pub-id-type="doi">10.7314/APJCP.2015.16.9.3843</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus</article-title>. <source>Int J Oncol</source>. (<year>2013</year>) <volume>43</volume>:<fpage>1151</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2013.2027</pub-id><?supplied-pmid 23877655?><pub-id pub-id-type="pmid">23877655</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santin</surname><given-names>AD</given-names></name><name><surname>Bellone</surname><given-names>S</given-names></name><name><surname>Palmieri</surname><given-names>M</given-names></name><name><surname>Zanolini</surname><given-names>A</given-names></name><name><surname>Ravaggi</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>ER</given-names></name><etal/></person-group>. <article-title>Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial</article-title>. <source>J Virol</source>. (<year>2008</year>) <volume>82</volume>:<fpage>1968</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02343-07</pub-id><?supplied-pmid 18057249?><pub-id pub-id-type="pmid">18057249</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>P</given-names></name><name><surname>Ganeshrajah</surname><given-names>S</given-names></name><name><surname>Raghanvan</surname><given-names>RK</given-names></name><name><surname>Singh</surname><given-names>SS</given-names></name><name><surname>Thangarajan</surname><given-names>R</given-names></name></person-group>. <article-title>Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer&#x02013;a feasibility study</article-title>. <source>Asian Pac J Cancer Prev</source>. (<year>2014</year>) <volume>15</volume>:<fpage>5909</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.7314/APJCP.2014.15.14.5909</pub-id><?supplied-pmid 25081721?><pub-id pub-id-type="pmid">25081721</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Castellsagu&#x000e9;</surname><given-names>X</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Szarewski</surname><given-names>A</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Lehtinen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial</article-title>. <source>Lancet Oncol</source>. (<year>2012</year>) <volume>13</volume>:<fpage>100</fpage>&#x02013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70287-X</pub-id><?supplied-pmid 22075170?><pub-id pub-id-type="pmid">22075170</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Tewari</surname><given-names>KS</given-names></name></person-group>. <article-title>Evidence-based therapy for recurrent cervical cancer</article-title>. <source>J Clin Oncol</source>. (<year>2014</year>) <volume>32</volume>:<fpage>2687</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.56.8733</pub-id><?supplied-pmid 25071120?><pub-id pub-id-type="pmid">25071120</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjalma</surname><given-names>WAA</given-names></name></person-group>. <article-title>There are two prophylactic human papillomavirus vaccines against cancer, and they are different</article-title>. <source>J Clin Oncol</source>. (<year>2015</year>) <volume>33</volume>:<fpage>964</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.59.0331</pub-id><?supplied-pmid 25667272?><pub-id pub-id-type="pmid">25667272</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>NP</given-names></name><name><surname>Velicer</surname><given-names>CM</given-names></name><name><surname>Sy</surname><given-names>LS</given-names></name><name><surname>Slezak</surname><given-names>JM</given-names></name><name><surname>Takhar</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine</article-title>. <source>J Intern Med</source>. (<year>2012</year>) <volume>271</volume>:<fpage>193</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2796.2011.02467.x</pub-id><?supplied-pmid 21973261?><pub-id pub-id-type="pmid">21973261</pub-id></mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>B</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>LE</given-names></name><name><surname>Tomljenovic</surname><given-names>L</given-names></name><name><surname>Agmon-Levin</surname><given-names>N</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases</article-title>. <source>Expert Opin Drug Saf</source>. (<year>2015</year>) <volume>14</volume>, <fpage>1387</fpage>&#x02013;<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.2015.1073710</pub-id><?supplied-pmid 26216756?><pub-id pub-id-type="pmid">26216756</pub-id></mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Kulkarni</surname><given-names>AS</given-names></name><name><surname>Pillsbury</surname><given-names>M</given-names></name><name><surname>Luxembourg</surname><given-names>A</given-names></name><name><surname>Saah</surname><given-names>A</given-names></name></person-group>. <article-title>Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>1940</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2016.1143159</pub-id><?supplied-pmid 26857560?><pub-id pub-id-type="pmid">26857560</pub-id></mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>TR</given-names></name><name><surname>Graybill</surname><given-names>WS</given-names></name><name><surname>Pierce</surname><given-names>JY</given-names></name></person-group>. <article-title>Morbidity and mortality of vulvar and vaginal cancers: impact of 2-, 4-, and 9-valent HPV vaccines</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>1352</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2016.1147634</pub-id><?supplied-pmid 26901390?><pub-id pub-id-type="pmid">26901390</pub-id></mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Costa</surname><given-names>RL</given-names></name><name><surname>Petta</surname><given-names>CA</given-names></name><name><surname>Andrade</surname><given-names>RP</given-names></name><name><surname>Ault</surname><given-names>KA</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><etal/></person-group>
<article-title>Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicenter phase II efficacy trial</article-title>. <source>Lancet Oncol</source>. (<year>2005</year>) <volume>6</volume>:<fpage>271</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(05)70101-7</pub-id><pub-id pub-id-type="pmid">15863374</pub-id></mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Future</surname><given-names>I/II Study Group</given-names></name></person-group>
<article-title>Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial</article-title>. <source>BMJ</source> (<year>2010</year>) <volume>341</volume>:<fpage>c3493</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.c3493</pub-id><pub-id pub-id-type="pmid">20647284</pub-id></mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyg&#x000e5;rd</surname><given-names>M</given-names></name><name><surname>Saah</surname><given-names>A</given-names></name><name><surname>Munk</surname><given-names>C</given-names></name><name><surname>Tryggvadottir</surname><given-names>L</given-names></name><name><surname>Enerly</surname><given-names>E</given-names></name><name><surname>Hortlund</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine</article-title>. <source>Clin Vaccine Immunol</source>. (<year>2015</year>) <volume>22</volume>:<fpage>943</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00133-15</pub-id><?supplied-pmid 26084514?><pub-id pub-id-type="pmid">26084514</pub-id></mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centers</surname><given-names>for Disease Control and Prevention (CDC)</given-names></name></person-group>
<article-title>FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>Morb Mortal Wkly Rep</source>. (<year>2010</year>) <volume>59</volume>:<fpage>626</fpage>.</mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monie</surname><given-names>A</given-names></name><name><surname>Hung</surname><given-names>CF</given-names></name><name><surname>Roden</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name></person-group>
<article-title>Cervarix&#x02122;: a vaccine for the prevention of HPV 16, 18-associated cervical cancer</article-title>. <source>Biol Targets Ther</source>. (<year>2008</year>) <volume>2</volume>:<fpage>107</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Castellsagu&#x000e9;</surname><given-names>X</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name></person-group>. <article-title>A review of clinical trials of human papillomavirus prophylactic vaccines</article-title>. <source>Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>F123</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.108</pub-id><?supplied-pmid 23199956?><pub-id pub-id-type="pmid">23199956</pub-id></mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillison</surname><given-names>ML</given-names></name><name><surname>Chaturvedi</surname><given-names>AK</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name></person-group>. <article-title>HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women</article-title>. <source>Cancer</source> (<year>2008</year>) <volume>113</volume>:<fpage>3036</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.23764</pub-id><?supplied-pmid 18980286?><pub-id pub-id-type="pmid">18980286</pub-id></mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Sanjose</surname><given-names>S</given-names></name><name><surname>Quint</surname><given-names>WG</given-names></name><name><surname>Alemany</surname><given-names>L</given-names></name><name><surname>Geraets</surname><given-names>DT</given-names></name><name><surname>Klaustermeier</surname><given-names>JE</given-names></name><name><surname>Lloveras</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study</article-title>. <source>Lancet Oncol</source>. (<year>2010</year>) <volume>11</volume>:<fpage>1048</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70230-8</pub-id><?supplied-pmid 20952254?><pub-id pub-id-type="pmid">20952254</pub-id></mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bergh</surname><given-names>JMJ</given-names></name><name><surname>Guerti</surname><given-names>K</given-names></name><name><surname>Willemen</surname><given-names>Y</given-names></name><name><surname>Lion</surname><given-names>E</given-names></name><name><surname>Cools</surname><given-names>N</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumor cells</article-title>. <source>J Cell Mol Med</source>. (<year>2014</year>) <volume>18</volume>:<fpage>1372</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.12284</pub-id><pub-id pub-id-type="pmid">24979331</pub-id></mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Franco</surname><given-names>EL</given-names></name><name><surname>Wheeler</surname><given-names>C</given-names></name><name><surname>Ferris</surname><given-names>DG</given-names></name><name><surname>Jenkins</surname><given-names>D</given-names></name><name><surname>Schuind</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial</article-title>. <source>Lancet</source> (<year>2004</year>) <volume>364</volume>:<fpage>1757</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17398-4</pub-id><pub-id pub-id-type="pmid">15541448</pub-id></mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>D</given-names></name><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>Naud</surname><given-names>P</given-names></name><name><surname>Salmer&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial</article-title>. <source>Lancet</source> (<year>2007</year>) <volume>369</volume>:<fpage>2161</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60946-5</pub-id><pub-id pub-id-type="pmid">17602732</pub-id></mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannini</surname><given-names>SL</given-names></name><name><surname>Hanon</surname><given-names>E</given-names></name><name><surname>Moris</surname><given-names>P</given-names></name><name><surname>Van Mechelen</surname><given-names>M</given-names></name><name><surname>Morel</surname><given-names>S</given-names></name><name><surname>Dessy</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Enhanced humoral and memory B cellular immunity using HPV16/ 18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>5937</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.005</pub-id><?supplied-pmid 16828940?><pub-id pub-id-type="pmid">16828940</pub-id></mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naud</surname><given-names>PS</given-names></name><name><surname>Roteli-Martins</surname><given-names>CM</given-names></name><name><surname>De Carvalho</surname><given-names>NS</given-names></name><name><surname>Teixeira</surname><given-names>JC</given-names></name><name><surname>de Borba</surname><given-names>PC</given-names></name><name><surname>Sanchez</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9</article-title>.4 years post-vaccination. <source>Hum Vaccin Immunother.</source> (<year>2014</year>) <volume>10</volume>:<fpage>2147</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.4161/hv.29532</pub-id><?supplied-pmid 25424918?><pub-id pub-id-type="pmid">25424918</pub-id></mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Spaczynski</surname><given-names>M</given-names></name><name><surname>Kaufmann</surname><given-names>A</given-names></name><name><surname>Wysocki</surname><given-names>J</given-names></name><name><surname>Ga&#x00142;aj</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15&#x02013;55 years and first-time modelling of antibody responses in mature women: results from an open-label 6&#x02013;year follow-up study</article-title>. <source>BJOG</source> (<year>2015</year>) <volume>122</volume>:<fpage>107</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1111/1471-0528.13070</pub-id><?supplied-pmid 25208608?><pub-id pub-id-type="pmid">25208608</pub-id></mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Effelterre</surname><given-names>TPV</given-names></name><name><surname>Hogea</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>SM</given-names></name></person-group>. <article-title>Projected impact of Cervarix&#x02122; vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<fpage>8</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1054584</pub-id><?supplied-pmid 26090944?><pub-id pub-id-type="pmid">26090944</pub-id></mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosky</surname><given-names>E</given-names></name><name><surname>Bocchini</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Hariri</surname><given-names>S</given-names></name><name><surname>Chesson</surname><given-names>H</given-names></name><name><surname>Curtis</surname><given-names>CR</given-names></name><name><surname>Saraiya</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2015</year>) <volume>64</volume>:<fpage>300</fpage>&#x02013;<lpage>4</lpage>. <?supplied-pmid 25811679?><pub-id pub-id-type="pmid">25811679</pub-id></mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vincenzo</surname><given-names>R</given-names></name><name><surname>Conte</surname><given-names>C</given-names></name><name><surname>Ricci</surname><given-names>C</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><name><surname>Capelli</surname><given-names>G</given-names></name></person-group>. <article-title>Long-term efficacy and safety of human papillomavirus vaccination</article-title>. <source>Int J Womens Health</source> (<year>2014</year>) <volume>6</volume>:<fpage>999</fpage>. <pub-id pub-id-type="doi">10.2147/IJWH.S50365</pub-id><?supplied-pmid 25587221?><pub-id pub-id-type="pmid">25587221</pub-id></mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luxembourg</surname><given-names>A</given-names></name><name><surname>Kjaer</surname><given-names>SK</given-names></name><name><surname>Nygard</surname><given-names>M</given-names></name><name><surname>Ellison</surname><given-names>MC</given-names></name><name><surname>Marshall</surname><given-names>JB</given-names></name><name><surname>Radley</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine</article-title>. <source>Contemp. Clin. Trials</source> (<year>2017</year>) <volume>52</volume>:<fpage>54</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2016.10.006</pub-id><?supplied-pmid 27777126?><pub-id pub-id-type="pmid">27777126</pub-id></mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>ED</given-names></name><name><surname>Block</surname><given-names>SL</given-names></name><name><surname>Ferris</surname><given-names>D</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><name><surname>Iversen</surname><given-names>OE</given-names></name><name><surname>Joura</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials</article-title>. <source>Pediatrics.</source> (<year>2016</year>) <volume>138</volume>:<fpage>e20154387</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2015-4387</pub-id><?supplied-pmid 27422279?><pub-id pub-id-type="pmid">27422279</pub-id></mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarelli</surname><given-names>GD</given-names></name><name><surname>Derkay</surname><given-names>CS</given-names></name></person-group>
<article-title>HPV vaccines for treatment and prevention of recurrent respiratory papillomatosis</article-title>. <source>Curr Otorhinolaryngol Rep</source>. (<year>2016</year>) <volume>4</volume>:<fpage>85</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s40136-016-0119-z</pub-id></mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Largeron</surname><given-names>N</given-names></name><name><surname>Petry</surname><given-names>KU</given-names></name><name><surname>Jacob</surname><given-names>J</given-names></name><name><surname>Bianic</surname><given-names>F</given-names></name><name><surname>Anger</surname><given-names>D</given-names></name><name><surname>Uhart</surname><given-names>M</given-names></name></person-group>. <article-title>An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. (<year>2016</year>) <volume>17</volume>:<fpage>85</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1080/14737167.2016.1208087</pub-id><?supplied-pmid 27366939?><pub-id pub-id-type="pmid">27366939</pub-id></mixed-citation></ref><ref id="B214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Tumban</surname><given-names>E</given-names></name></person-group>. <article-title>Gardasil-9: A global survey of projected efficacy</article-title>. <source>Antivir Res.</source> (<year>2016</year>) <volume>130</volume>:<fpage>101</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.03.016</pub-id><?supplied-pmid 27040313?><pub-id pub-id-type="pmid">27040313</pub-id></mixed-citation></ref><ref id="B215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeage</surname><given-names>K</given-names></name><name><surname>Lyseng-Williamson</surname><given-names>KA</given-names></name></person-group>
<article-title>9-Valent human papillomavirus recombinant vaccine (Gardasil&#x000ae; 9): a guide to its use in the EU</article-title>. <source>Drugs Ther Perspect</source>. (<year>2016</year>) <volume>32</volume>:<fpage>414</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s40267-016-0337-y</pub-id></mixed-citation></ref><ref id="B216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pink</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>B</given-names></name><name><surname>Petrou</surname><given-names>S</given-names></name></person-group>. <article-title>Cost effectiveness of HPV vaccination: asystematic review of modelling approaches</article-title>. <source>Pharmaco Economics</source> (<year>2016</year>) <volume>34</volume>:<fpage>847</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/s40273-016-0407-y</pub-id><?supplied-pmid 27178048?><pub-id pub-id-type="pmid">27178048</pub-id></mixed-citation></ref><ref id="B217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquerr&#x000e9;</surname><given-names>M</given-names></name><name><surname>Bouillette-Marussig</surname><given-names>M</given-names></name><name><surname>Goubier</surname><given-names>A</given-names></name><name><surname>Momot</surname><given-names>M</given-names></name><name><surname>Gonindard</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8<sup>+</sup> T cell responses leading to tumor regression</article-title>. <source>PLoS ONE</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0174038</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0174038</pub-id><?supplied-pmid 28301611?><pub-id pub-id-type="pmid">28301611</pub-id></mixed-citation></ref><ref id="B218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preville</surname><given-names>X</given-names></name><name><surname>Ladant</surname><given-names>D</given-names></name><name><surname>Timmerman</surname><given-names>B</given-names></name><name><surname>Leclerc</surname><given-names>C</given-names></name></person-group>. <article-title>Eradication of established tumors by vaccination with recombinant <italic>Bordetella pertussis</italic> adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein</article-title>. <source>Cancer Res</source>. (<year>2005</year>) <volume>65</volume>:<fpage>641</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 15695409?><pub-id pub-id-type="pmid">15695409</pub-id></mixed-citation></ref><ref id="B219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berraondo</surname><given-names>P</given-names></name><name><surname>Nouze</surname><given-names>C</given-names></name><name><surname>Preville</surname><given-names>X</given-names></name><name><surname>Ladant</surname><given-names>D</given-names></name><name><surname>Leclerc</surname><given-names>C</given-names></name></person-group>. <article-title>Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system</article-title>. <source>Cancer Res</source>. (<year>2007</year>) <volume>67</volume>:<fpage>8847</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0321</pub-id><?supplied-pmid 17875726?><pub-id pub-id-type="pmid">17875726</pub-id></mixed-citation></ref><ref id="B220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>DY</given-names></name><name><surname>Bracken</surname><given-names>K</given-names></name></person-group>. <article-title>Update of the new 9-valent vaccine for human papilloma virus prevention</article-title>. <source>Can Fam Physician</source>. (<year>2016</year>) <volume>62</volume>:<fpage>399</fpage>&#x02013;<lpage>402</lpage>. <?supplied-pmid 27255620?><pub-id pub-id-type="pmid">27255620</pub-id></mixed-citation></ref><ref id="B221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Olsson</surname><given-names>SE</given-names></name><name><surname>Block</surname><given-names>S</given-names></name><name><surname>Castellsague</surname><given-names>X</given-names></name><name><surname>Gray</surname><given-names>GE</given-names></name><name><surname>Herrera</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Immunogenicity and safety of a 9-valent HPV vaccine</article-title>. <source>Pediatrics</source> (<year>2015</year>) <volume>136</volume>:<fpage>e28</fpage>&#x02013;<lpage>e39</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-3745</pub-id><?supplied-pmid 26101366?><pub-id pub-id-type="pmid">26101366</pub-id></mixed-citation></ref><ref id="B222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesikari</surname><given-names>T</given-names></name><name><surname>Brodszki</surname><given-names>N</given-names></name><name><surname>van Damme</surname><given-names>P</given-names></name><name><surname>Diez-Domingo</surname><given-names>J</given-names></name><name><surname>Icardi</surname><given-names>G</given-names></name><name><surname>Petersen</surname><given-names>LK</given-names></name><etal/></person-group> (<year>2015</year>). A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil&#x000ae; in 9&#x02013;15-year-old girls. <italic>Pediatr Infect Dis</italic>
<source>J</source>. <volume>34</volume>, <fpage>992</fpage>&#x02013;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0000000000000773</pub-id></mixed-citation></ref><ref id="B223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellsagu</surname><given-names>&#x000e9;X</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><name><surname>Goldstone</surname><given-names>S</given-names></name><name><surname>Guevara</surname><given-names>A</given-names></name><name><surname>Mogensen</surname><given-names>O</given-names></name><name><surname>Palefsky</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Immunogenicity and safety of the 9-valent HPV vaccine in men</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<fpage>6892</fpage>&#x02013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.088</pub-id><pub-id pub-id-type="pmid">26144901</pub-id></mixed-citation></ref><ref id="B224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van'tKlooster</surname><given-names>TM</given-names></name><name><surname>Kemmeren</surname><given-names>JM</given-names></name><name><surname>van der Maas</surname><given-names>NAT</given-names></name><name><surname>de Melker</surname><given-names>HE</given-names></name></person-group>
<article-title>Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in Netherlands</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<fpage>4601</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.050</pub-id><pub-id pub-id-type="pmid">21549785</pub-id></mixed-citation></ref><ref id="B225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luna</surname><given-names>J</given-names></name><name><surname>Plata</surname><given-names>M</given-names></name><name><surname>Gonzales</surname><given-names>A</given-names></name><name><surname>Maldonado</surname><given-names>I</given-names></name><name><surname>Nossa</surname><given-names>C</given-names></name><name><surname>Radley</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Long-term foll ow-up observation of the safety, immunogenicity, and effectiveness of GardasilTM in adult women</article-title>. <source>PLoS ONE</source> (<year>2013</year>) <volume>8</volume>:<fpage>e83431</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0083431</pub-id><pub-id pub-id-type="pmid">24391768</pub-id></mixed-citation></ref><ref id="B226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Chuengg</surname><given-names>TK</given-names></name><name><surname>McNeil</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>LK</given-names></name><name><surname>Romaguera</surname><given-names>J</given-names></name><name><surname>Vazquez-Narvaez</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Safety and immunogenicity of 1 9-valent HV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>30</volume>:<fpage>6855</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.059</pub-id></mixed-citation></ref><ref id="B227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>A</given-names></name><name><surname>Isaac-Soriano</surname><given-names>K</given-names></name><name><surname>Torres</surname><given-names>AN</given-names></name><name><surname>Abrahamsen</surname><given-names>M</given-names></name><name><surname>Ingles</surname><given-names>DJ</given-names></name><name><surname>Sirak</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years(-the MAM study</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<fpage>5640</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.072</pub-id><?supplied-pmid 26343499?><pub-id pub-id-type="pmid">26343499</pub-id></mixed-citation></ref><ref id="B228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XC</given-names></name><name><surname>Bell</surname><given-names>CA</given-names></name><name><surname>Simmonds</surname><given-names>KA</given-names></name><name><surname>Svensen</surname><given-names>LW</given-names></name><name><surname>Russel</surname><given-names>ML</given-names></name></person-group>. <article-title>Adverse events following HPV vaccination, Alberta 2006-2014</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<fpage>1800</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.040</pub-id><?supplied-pmid 26921782?><pub-id pub-id-type="pmid">26921782</pub-id></mixed-citation></ref><ref id="B229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Meijer</surname><given-names>CJLM</given-names></name><name><surname>Kieninger</surname><given-names>D</given-names></name><name><surname>Schuyleman</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Luxembourg</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A phase-III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<fpage>4205</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.06.056</pub-id><?supplied-pmid 27354258?><pub-id pub-id-type="pmid">27354258</pub-id></mixed-citation></ref><ref id="B230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonde</surname><given-names>U</given-names></name><name><surname>Jorgensen</surname><given-names>JS</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name><name><surname>Mogensen</surname><given-names>O</given-names></name></person-group>. <article-title>Is HPV vaccination in pregnancy safe?</article-title>
<source>Hum Vacc Immunotherapeut.</source> (<year>2016</year>) <volume>12</volume>:<fpage>1960</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2016.1160178</pub-id><?supplied-pmid 27172372?><pub-id pub-id-type="pmid">27172372</pub-id></mixed-citation></ref><ref id="B231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimaldi-Bensouda</surname><given-names>L</given-names></name><name><surname>Rossignol</surname><given-names>M</given-names></name><name><surname>Kon&#x000e9;-Paut</surname><given-names>I</given-names></name><name><surname>Krivitzky</surname><given-names>A</given-names></name><name><surname>Lebrun-Frenay</surname><given-names>C</given-names></name><name><surname>Clet</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Risk of autoimmune diseases and human papillomavirus (HPV) vaccines: six years of case-referent surveillance</article-title>. <source>J Autoimmun</source>. (<year>2017</year>) <volume>79</volume>:<fpage>84</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2017.01.005</pub-id><pub-id pub-id-type="pmid">28190705</pub-id></mixed-citation></ref><ref id="B232"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Chaignot</surname><given-names>C</given-names></name><name><surname>Collin</surname><given-names>C</given-names></name><name><surname>Dray-Spira</surname><given-names>R</given-names></name><name><surname>Weill</surname><given-names>A</given-names></name></person-group>
<article-title>Huamn papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<fpage>4761</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.030</pub-id><pub-id pub-id-type="pmid">28750853</pub-id></mixed-citation></ref><ref id="B233"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouchet</surname><given-names>J</given-names></name><name><surname>Salvo</surname><given-names>F</given-names></name><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Poluzzi</surname><given-names>E</given-names></name><name><surname>Antonazzo</surname><given-names>IC</given-names></name><name><surname>De Ponti</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis</article-title>. <source>Pharmacol Res.</source> (<year>2018</year>) <volume>132</volume>:<fpage>108</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2018.04.007</pub-id><?supplied-pmid 29665426?><pub-id pub-id-type="pmid">29665426</pub-id></mixed-citation></ref><ref id="B234"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Sternberg</surname><given-names>AM</given-names></name><name><surname>Moreira</surname><given-names>EDJr</given-names></name><name><surname>Restrepo</surname><given-names>JA</given-names></name><name><surname>Lazcano-Ponce</surname><given-names>E</given-names></name><name><surname>Carbello</surname><given-names>R</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Efficacy, immunogenicity and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women</article-title>. <source>Papillomavirus Res</source>. (<year>2018</year>) <volume>5</volume>:<fpage>63</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.pvr.2017.12.004</pub-id><?supplied-pmid 29269325?><pub-id pub-id-type="pmid">29269325</pub-id></mixed-citation></ref><ref id="B235"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Stowe</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name></person-group>
<article-title>No increased risk of Guillain-Barre syndrome after human papillomavirus vaccine: a sefl-controlled case-series study in England</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<fpage>1729</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.01.076</pub-id><pub-id pub-id-type="pmid">28245941</pub-id></mixed-citation></ref><ref id="B236"><label>236.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000e4;ffer</surname><given-names>V</given-names></name><name><surname>Wimmer</surname><given-names>S</given-names></name><name><surname>Rotaru</surname><given-names>I</given-names></name><name><surname>Topakian</surname><given-names>R</given-names></name><name><surname>Haring</surname><given-names>HP</given-names></name><name><surname>Aichner</surname><given-names>FT</given-names></name></person-group>. <article-title>HPV vaccine: a cornerstone of female health &#x02013; a possible cause of ADEM?</article-title>
<source>J Neurol</source>. (<year>2008</year>) <volume>255</volume>:<fpage>1818</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-008-0867-x</pub-id><?supplied-pmid 18491173?><pub-id pub-id-type="pmid">18491173</pub-id></mixed-citation></ref><ref id="B237"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>I</given-names></name><name><surname>Lahoria</surname><given-names>R</given-names></name></person-group>
<article-title>Clouston P, Barnett MH</article-title>. CNS demyelination and quadrivalent HPV vaccination Multiple. <source>Sclerosis</source> (<year>2009</year>) <volume>15</volume>:<fpage>116</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/1352458508096868</pub-id></mixed-citation></ref><ref id="B238"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimario</surname><given-names>FJ</given-names></name><name><surname>Haijar</surname><given-names>M</given-names></name><name><surname>Ciesielski</surname><given-names>T</given-names></name></person-group>. <article-title>A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus</article-title>. <source>J Child Neurol</source>. (<year>2010</year>) <volume>25</volume>:<fpage>321</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/0883073809349322</pub-id><?supplied-pmid 20189933?><pub-id pub-id-type="pmid">20189933</pub-id></mixed-citation></ref><ref id="B239"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karussis</surname><given-names>D</given-names></name><name><surname>Petrou</surname><given-names>P</given-names></name></person-group>
<article-title>The spectrum of post-vaccination inflammatory CNS demyelinating syndrome</article-title>. <source>Autoimmun Rev</source>. (<year>2014</year>) <volume>13</volume>:<fpage>215</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2013.10.003</pub-id><pub-id pub-id-type="pmid">24514081</pub-id></mixed-citation></ref><ref id="B240"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>N</given-names></name><name><surname>Kowa</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>F</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name></person-group>. <article-title>Two cases of acute disseminated encephalomyelitis following vaccination against human papilloma virus</article-title>. <source>Intern Med</source>. (<year>2016</year>) <volume>55</volume>:<fpage>3181</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.2169/internalmedicine.55.5472</pub-id><?supplied-pmid 27803416?><pub-id pub-id-type="pmid">27803416</pub-id></mixed-citation></ref><ref id="B241"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HL</given-names></name><name><surname>Yeo</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>DI</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations</article-title>. <source>Clin Neurol Neurosurg</source> (<year>2016</year>) <volume>144</volume>:<fpage>126</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.clineuro.2016.03.023</pub-id><?supplied-pmid 27046292?><pub-id pub-id-type="pmid">27046292</pub-id></mixed-citation></ref><ref id="B242"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geier</surname><given-names>DA</given-names></name><name><surname>Geier</surname><given-names>MR</given-names></name></person-group>. <article-title>Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database</article-title>. <source>Immunol Rev</source>. (<year>2017</year>) <volume>65</volume>:<fpage>46</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-016-8815-9</pub-id><?supplied-pmid 27406735?><pub-id pub-id-type="pmid">27406735</pub-id></mixed-citation></ref><ref id="B243"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melief</surname><given-names>CJ</given-names></name></person-group>. <article-title>Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine</article-title>. <source>J Immunother.</source> (<year>2012</year>) <volume>35</volume>:<fpage>215</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/CJI.0b013e318248f17f</pub-id><?supplied-pmid 22421938?><pub-id pub-id-type="pmid">22421938</pub-id></mixed-citation></ref><ref id="B244"><label>244.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conesa-Zamora</surname><given-names>P</given-names></name></person-group>. <article-title>Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape</article-title>. <source>Gynecol Oncol</source>. (<year>2013</year>) <volume>131</volume>:<fpage>480</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2013.08.025</pub-id><?supplied-pmid 23994536?><pub-id pub-id-type="pmid">23994536</pub-id></mixed-citation></ref><ref id="B245"><label>245.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group>. <article-title>Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)</article-title>. <source>J Biol Chem</source>. (<year>1995</year>) <volume>270</volume>:<fpage>24995</fpage>&#x02013;<lpage>5000</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.42.24995</pub-id><?supplied-pmid 7559628?><pub-id pub-id-type="pmid">7559628</pub-id></mixed-citation></ref><ref id="B246"><label>246.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Bharti</surname><given-names>AC</given-names></name></person-group>. <article-title>Anticancer potential of curcumin: preclinical and clinical studies</article-title>. <source>Anticancer Res</source>. (<year>2003</year>) <volume>23</volume>:<fpage>363</fpage>&#x02013;<lpage>98</lpage>. <?supplied-pmid 12680238?><pub-id pub-id-type="pmid">12680238</pub-id></mixed-citation></ref><ref id="B247"><label>247.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divya</surname><given-names>CS</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name></person-group>
<article-title>Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NF-&#x003ba;B and AP-1 translocation, and modulation of apoptosis</article-title>. <source>Mol Carcinog</source>. (<year>2006</year>) <volume>45</volume>:<fpage>320</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20170</pub-id><pub-id pub-id-type="pmid">16526022</pub-id></mixed-citation></ref><ref id="B248"><label>248.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Tyagi</surname><given-names>A</given-names></name><name><surname>Kohaar</surname><given-names>I</given-names></name><name><surname>Hedau</surname><given-names>S</given-names></name><name><surname>Bharti</surname><given-names>AC</given-names></name><etal/></person-group>
<article-title>Curcumin modulates cellular AP-1, NF-&#x003ba;B, and HPV16 E6 proteins in oral cancer</article-title>. <source>Ecancermedicalscience</source> (<year>2015</year>) <volume>9</volume>:<fpage>525</fpage>
<pub-id pub-id-type="doi">10.3332/ecancer.2015.525</pub-id><pub-id pub-id-type="pmid">25932049</pub-id></mixed-citation></ref><ref id="B249"><label>249.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banister</surname><given-names>CE</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Pirisi</surname><given-names>L</given-names></name><name><surname>Creek</surname><given-names>KE</given-names></name><name><surname>Buckhaults</surname><given-names>PJ</given-names></name></person-group>. <article-title>Identification and characterization of HPV-independent cervical cancers</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<fpage>13375</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14533</pub-id><?supplied-pmid 28077784?><pub-id pub-id-type="pmid">28077784</pub-id></mixed-citation></ref><ref id="B250"><label>250.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CW</given-names></name><name><surname>Trimble</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Monie</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts</article-title>. <source>Cancer Immunol Immunother.</source> (<year>2009</year>) <volume>58</volume>:<fpage>737</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-008-0596-0</pub-id><?supplied-pmid 18815785?><pub-id pub-id-type="pmid">18815785</pub-id></mixed-citation></ref><ref id="B251"><label>251.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy</article-title>. <source>Clin Immunol</source>. (<year>2010</year>) <volume>136</volume>:<fpage>21</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2010.02.020</pub-id><?supplied-pmid 20338811?><pub-id pub-id-type="pmid">20338811</pub-id></mixed-citation></ref><ref id="B252"><label>252.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group>. <article-title>Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know</article-title>. <source>Nat Rev Clin Oncol.</source> (<year>2011</year>) <volume>8</volume>:<fpage>577</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2011.116</pub-id><?supplied-pmid 21808266?><pub-id pub-id-type="pmid">21808266</pub-id></mixed-citation></ref><ref id="B253"><label>253.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>AR</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Vachani</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>AF</given-names></name><name><surname>Silverberg</surname><given-names>M</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine</article-title>. <source>Clin Cancer Res.</source> (<year>2006</year>) <volume>12</volume>:<fpage>214</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1178</pub-id><?supplied-pmid 16397045?><pub-id pub-id-type="pmid">16397045</pub-id></mixed-citation></ref><ref id="B254"><label>254.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Buchlis</surname><given-names>G</given-names></name><name><surname>Fridlender</surname><given-names>ZG</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy</article-title>. <source>Cancer Res</source>. (<year>2008</year>) <volume>68</volume>:<fpage>10247</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1494</pub-id><?supplied-pmid 19074893?><pub-id pub-id-type="pmid">19074893</pub-id></mixed-citation></ref><ref id="B255"><label>255.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castano</surname><given-names>AP</given-names></name><name><surname>Mroz</surname><given-names>P</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name></person-group>. <article-title>Photodynamic therapy and anti-tumour immunity</article-title>. <source>Nat Rev Cancer</source> (<year>2006</year>) <volume>6</volume>:<fpage>535</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1894</pub-id><?supplied-pmid 16794636?><pub-id pub-id-type="pmid">16794636</pub-id></mixed-citation></ref><ref id="B256"><label>256.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brackett</surname><given-names>CM</given-names></name><name><surname>Gollnick</surname><given-names>SO</given-names></name></person-group>. <article-title>Photodynamic therapy enhancement of anti-tumor immunity</article-title>. <source>Photochem Photobiol Sci.</source> (<year>2011</year>) <volume>10</volume>:<fpage>649</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1039/c0pp00354a</pub-id><?supplied-pmid 21253659?><pub-id pub-id-type="pmid">21253659</pub-id></mixed-citation></ref><ref id="B257"><label>257.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korbelik</surname><given-names>M</given-names></name></person-group>. <article-title>Cancer vaccines generated by photodynamic therapy</article-title>. <source>Photochem Photobiol Sci</source>. (<year>2011</year>) <volume>10</volume>:<fpage>664</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1039/c0pp00343c</pub-id><?supplied-pmid 21258728?><pub-id pub-id-type="pmid">21258728</pub-id></mixed-citation></ref><ref id="B258"><label>258.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>PL</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Hampson</surname><given-names>IN</given-names></name><name><surname>Broker</surname><given-names>T</given-names></name><name><surname>Fiander</surname><given-names>A</given-names></name><name><surname>Lacey</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Therapy of human papillomavirus-related disease</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>F71</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.05.091</pub-id><?supplied-pmid 23199967?><pub-id pub-id-type="pmid">23199967</pub-id></mixed-citation></ref><ref id="B259"><label>259.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Hui</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name></person-group>. <article-title>Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection</article-title>. <source>Photodiag Photodyn Ther</source>. (<year>2016</year>) <volume>13</volume>:<fpage>29</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.pdpdt.2015.12.004</pub-id><?supplied-pmid 26687616?><pub-id pub-id-type="pmid">26687616</pub-id></mixed-citation></ref><ref id="B260"><label>260.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Zhang</surname><given-names>LL</given-names></name><name><surname>Miao</surname><given-names>F</given-names></name><name><surname>Lv</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group>. <article-title>Treatment of HPV infection-associated cervical condylomata acuminata with 5-aminolevulinic acid-mediated photodynamic therapy</article-title>. <source>Photochem Photobiol</source>. (<year>2012</year>) <volume>88</volume>:<fpage>565</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1751-1097.2011.01060.x</pub-id><?supplied-pmid 22150321?><pub-id pub-id-type="pmid">22150321</pub-id></mixed-citation></ref><ref id="B261"><label>261.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kines</surname><given-names>R</given-names></name><name><surname>&#x000c7;uburu</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>MacDougall</surname><given-names>J</given-names></name><name><surname>Pinos</surname><given-names>EDL</given-names></name><name><surname>Schiller</surname><given-names>J</given-names></name></person-group>
<article-title>HPV based photodynamic therapy: a new approach for anti-cancer therapy (VAC12P</article-title>.1019). <source>J Immunol.</source> (<year>2014</year>) <volume>192</volume> (<issue>1 Suppl.</issue>):<fpage>206.8</fpage>.<pub-id pub-id-type="pmid">24293634</pub-id></mixed-citation></ref><ref id="B262"><label>262.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soergel</surname><given-names>P</given-names></name><name><surname>Dahl</surname><given-names>GF</given-names></name><name><surname>Onsrud</surname><given-names>M</given-names></name><name><surname>Hillemanns</surname><given-names>P</given-names></name></person-group>
<article-title>Photodynamic therapy for cervical intraepithelial neoplasia 1-3 and human papillomavirus (HPV) infection with methylaminolevulinate and hexaminolevulinate &#x02013; adouble-blind, dose-finding study</article-title>. <source>Lasers Surg Med</source>. (<year>2012</year>) <volume>44</volume>:<fpage>468</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1002/lsm.22041</pub-id><pub-id pub-id-type="pmid">22693121</pub-id></mixed-citation></ref><ref id="B263"><label>263.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillemanns</surname><given-names>P</given-names></name><name><surname>Einstein</surname><given-names>MH</given-names></name><name><surname>Iversen</surname><given-names>OE</given-names></name></person-group>. <article-title>Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia</article-title>. <source>Expert Opin Investig Drugs</source> (<year>2015</year>) <volume>24</volume>:<fpage>273</fpage>&#x02013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1517/13543784.2015.990150</pub-id><?supplied-pmid 25514095?><pub-id pub-id-type="pmid">25514095</pub-id></mixed-citation></ref><ref id="B264"><label>264.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Vecchiotti</surname><given-names>MA</given-names></name><name><surname>Heaphy</surname><given-names>J</given-names></name><name><surname>Panneerselvam</surname><given-names>A</given-names></name><name><surname>Schluchter</surname><given-names>MD</given-names></name><name><surname>Oleinick</surname><given-names>NL</given-names></name><etal/></person-group>. <article-title>Photodynamic therapy of cottontail rabbit papillomavirus-induced papillomas in a severe combined immunodeficient mouse xenograft system</article-title>. <source>Laryngoscope</source>. (<year>2010</year>) <volume>120</volume>:<fpage>618</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1002/lary.20709</pub-id><?supplied-pmid 20091778?><pub-id pub-id-type="pmid">20091778</pub-id></mixed-citation></ref><ref id="B265"><label>265.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>LP</given-names></name><name><surname>da Silva</surname><given-names>FC</given-names></name></person-group>
<article-title>Antimicrobial photodynamic therapy: anew therapeutic option to combat infections</article-title>. <source>J Med Microb Diagn</source>. (<year>2014</year>) <volume>3</volume>:<fpage>158</fpage>
<pub-id pub-id-type="doi">10.4172/2161-0703.1000158</pub-id></mixed-citation></ref><ref id="B266"><label>266.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauvaget</surname><given-names>C</given-names></name><name><surname>Muwonge</surname><given-names>R</given-names></name><name><surname>Sankaranarayanan</surname><given-names>R</given-names></name></person-group>. <article-title>Meta-analysis of the effectiveness of cryotehrapy in the treatment of cervical intraepithelial neoplasia</article-title>. <source>Int J Gynaecol Obstet</source>. (<year>2013</year>) <volume>120</volume>:<fpage>218</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijgo.2012.10.014</pub-id><?supplied-pmid 23265830?><pub-id pub-id-type="pmid">23265830</pub-id></mixed-citation></ref><ref id="B267"><label>267.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>TC</given-names><suffix>Jr</suffix></name><name><surname>Kuhn</surname><given-names>L</given-names></name></person-group>. <article-title>Alternative approaches to cervical cancer screening for developing countries</article-title>. <source>Best Pract Res Clin Obstet Gynaecol</source>. (<year>2012</year>) <volume>26</volume>:<fpage>197</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2011.11.004</pub-id><?supplied-pmid 22385539?><pub-id pub-id-type="pmid">22385539</pub-id></mixed-citation></ref><ref id="B268"><label>268.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutombo</surname><given-names>AB</given-names></name><name><surname>Tozin</surname><given-names>R</given-names></name><name><surname>Simoens</surname><given-names>C</given-names></name><name><surname>Lisbeth</surname><given-names>R</given-names></name><name><surname>Bogers</surname><given-names>J</given-names></name><name><surname>Van Geertruyden</surname><given-names>J-P</given-names></name><etal/></person-group>
<article-title>Efficacy of antiviral drug AV2 in the treatment of human papilloma virus&#x02013;associated precancerous lesions of the uterine cervix: arandomized placebo-controlled clinical trial in Kinshasa, DR Congo</article-title>. <source>(KINVAV study) Contemp Clin Trials Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>135</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.conctc.2017.09.008</pub-id><pub-id pub-id-type="pmid">29696202</pub-id></mixed-citation></ref><ref id="B269"><label>269.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katundu</surname><given-names>K</given-names></name><name><surname>Bateman</surname><given-names>AC</given-names></name><name><surname>Pfaendler</surname><given-names>KS</given-names></name><name><surname>Mwanahamuntu</surname><given-names>MH</given-names></name><name><surname>Kapambwe</surname><given-names>S</given-names></name><name><surname>Vermund</surname><given-names>SH</given-names></name><etal/></person-group>
<article-title>The effect of cryotherapy on human papilloma virus clearance among HIV-positive women in Lusaka, Zambia</article-title>. <source>J Low Genit Tract Dis</source>. (<year>2015</year>) <volume>19</volume>:<fpage>301</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/LGT.0000000000000131</pub-id><pub-id pub-id-type="pmid">26125097</pub-id></mixed-citation></ref><ref id="B270"><label>270.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>I</given-names></name><name><surname>Cuthill</surname><given-names>S</given-names></name></person-group>
<article-title>Antivirals</article-title>. In: <source>Human Papillomaviruses. Clinical and Scientific Advances</source>. <person-group person-group-type="editor"><name><surname>Sterling</surname><given-names>JC</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name></person-group> editors. <publisher-loc>London</publisher-loc>: <publisher-name>Arnold Publisher</publisher-name> (<year>2001</year>). pp. <fpage>120</fpage>&#x02013;<lpage>130</lpage>.</mixed-citation></ref><ref id="B271"><label>271.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>HB</given-names></name><name><surname>Helmkamp</surname><given-names>BF</given-names></name></person-group>. <article-title>Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions</article-title>. <source>Obstet Gynecol</source>. (<year>1991</year>) <volume>78</volume>:<fpage>205</fpage>&#x02013;<lpage>208</lpage>. <?supplied-pmid 1648696?><pub-id pub-id-type="pmid">1648696</pub-id></mixed-citation></ref><ref id="B272"><label>272.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Myoung</surname><given-names>J</given-names></name><name><surname>Namkoong</surname><given-names>SE</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name></person-group>. <article-title>Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells</article-title>. <source>Cancer Lett</source>. (<year>2002</year>) <volume>181</volume>:<fpage>11</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3835(02)00039-3</pub-id><?supplied-pmid 12430174?><pub-id pub-id-type="pmid">12430174</pub-id></mixed-citation></ref><ref id="B273"><label>273.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Bhat</surname><given-names>MK</given-names></name></person-group>
<article-title>Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factorkappaB in human HPV-18 E6-positive HEp-2 cells</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2004</year>) <volume>318</volume>:<fpage>346</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.04.037</pub-id><pub-id pub-id-type="pmid">15120608</pub-id></mixed-citation></ref><ref id="B274"><label>274.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>FP</given-names></name></person-group>. <article-title>Efficacy of imiquimod 5% cream for persistent human papillomavirus in genital intraepithelial neoplasm</article-title>. <source>Taiwan J Obstet Gynecol</source>. (<year>2013</year>) <volume>52</volume>:<fpage>475</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tjog.2013.10.004</pub-id><?supplied-pmid 24411029?><pub-id pub-id-type="pmid">24411029</pub-id></mixed-citation></ref><ref id="B275"><label>275.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svahn</surname><given-names>KS</given-names></name><name><surname>G&#x000f6;ransson</surname><given-names>U</given-names></name><name><surname>Chryssanthou</surname><given-names>E</given-names></name><name><surname>Olsen</surname><given-names>Sj&#x000f6;lin J</given-names></name><name><surname>Str&#x000f6;mstedt</surname><given-names>AA</given-names></name></person-group>. (<year>2014</year>). <article-title>Induction of gliotoxin secretion in <italic>Aspergillus fumigatus</italic> by bacteria-associated molecules</article-title>. <source>PLoS ONE</source>
<volume>9</volume>:<fpage>e93685</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0093685</pub-id><?supplied-pmid 24705440?><pub-id pub-id-type="pmid">24705440</pub-id></mixed-citation></ref><ref id="B276"><label>276.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>VT</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Qian</surname><given-names>ZJ</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Kim</surname><given-names>KN</given-names></name><name><surname>Heo</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Gliotoxin isolated from marine fungus <italic>Aspergillus</italic> sp. induces apoptosis of human cervical cancer and chondrosarcoma cells</article-title>. <source>Mar Drugs</source> (<year>2013</year>) <volume>12</volume>:<fpage>69</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.3390/md12010069</pub-id><?supplied-pmid 24368570?><pub-id pub-id-type="pmid">24368570</pub-id></mixed-citation></ref><ref id="B277"><label>277.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clamp</surname><given-names>PJ</given-names></name><name><surname>Saunders</surname><given-names>MW</given-names></name></person-group>
<article-title>Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis</article-title>. <source>Int J Pediatr Otorhinolaryngol</source>. (<year>2013</year>) <volume>77</volume>:<fpage>323</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijporl.2012.12.027</pub-id><pub-id pub-id-type="pmid">23369614</pub-id></mixed-citation></ref><ref id="B278"><label>278.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derkay</surname><given-names>CS</given-names></name><name><surname>Volsky</surname><given-names>PG</given-names></name><name><surname>Rosen</surname><given-names>CA</given-names></name><name><surname>Pransky</surname><given-names>SM</given-names></name><name><surname>McMurray</surname><given-names>JS</given-names></name><name><surname>Chadha</surname><given-names>NK</given-names></name><etal/></person-group>. <article-title>Current use of intralesional cidofovir for recurrent respiratory papillomatosis</article-title>. <source>Laryngoscope</source> (<year>2013</year>) <volume>123</volume>:<fpage>705</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1002/lary.23673</pub-id><?supplied-pmid 23070868?><pub-id pub-id-type="pmid">23070868</pub-id></mixed-citation></ref><ref id="B279"><label>279.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mlynarczyk-Bonikowska</surname><given-names>B</given-names></name><name><surname>Majewska</surname><given-names>A</given-names></name><name><surname>Malejczyk</surname><given-names>M</given-names></name><name><surname>Mlynarczyk</surname><given-names>G</given-names></name><name><surname>Majewski</surname><given-names>S</given-names></name></person-group>. <article-title>Antiviral medication in sexually transmitted diseases</article-title>. Part I: HSV, HPV. Mini Rev. Med. <source>Chem</source>. (<year>2013</year>) <volume>13</volume>:<fpage>1837</fpage>&#x02013;<lpage>45</lpage>. <?supplied-pmid 24032509?><pub-id pub-id-type="pmid">24032509</pub-id></mixed-citation></ref><ref id="B280"><label>280.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>J</given-names></name><name><surname>Prager</surname><given-names>JD</given-names></name><name><surname>Sun</surname><given-names>GH</given-names></name><name><surname>Wood</surname><given-names>RE</given-names></name><name><surname>Arjmand</surname><given-names>EM</given-names></name></person-group>. <article-title>Inhaled cidofovir as an adjuvant therapy for recurrent respiratory papillomatosis</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>2011</year>) <volume>144</volume>:<fpage>639</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1177/0194599810395353</pub-id><?supplied-pmid 21493248?><pub-id pub-id-type="pmid">21493248</pub-id></mixed-citation></ref><ref id="B281"><label>281.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amine</surname><given-names>A</given-names></name><name><surname>Rivera</surname><given-names>S</given-names></name><name><surname>Opolon</surname><given-names>P</given-names></name><name><surname>Dekkal</surname><given-names>M</given-names></name><name><surname>Biard</surname><given-names>DS</given-names></name><name><surname>Bouamar</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells</article-title>. <source>PLoS ONE</source> (<year>2009</year>) <volume>4</volume>:<fpage>e5018</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0005018</pub-id><?supplied-pmid 19325708?><pub-id pub-id-type="pmid">19325708</pub-id></mixed-citation></ref><ref id="B282"><label>282.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>GFV</given-names></name><name><surname>Perez</surname><given-names>E</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Suarez</surname><given-names>E</given-names></name></person-group>
<source>A Randomized Double-Blind Placebo-Controlled Trial of AV2-BOBE-1 in the Treatment of Cervical Dysplasia</source>. Internal Confident Report. (<year>2010</year>).</mixed-citation></ref><ref id="B283"><label>283.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>XX</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Hao</surname><given-names>QY</given-names></name></person-group>
<article-title>Xinfuning combined with Baofukang suppository for 53 cases with cervical high risk human papillomavirus infection</article-title>. <source>J Oncol</source>. (<year>2011</year>) <volume>17</volume>:<fpage>825</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="B284"><label>284.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Pu</surname><given-names>YG</given-names></name><name><surname>Zeng</surname><given-names>ZM</given-names></name><name><surname>Yu</surname><given-names>ZJ</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>QW</given-names></name></person-group>. <article-title>Interferon for the treatment of genital warts: a systematic review</article-title>. <source>BMC Infect Dis</source>. (<year>2009</year>) <volume>9</volume>:<fpage>156</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-9-156</pub-id><?supplied-pmid 19772554?><pub-id pub-id-type="pmid">19772554</pub-id></mixed-citation></ref><ref id="B285"><label>285.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foldvari</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name></person-group>. <article-title>Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection</article-title>. <source>Ther Deliv</source>. (<year>2012</year>) <volume>3</volume>:<fpage>1005</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.4155/tde.12.78</pub-id><?supplied-pmid 22946433?><pub-id pub-id-type="pmid">22946433</pub-id></mixed-citation></ref><ref id="B286"><label>286.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Michel</surname><given-names>D</given-names></name><name><surname>Batta</surname><given-names>R</given-names></name><name><surname>Foldvari</surname><given-names>M</given-names></name></person-group>
<article-title>In vivo sustained der-mal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application</article-title>. <source>Eur J Pharm Biopharm</source>. (<year>2013</year>) <volume>84</volume>:<fpage>532</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2013.01.014</pub-id><pub-id pub-id-type="pmid">23500117</pub-id></mixed-citation></ref><ref id="B287"><label>287.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>DiPaola</surname><given-names>RS</given-names></name><name><surname>Cracchiolo</surname><given-names>BM</given-names></name><name><surname>Gibbon</surname><given-names>DG</given-names></name><name><surname>Hellmann</surname><given-names>M</given-names></name><name><surname>Nieves-Neira</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer</article-title>. <source>Int J Gynecol Cancer</source>. (<year>2014</year>) <volume>24</volume>:<fpage>1636</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1097/IGC.0000000000000258</pub-id><pub-id pub-id-type="pmid">25304678</pub-id></mixed-citation></ref><ref id="B288"><label>288.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosa</surname><given-names>C</given-names></name><name><surname>Trizzino</surname><given-names>A</given-names></name><name><surname>Trizzino</surname><given-names>A</given-names></name><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>D'Angelo</surname><given-names>P</given-names></name><name><surname>Farruggia</surname><given-names>P</given-names></name></person-group>
<article-title>Treatment of human papilloma virus infection with interferon alpha and ribavirin in a patient with acquired aplastic anemia</article-title>. <source>Int J Infect Dis</source>. (<year>2014</year>) <volume>23</volume>:<fpage>25</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.11.021</pub-id><pub-id pub-id-type="pmid">24661930</pub-id></mixed-citation></ref><ref id="B289"><label>289.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>NK</given-names></name><name><surname>Hamrock</surname><given-names>DJ</given-names></name></person-group>. <article-title>Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin</article-title>. <source>Clin Infect Dis</source>. (<year>2010</year>) <volume>51</volume>:<fpage>e4</fpage>&#x02013;<lpage>e-6</lpage>. <pub-id pub-id-type="doi">10.1086/653428</pub-id><?supplied-pmid 20504235?><pub-id pub-id-type="pmid">20504235</pub-id></mixed-citation></ref><ref id="B290"><label>290.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo-Qin</surname><given-names>H</given-names></name></person-group>
<article-title>Clinical observation of paiteling on treatment of cervicitis combined with high-risk HPV infection</article-title>. <source>Chin J Woman Child Health Res</source>. (<year>2012</year>) <volume>23</volume>:<fpage>675</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="B291"><label>291.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>CB</given-names></name><name><surname>Thompson</surname><given-names>CD</given-names></name><name><surname>Roberts</surname><given-names>JN</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name></person-group>. <article-title>Carrageenan is a potent inhibitor of papillomavirus infection</article-title>. <source>PLoS Pathog</source>. (<year>2006</year>) <volume>2</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0020069</pub-id><?supplied-pmid 16839203?><pub-id pub-id-type="pmid">16839203</pub-id></mixed-citation></ref><ref id="B292"><label>292.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novetsky</surname><given-names>AP</given-names></name><name><surname>Keller</surname><given-names>MJ</given-names></name><name><surname>Gradissimo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Morgan</surname><given-names>SL</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><etal/></person-group>. <article-title><italic>In vitro</italic> inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel</article-title>. <source>Gynecol Oncol</source>. (<year>2016</year>) <volume>143</volume>:<fpage>313</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2016.09.003</pub-id><?supplied-pmid 27625046?><pub-id pub-id-type="pmid">27625046</pub-id></mixed-citation></ref><ref id="B293"><label>293.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>KZ</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>WN</given-names></name><name><surname>Lai</surname><given-names>SP</given-names></name></person-group>
<article-title>Laboratory study on anti-human papillomavirus activity of <italic>Bupleurum chinese</italic></article-title>. <source>Chin J Dermato Venerol Integ Trad W Med.</source> (<year>2005</year>) <volume>4</volume>:<fpage>171</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="B294"><label>294.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name></person-group>. <article-title>Therapeutic efficacy of Youdujing preparation in treating cervical high-risk papilloma virus infection patients</article-title>. <source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source>. (<year>2012</year>) <volume>32</volume>:<fpage>1212</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 23185761?><pub-id pub-id-type="pmid">23185761</pub-id></mixed-citation></ref><ref id="B295"><label>295.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>XS</given-names></name><name><surname>Guan</surname><given-names>HS</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group>. <article-title>Potential anti-HPV and related cancer agents from marine resources: an overview</article-title>. <source>Mar Drugs</source> (<year>2014</year>) <volume>12</volume>:<fpage>2019</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.3390/md12042019</pub-id><?supplied-pmid 24705500?><pub-id pub-id-type="pmid">24705500</pub-id></mixed-citation></ref><ref id="B296"><label>296.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GL</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Gui</surname><given-names>SQ</given-names></name><name><surname>Xu</surname><given-names>CJ</given-names></name></person-group>
<article-title>Effects of <italic>Pinellia</italic> extract fraction on expressions of HPVE6 and P53 genes in cervical cancer cell lines</article-title>. <source>China J Tradit Chin Med Pharm.</source> (<year>2012</year>) <volume>27</volume>:<fpage>113</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="B297"><label>297.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Traditional Chinese medicine for human papillomavirus (HPV) infections: a systematic review</article-title>. <source>Biosci Trends</source> (<year>2017</year>) <volume>11</volume>:<fpage>267</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2017.01056</pub-id><?supplied-pmid 28484110?><pub-id pub-id-type="pmid">28484110</pub-id></mixed-citation></ref><ref id="B298"><label>298.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>XL</given-names></name><name><surname>Xue</surname><given-names>XO</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name></person-group>
<article-title>Clinical study of Zibai gel on treatment of cervical high-risk human papillomavirus infection</article-title>. <source>Chin J Inform TCM.</source> (<year>2012</year>) <volume>19</volume>:<fpage>9</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="B299"><label>299.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>MJ</given-names></name><name><surname>Fan</surname><given-names>RQ</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xuan</surname><given-names>GW</given-names></name><name><surname>Chi</surname><given-names>FH</given-names></name></person-group>
<article-title>Effect of Chinese medicine Youdujing for human papilloma virus DNA</article-title>. <source>J Guangzhou Univ Tradit Chin Med</source>. (<year>1998</year>) <volume>15</volume>, <fpage>57</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="B300"><label>300.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>YH</given-names></name><name><surname>Xuan</surname><given-names>GW</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>XH</given-names></name><etal/></person-group>
<article-title>Preparation and <italic>in vitro</italic> pharmacodynamics effect of the Youdujing cream</article-title>. <source>Chin Hosp Pharm J</source>. (<year>2004</year>) <volume>24</volume>:<fpage>7</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="B301"><label>301.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Cai</surname><given-names>LE</given-names></name></person-group>
<article-title>Study of Youdujing in treating HR-HPV infected cervical lesions</article-title>. <source>Guangdong Med J</source>. (<year>2011</year>) <volume>32</volume>:<fpage>2036</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="B302"><label>302.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squiquera</surname><given-names>L</given-names></name><name><surname>Taxman</surname><given-names>DJ</given-names></name><name><surname>Brendle</surname><given-names>SA</given-names></name><name><surname>Torres</surname><given-names>R</given-names></name><name><surname>Sulley</surname><given-names>J</given-names></name><name><surname>Hodge</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a phase I study</article-title>. <source>Antivir Ther</source>. (<year>2017</year>) <volume>22</volume>:<fpage>247</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.3851/IMP3133</pub-id><?supplied-pmid 28121292?><pub-id pub-id-type="pmid">28121292</pub-id></mixed-citation></ref><ref id="B303"><label>303.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulley</surname><given-names>J</given-names></name><name><surname>Squiquera</surname><given-names>L</given-names></name></person-group>
<article-title>Topical composition containing ranpirnase</article-title>. WO 2016028634 A1 (<year>2016</year>).</mixed-citation></ref><ref id="B304"><label>304.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>SK</given-names></name><name><surname>Ardelt</surname><given-names>W</given-names></name></person-group>
<article-title>Methods of treating human papillomavirus</article-title>. US 8663964 B2 (<year>2014</year>).</mixed-citation></ref><ref id="B305"><label>305.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putral</surname><given-names>LN</given-names></name><name><surname>Bywater</surname><given-names>MJ</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Saunders</surname><given-names>NA</given-names></name><name><surname>Gabrielli</surname><given-names>BG</given-names></name><name><surname>Leggatt</surname><given-names>GR</given-names></name><etal/></person-group>
<article-title>RNA interference against human papilloma virus oncogenes in cervical cancer cells results in increased sensitivity to cisplastin</article-title>. <source>Mol Pharmacol</source>. (<year>2005</year>) <volume>68</volume>:<fpage>1311</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1124/mol.105.014191</pub-id><pub-id pub-id-type="pmid">16120770</pub-id></mixed-citation></ref><ref id="B306"><label>306.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhania</surname><given-names>R</given-names></name><name><surname>Khairuddin</surname><given-names>N</given-names></name><name><surname>Clarke</surname><given-names>D</given-names></name><name><surname>McMillan</surname><given-names>NA</given-names></name></person-group>. <article-title>RNA interference for the treatment of papillomavirus disease</article-title>. <source>Open Virol J</source>. (<year>2012</year>) <volume>6</volume>:<fpage>204</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.2174/1874357901206010204</pub-id><?supplied-pmid 23341856?><pub-id pub-id-type="pmid">23341856</pub-id></mixed-citation></ref><ref id="B307"><label>307.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sima</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Deng</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53</article-title>. <source>Apoptosis</source> (<year>2008</year>) <volume>13</volume>:<fpage>273</fpage>&#x02013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-007-0163-8</pub-id><?supplied-pmid 18060502?><pub-id pub-id-type="pmid">18060502</pub-id></mixed-citation></ref><ref id="B308"><label>308.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamato</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Kizaki</surname><given-names>M</given-names></name><name><surname>Ui-Tei</surname><given-names>K</given-names></name><name><surname>Natori</surname><given-names>Y</given-names></name><name><surname>Fujino</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer</article-title>. <source>Cancer Gene Ther</source>. (<year>2008</year>) <volume>15</volume>:<fpage>140</fpage>&#x02013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cgt.7701118</pub-id><?supplied-pmid 18157144?><pub-id pub-id-type="pmid">18157144</pub-id></mixed-citation></ref><ref id="B309"><label>309.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Gynecol Oncol</source>. (<year>2012</year>) <volume>124</volume>:<fpage>296</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2011.10.028</pub-id><?supplied-pmid 22056554?><pub-id pub-id-type="pmid">22056554</pub-id></mixed-citation></ref><ref id="B310"><label>310.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Kuo</surname><given-names>TF</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Chiu</surname><given-names>CC</given-names></name><name><surname>Lu</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>HF</given-names></name><etal/></person-group>
<article-title>Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers</article-title>. <source>Cancer Gene Ther</source>. (<year>2010</year>) <volume>17</volume>:<fpage>827</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1038/cgt.2010.38</pub-id><pub-id pub-id-type="pmid">20885450</pub-id></mixed-citation></ref><ref id="B311"><label>311.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairuddin</surname><given-names>N</given-names></name><name><surname>Gantier</surname><given-names>MP</given-names></name><name><surname>Blake</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Behlke</surname><given-names>MA</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors <italic>in vivo</italic></article-title>. <source>Immunol. Cell Biol.</source> (<year>2012</year>) <volume>90</volume>:<fpage>187</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2011.19</pub-id><?supplied-pmid 21423261?><pub-id pub-id-type="pmid">21423261</pub-id></mixed-citation></ref><ref id="B312"><label>312.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>X-Y</given-names></name><name><surname>Peng</surname><given-names>Z-L</given-names></name><name><surname>Duan</surname><given-names>W-Q</given-names></name><name><surname>Wang</surname><given-names>H Wang P</given-names></name></person-group>. <article-title>Inhibition of HPV 16 E6 oncogene expression by RNA interference <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Int J Gynecol. Cancer.</source> (<year>2006</year>) <volume>16</volume>:<fpage>743</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1525-1438.2006.00384.x</pub-id><?supplied-pmid 16681755?><pub-id pub-id-type="pmid">16681755</pub-id></mixed-citation></ref><ref id="B313"><label>313.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Rajasekaran</surname><given-names>N</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name></person-group>. <article-title>Human papillomavirus: current and future RNAi therapeutic strategies for cervical cancer</article-title>. <source>J Clin Med</source>. (<year>2015</year>) <volume>4</volume>:<fpage>1126</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.3390/jcm4051126</pub-id><?supplied-pmid 26239469?><pub-id pub-id-type="pmid">26239469</pub-id></mixed-citation></ref><ref id="B314"><label>314.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>JC</given-names></name><name><surname>Rossi</surname><given-names>JJ</given-names></name></person-group>. <article-title>RNA-based therapeutics: current progress and future prospects</article-title>. <source>Chem Biol</source>. (<year>2012</year>) <volume>19</volume>:<fpage>60</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2011.12.008</pub-id><?supplied-pmid 22284355?><pub-id pub-id-type="pmid">22284355</pub-id></mixed-citation></ref><ref id="B315"><label>315.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>CF</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Allam</surname><given-names>JP</given-names></name></person-group>. <article-title>Toll-like receptor 7 agonists and skin</article-title>. <source>Drug News Perspect</source>. (<year>2008</year>) <volume>21</volume>:<fpage>158</fpage>&#x02013;<lpage>65</lpage>. <?supplied-pmid 18560614?><pub-id pub-id-type="pmid">18560614</pub-id></mixed-citation></ref><ref id="B316"><label>316.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archambault</surname><given-names>J</given-names></name><name><surname>Melendy</surname><given-names>T</given-names></name></person-group>. <article-title>Targeting human papilloma virus genome replication for antiviral drug discovery</article-title>. <source>Antivir Ther</source>. (<year>2013</year>) <volume>18</volume>:<fpage>271</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.3851/IMP2612</pub-id><?supplied-pmid 23615820?><pub-id pub-id-type="pmid">23615820</pub-id></mixed-citation></ref><ref id="B317"><label>317.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terlou</surname><given-names>A</given-names></name><name><surname>van Seters</surname><given-names>M</given-names></name><name><surname>Kleinjan</surname><given-names>A</given-names></name><name><surname>Heijmans-Antonissen</surname><given-names>C</given-names></name><name><surname>Santegoets</surname><given-names>LA</given-names></name><name><surname>Beckmann</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia</article-title>. <source>Int J Cancer</source>. (<year>2010</year>) <volume>127</volume>:<fpage>2831</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25302</pub-id><?supplied-pmid 21351262?><pub-id pub-id-type="pmid">21351262</pub-id></mixed-citation></ref><ref id="B318"><label>318.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoy</surname><given-names>SM</given-names></name></person-group>. <article-title>Polyphenon E 10% ointment: in immunocompetent adults with external genital and perianal warts</article-title>. <source>Am J Clin Dermatol.</source> (<year>2012</year>) <volume>13</volume>:<fpage>275</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.2165/11209370-000000000-00000</pub-id><?supplied-pmid 22667336?><pub-id pub-id-type="pmid">22667336</pub-id></mixed-citation></ref><ref id="B319"><label>319.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Luan</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group>
<article-title>PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer</article-title>. <source>PLoS ONE</source> (<year>2014</year>) 9: e89350. <pub-id pub-id-type="doi">10.1371/journal.pone.0089350</pub-id></mixed-citation></ref><ref id="B320"><label>320.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Neelalpu</surname><given-names>SS</given-names></name></person-group>. <article-title>Versatile CAR T-cells for cancer immunotherapy</article-title>. <source>Contemp Oncol (Pozn)</source> (<year>2018</year>) <volume>22</volume>:<fpage>73</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2018.73892</pub-id><?supplied-pmid 29628798?><pub-id pub-id-type="pmid">29628798</pub-id></mixed-citation></ref><ref id="B321"><label>321.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Avi</surname><given-names>R</given-names></name><name><surname>Farhi</surname><given-names>R</given-names></name><name><surname>Ben-Nun</surname><given-names>A</given-names></name><name><surname>Gorodner</surname><given-names>M</given-names></name><name><surname>Greenberg</surname><given-names>E</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2018</year>) <volume>67</volume>:<fpage>1221</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-018-2174-4</pub-id><?supplied-pmid 29845338?><pub-id pub-id-type="pmid">29845338</pub-id></mixed-citation></ref><ref id="B322"><label>322.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>O</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group>
<article-title>Characterization of two new monoclonal antibodies agaisnst human papillomavirus type 16 L1 protein</article-title>. <source>Diag Pathol.</source> (<year>2014</year>) <volume>1</volume>:<fpage>101</fpage>
<pub-id pub-id-type="doi">10.1186/1746-1596-9-101</pub-id></mixed-citation></ref><ref id="B323"><label>323.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhadauria</surname><given-names>P</given-names></name><name><surname>Hockenberry</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Christensen</surname><given-names>N</given-names></name><name><surname>Dadachova</surname><given-names>E</given-names></name><name><surname>Phaeton</surname><given-names>R</given-names></name></person-group>
<article-title>Serial monoclonal antibody administration demonstrates theraprutic effects via induction of apoptosis in HPV related cervical cancer</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>196</volume>:<fpage>214</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="B324"><label>324.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalogeropoulos</surname><given-names>CD</given-names></name><name><surname>Moschos</surname><given-names>MM</given-names></name></person-group>
<article-title>Advances in diagnosis and treatment of HPV ocular surface infections</article-title>. <source>Med Hypothesis Discov Innov. Opthalmol</source>. (<year>2015</year>) <volume>4</volume>:<fpage>31</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="B325"><label>325.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>RP</given-names></name><name><surname>Wankum</surname><given-names>G</given-names></name><name><surname>Giangiacomo</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>PC</given-names></name></person-group>. <article-title>Dinitrochlorobenzene and debulking therapy of conjunctival papilloma</article-title>. <source>J Pedriatr Ophthalmol Strabismus</source> (<year>1983</year>) <volume>20</volume>:<fpage>221</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 6644483?><pub-id pub-id-type="pmid">6644483</pub-id></mixed-citation></ref><ref id="B326"><label>326.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>CL</given-names></name><name><surname>Shields</surname><given-names>JA</given-names></name></person-group>. <article-title>Tumors of the conjunctiva and cornea</article-title>. <source>Surv. Ophthalmol</source>. (<year>2004</year>) <volume>49</volume>:<fpage>3</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.survophthal.2003.10.008</pub-id><?supplied-pmid 14711437?><pub-id pub-id-type="pmid">14711437</pub-id></mixed-citation></ref><ref id="B327"><label>327.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorzelski</surname><given-names>M</given-names></name><name><surname>Ting</surname><given-names>S</given-names></name><name><surname>Gauler</surname><given-names>TC</given-names></name><name><surname>Breitenbuecher</surname><given-names>F</given-names></name><name><surname>Vossebein</surname><given-names>I</given-names></name><name><surname>Hoffarth</surname><given-names>S</given-names></name></person-group>. <article-title>Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy</article-title>. <source>Cell Death Dis</source>. (<year>2014</year>) <volume>5</volume>:<fpage>e1091</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2014.62</pub-id><?supplied-pmid 24577089?><pub-id pub-id-type="pmid">24577089</pub-id></mixed-citation></ref><ref id="B328"><label>328.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piramal</surname><given-names>SA</given-names></name><name><surname>Padigaru</surname><given-names>M</given-names></name><name><surname>Agarwal</surname><given-names>VR</given-names></name><name><surname>Deshpande</surname><given-names>GA</given-names></name></person-group>
<article-title>Compounds for the treatment of cancers associated with human papillomavirus</article-title>. <source>WO</source> 2012176163 A2 (<year>2012</year>).</mixed-citation></ref><ref id="B329"><label>329.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>SK</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>YBF</given-names></name><name><surname>Eklund</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>JE</given-names></name></person-group>
<article-title>Compounds for the treatment of HPV-induced carcinoma.WO 2016027005 A1</article-title> (<year>2016</year>).</mixed-citation></ref><ref id="B330"><label>330.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>JR</given-names></name><name><surname>Wick</surname><given-names>DA</given-names></name></person-group>
<article-title>Human papillomavirus E7 antigen compositions and uses thereof</article-title>. US 20130209402 A1 (<year>2013</year>).</mixed-citation></ref><ref id="B331"><label>331.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colau</surname><given-names>BDA</given-names></name><name><surname>Giannini</surname><given-names>S</given-names></name><name><surname>Lockman</surname><given-names>L</given-names></name></person-group>
<article-title>Method of vaccination against human papilloma virus</article-title>. WO 2013139744 A1 (<year>2013</year>).</mixed-citation></ref><ref id="B332"><label>332.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preville</surname><given-names>XEE</given-names></name><name><surname>Leclerc</surname><given-names>C</given-names></name><name><surname>Ladant</surname><given-names>D</given-names></name><name><surname>Timmerman</surname><given-names>B</given-names></name></person-group>
<article-title>Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof</article-title>. US 8637039 B2 (<year>2014</year>).</mixed-citation></ref><ref id="B333"><label>333.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neefe</surname><given-names>J</given-names></name><name><surname>Goldstone</surname><given-names>S</given-names></name><name><surname>Winnett</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>M</given-names></name><name><surname>Boux</surname><given-names>L</given-names></name></person-group>
<article-title>Human papilloma virus treatment</article-title>. US 20080063661 A1 (<year>2008</year>).</mixed-citation></ref><ref id="B334"><label>334.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Hung</surname><given-names>CF</given-names></name><name><surname>Roden</surname><given-names>R</given-names></name></person-group>
<article-title>Methods of treatment of hpv related diseases</article-title>. WO 2015021155 A1 (<year>2015</year>).</mixed-citation></ref><ref id="B335"><label>335.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quake</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>
<article-title>Compositions and methods for cell targeted hpv treatment</article-title>. WO 2016196282 A1 (<year>2016</year>).</mixed-citation></ref><ref id="B336"><label>336.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>G</given-names></name></person-group>
<source>Use of New Type of anti-HPVpharmaceutical Preparation</source>. EP 3072512 A1 (<year>2016</year>).</mixed-citation></ref><ref id="B337"><label>337.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>R</given-names></name></person-group>
<article-title>Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection</article-title>. US 20100297144 A1 (<year>2010</year>).</mixed-citation></ref><ref id="B338"><label>338.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lide</surname><given-names>Y</given-names></name><name><surname>Wensi</surname><given-names>Z</given-names></name><name><surname>Qixiong</surname><given-names>X</given-names></name></person-group>
<article-title>Compound podophyllotoxin gel for treating HPV virus and preparation method thereof</article-title>. CN 105287365 A (<year>2016</year>).</mixed-citation></ref><ref id="B339"><label>339.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neto</surname><given-names>MADFL</given-names></name><name><surname>Caetano</surname><given-names>LC</given-names></name><name><surname>Neto</surname><given-names>PADSP</given-names></name><name><surname>Silva</surname><given-names>ZPD</given-names></name></person-group>
<article-title>Pharmaceutical composition using stryphnodendron extracts for treating HPV infections</article-title>. US 9023405 B2 (<year>2015</year>).</mixed-citation></ref><ref id="B340"><label>340.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RCC</given-names></name></person-group>
<article-title>Abd-Elazem IS</article-title>. Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor. US 9005889 B2 (<year>2015</year>).</mixed-citation></ref><ref id="B341"><label>341.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertin</surname><given-names>W</given-names></name><name><surname>Pecora</surname><given-names>T</given-names></name></person-group>
<article-title>Vaginal cream for the treatment of papilloma infection comprising docosanol, turmeric, amla and aloe</article-title>. WO 2013171607 A1 (<year>2013</year>).</mixed-citation></ref><ref id="B342"><label>342.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampson</surname><given-names>I</given-names></name><name><surname>Hampson</surname><given-names>L</given-names></name></person-group>
<article-title>Treatment of cancer and benign proliferative disorders</article-title>. WO 2015059485 A1 (<year>2015</year>).</mixed-citation></ref><ref id="B343"><label>343.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>JG</given-names></name><name><surname>George</surname><given-names>HA</given-names></name><name><surname>Hofman</surname><given-names>KJ</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Neeper</surname><given-names>MP</given-names></name></person-group>
<article-title>Recombinant human papillomavirus type 18 vaccine</article-title>. US 5820870A (<year>1998</year>).</mixed-citation></ref><ref id="B344"><label>344.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessa</surname><given-names>NAA</given-names></name></person-group>
<article-title>Composition for treatment and preventative of the human papilloma virus HPV infection, ulcerations and boils</article-title>. CA 2967506 A1 (<year>2016</year>).</mixed-citation></ref><ref id="B345"><label>345.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clawson</surname><given-names>GA</given-names></name><name><surname>Pa</surname><given-names>WH</given-names></name><name><surname>Thiboutot</surname><given-names>D</given-names></name><name><surname>Christensen</surname><given-names>N</given-names></name></person-group>
<article-title>Methods and materials for treating human papillomavirus infections</article-title>. US 7704965 B2 (<year>2010</year>).</mixed-citation></ref><ref id="B346"><label>346.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buyuktimkin</surname><given-names>S</given-names></name><name><surname>Buyuktimkin</surname><given-names>N</given-names></name><name><surname>Yeager</surname><given-names>J</given-names></name></person-group>
<article-title>Topical treatment and prevention of human papilloma virus (HPV) infection</article-title>. US 20050272700 A1 (<year>2005</year>).</mixed-citation></ref><ref id="B347"><label>347.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Bashkin</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>TG</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>GD</given-names><suffix>Jr</suffix></name><name><surname>Koeller</surname><given-names>KJ</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Guanidinyl-substituted polyamides useful for treating human papilloma virus</article-title>. US 9133228 B2 (<year>2015</year>).</mixed-citation></ref><ref id="B348"><label>348.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Genes encoding major capsid protein L1 of human papilloma virus</article-title>. WO 2009076824 A1 (<year>2009</year>).</mixed-citation></ref><ref id="B349"><label>349.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>DB</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group>
<article-title>Vaccines for human papilloma virus and methods for using the same</article-title>. US 9050287 B2 (<year>2015</year>).</mixed-citation></ref><ref id="B350"><label>350.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Apt</surname><given-names>D</given-names></name><name><surname>Khavari</surname><given-names>P</given-names></name><name><surname>Stemmer</surname><given-names>WPC</given-names></name></person-group>
<source>Human Papilloma Virus Vectors</source>. US 6399383 B1 (<year>2002</year>).</mixed-citation></ref><ref id="B351"><label>351.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>AE</given-names></name><name><surname>Osorio</surname><given-names>PMO</given-names></name><name><surname>Moreno</surname><given-names>VA</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>GLA</given-names></name><name><surname>Melo</surname><given-names>PME</given-names></name><name><surname>Enriquez</surname><given-names>MZI</given-names></name><etal/></person-group>
<article-title>Effectiveness of photodynamic therapy in elimination of HPV-16 and HPV-18 associated with CIN I in Mexican women</article-title>. <source>Photochem Photobiol</source>. (<year>2017</year>) <volume>93</volume>:<fpage>1269</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/php.12769</pub-id><pub-id pub-id-type="pmid">28380684</pub-id></mixed-citation></ref><ref id="B352"><label>352.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Dynamics of HPV viral loads reflect the treatment effect of photodynamic therapy in genital warts</article-title>. <source>Photodiagnosis Photodyn Ther</source>. (<year>2018</year>) <volume>21</volume>:<fpage>86</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.pdpdt.2017.11.005</pub-id><?supplied-pmid 29155073?><pub-id pub-id-type="pmid">29155073</pub-id></mixed-citation></ref><ref id="B353"><label>353.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soergel</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Stepp</surname><given-names>H</given-names></name><name><surname>Hertel</surname><given-names>H</given-names></name><name><surname>Hillemanns</surname><given-names>P</given-names></name></person-group>. <article-title>Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate</article-title>. <source>Lasers Surg Med.</source> (<year>2008</year>) <volume>40</volume>:<fpage>611</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/lsm.20686</pub-id><?supplied-pmid 18951428?><pub-id pub-id-type="pmid">18951428</pub-id></mixed-citation></ref><ref id="B354"><label>354.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chumworathayi</surname><given-names>B</given-names></name><name><surname>Thinkhamrop</surname><given-names>J</given-names></name><name><surname>Blumenthal</surname><given-names>PD</given-names></name><name><surname>Thinkhamrop</surname><given-names>B</given-names></name><name><surname>Pientong</surname><given-names>C</given-names></name><name><surname>Ekalaksananan</surname><given-names>T</given-names></name></person-group>. <article-title>Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions</article-title>. <source>Int J Gynaecol Obstet</source>. (<year>2010</year>) <volume>108</volume>:<fpage>119</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijgo.2009.09.012</pub-id><?supplied-pmid 19892345?><pub-id pub-id-type="pmid">19892345</pub-id></mixed-citation></ref><ref id="B355"><label>355.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vuyst</surname><given-names>H</given-names></name><name><surname>Mugo</surname><given-names>NR</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>McKenzie</surname><given-names>K</given-names></name><name><surname>Tenet</surname><given-names>V</given-names></name><name><surname>Njoroge</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya</article-title>. <source>PLoS ONE</source> (<year>2014</year>) <volume>9</volume>:<fpage>e111037</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0111037</pub-id><?supplied-pmid 25343563?><pub-id pub-id-type="pmid">25343563</pub-id></mixed-citation></ref><ref id="B356"><label>356.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhat</surname><given-names>AS</given-names></name><name><surname>Mashayekhi</surname><given-names>V</given-names></name><name><surname>Mahdavi</surname><given-names>R</given-names></name><name><surname>Daghighi</surname><given-names>N</given-names></name></person-group>
<article-title>Treatment of a giant genital wart in an infant via cryotherapy: report of case</article-title>. <source>Iranian J Neonatol</source>. (<year>2011</year>) <volume>2</volume>:<fpage>46</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.22038/IJN.2011.5155</pub-id></mixed-citation></ref><ref id="B357"><label>357.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>PE</given-names></name><name><surname>Kreimer</surname><given-names>AR</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Koutsky</surname><given-names>LA</given-names></name><name><surname>Rydzak</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections</article-title>. <source>J Infect Dis</source>. (<year>2009</year>) <volume>199</volume>:<fpage>1612</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1086/598981</pub-id><?supplied-pmid 19405865?><pub-id pub-id-type="pmid">19405865</pub-id></mixed-citation></ref><ref id="B358"><label>358.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kwon</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>NR</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy of loop electrosurgical excision procedure with cold coagulation for treating cervical intraepithelial neoplasia: a two center cohort study</article-title>. <source>Obstet Gynecol Sci</source>. (<year>2017</year>) <volume>60</volume>:<fpage>200</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5468/ogs.2017.60.2.200</pub-id><?supplied-pmid 28344962?><pub-id pub-id-type="pmid">28344962</pub-id></mixed-citation></ref><ref id="B359"><label>359.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>IU</given-names></name><name><surname>Introcaso</surname><given-names>C</given-names></name><name><surname>Dunne</surname><given-names>EF</given-names></name></person-group>. <article-title>Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines</article-title>. <source>Clin Infect Dis</source>. (<year>2015</year>) <volume>61</volume>:<fpage>S849</fpage>&#x02013;<lpage>S55</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ813</pub-id><?supplied-pmid 26602622?><pub-id pub-id-type="pmid">26602622</pub-id></mixed-citation></ref><ref id="B360"><label>360.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davila</surname><given-names>GW</given-names></name><name><surname>Shroyer</surname><given-names>KR</given-names></name></person-group>. <article-title>Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection</article-title>. <source>Gynecol Obstet Invest</source>. (<year>1996</year>) <volume>41</volume>:<fpage>275</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1159/000292283</pub-id><?supplied-pmid 8793499?><pub-id pub-id-type="pmid">8793499</pub-id></mixed-citation></ref><ref id="B361"><label>361.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>K</given-names></name><name><surname>Tagami</surname><given-names>K</given-names></name><name><surname>Lian</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Tamaya</surname><given-names>T</given-names></name></person-group>. <article-title>Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions</article-title>. <source>Oncol Rep</source>. (<year>2003</year>) <volume>10</volume>:<fpage>1437</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.3892/or.10.5.1437</pub-id><?supplied-pmid 12883720?><pub-id pub-id-type="pmid">12883720</pub-id></mixed-citation></ref><ref id="B362"><label>362.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahangdale</surname><given-names>L</given-names></name><name><surname>Lippmann</surname><given-names>QK</given-names></name><name><surname>Garcia</surname><given-names>K</given-names></name><name><surname>Budwit</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>JS</given-names></name><name><surname>van Le</surname><given-names>L</given-names></name></person-group>. <article-title>Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial</article-title>. <source>Am J Obstet Gynecol</source>. (<year>2014</year>) <volume>210</volume>:<fpage>314.e1</fpage>&#x02013;<lpage>e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2013.12.042</pub-id><?supplied-pmid 24384495?><pub-id pub-id-type="pmid">24384495</pub-id></mixed-citation></ref><ref id="B363"><label>363.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>SX</given-names></name><name><surname>Ghali</surname><given-names>L</given-names></name><name><surname>Bell</surname><given-names>C</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name></person-group>. <article-title>Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study</article-title>. <source>Int J Mol Sci</source>. (<year>2018</year>) <volume>19</volume>:<fpage>E1081</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19041081</pub-id><?supplied-pmid 29617346?><pub-id pub-id-type="pmid">29617346</pub-id></mixed-citation></ref><ref id="B364"><label>364.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Ghali</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Munoz</surname><given-names>LP</given-names></name><name><surname>Garelick</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal Nanotechnology</article-title>. <source>Nanoscale Res Lett</source>. (<year>2016</year>) <volume>11</volume>:<fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/s11671-016-1307-y</pub-id><?supplied-pmid 26887578?><pub-id pub-id-type="pmid">26887578</pub-id></mixed-citation></ref><ref id="B365"><label>365.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koivusalo</surname><given-names>R</given-names></name><name><surname>Krausz</surname><given-names>E</given-names></name><name><surname>Ruotsalainen</surname><given-names>P</given-names></name><name><surname>Helenius</surname><given-names>H</given-names></name><name><surname>Hietanen</surname><given-names>S</given-names></name></person-group>. <article-title>Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand</article-title>. <source>Cancer Res</source>. (<year>2002</year>) <volume>62</volume>:<fpage>7364</fpage>&#x02013;<lpage>71</lpage>. <?supplied-pmid 12499281?><pub-id pub-id-type="pmid">12499281</pub-id></mixed-citation></ref><ref id="B366"><label>366.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CT</given-names></name><name><surname>Qiu</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Chang</surname><given-names>SD</given-names></name><name><surname>Tang</surname><given-names>YH</given-names></name><name><surname>Wu</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia</article-title>. <source>Taiwan J Obstet Gynecol</source>. (<year>2012</year>) <volume>51</volume>:<fpage>533</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tjog.2012.09.006</pub-id><?supplied-pmid 23276555?><pub-id pub-id-type="pmid">23276555</pub-id></mixed-citation></ref><ref id="B367"><label>367.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snoeck</surname><given-names>R</given-names></name><name><surname>Andrei</surname><given-names>G</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group>. <article-title>Cidofovir in the treatment of HPV-associated lesions</article-title>. <source>Verh K Acad Geneeskd Belg</source>. (<year>2001</year>) <volume>63</volume>:<fpage>93</fpage>&#x02013;<lpage>120</lpage>. <?supplied-pmid 11436421?><pub-id pub-id-type="pmid">11436421</pub-id></mixed-citation></ref><ref id="B368"><label>368.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>B</given-names></name><name><surname>Nogueira</surname><given-names>T</given-names></name><name><surname>Stranska</surname><given-names>R</given-names></name><name><surname>Naesens</surname><given-names>L</given-names></name><name><surname>Andrei</surname><given-names>G</given-names></name><name><surname>Snoeck</surname><given-names>R</given-names></name></person-group>. <article-title>Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>:<fpage>47302</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.10100</pub-id><?supplied-pmid 27331622?><pub-id pub-id-type="pmid">27331622</pub-id></mixed-citation></ref><ref id="B369"><label>369.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>M</given-names></name><name><surname>Remacle</surname><given-names>M</given-names></name><name><surname>Bachy</surname><given-names>V</given-names></name><name><surname>Van Der Vorst</surname><given-names>S</given-names></name><name><surname>Lawson</surname><given-names>G</given-names></name></person-group>. <article-title>Use of cidofovir in HPV patients with recurrent respiratory papillomatosis</article-title>. <source>Eur Arch Otorhinolaryngol</source>. (<year>2014</year>) <volume>271</volume>:<fpage>2983</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s00405-014-3055-x</pub-id><?supplied-pmid 24756616?><pub-id pub-id-type="pmid">24756616</pub-id></mixed-citation></ref><ref id="B370"><label>370.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavan</surname><given-names>MH</given-names></name><name><surname>Velho</surname><given-names>PE</given-names></name><name><surname>Vigani</surname><given-names>AG</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>FLJr</given-names></name><name><surname>Aoki</surname><given-names>FH</given-names></name></person-group>. <article-title>Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin</article-title>. <source>Braz J Infect Dis</source>. (<year>2007</year>) <volume>11</volume>:<fpage>383</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1590/S1413-86702007000300017</pub-id><?supplied-pmid 17684645?><pub-id pub-id-type="pmid">17684645</pub-id></mixed-citation></ref><ref id="B371"><label>371.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Elmi</surname><given-names>R</given-names></name></person-group>. <article-title>Herpes simplex virus and human papillomavirus coinfections in hyperimmunoglobulin E syndrome presenting as a conjunctival mass lesion</article-title>. <source>Case Rep Med</source>. (<year>2017</year>) 1650841. <pub-id pub-id-type="doi">10.1155/2017/1650841</pub-id><?supplied-pmid 29158737?><pub-id pub-id-type="pmid">29158737</pub-id></mixed-citation></ref><ref id="B372"><label>372.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>N</given-names></name><name><surname>Palefsky</surname><given-names>J</given-names></name></person-group> (<year>2003</year>). Treatment of human papillomavirus (HPV) type 16-infected cells using herpes simplex virus type 1 thymidine kinase-mediated gene therapy transcriptionally regulated by the HPV E2 protein. <source>Hum Gene Ther</source>. <volume>14</volume>, <fpage>45</fpage>&#x02013;<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1089/10430340360464705</pub-id><pub-id pub-id-type="pmid">12573058</pub-id></mixed-citation></ref><ref id="B373"><label>373.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doudi</surname><given-names>M</given-names></name><name><surname>Setorki</surname><given-names>M</given-names></name></person-group>
<article-title>Miraculous effect of smoke of pine tree fruit on human wart treatment: a case series</article-title>. <source>J Biol Sci</source>. (<year>2014</year>) <volume>14</volume>:<fpage>381</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3923/jbs.2014.381.386</pub-id></mixed-citation></ref><ref id="B374"><label>374.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Shou</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Effect of paiteling on human papillomavirus infection of the cervix</article-title>. <source>Mol Clin Oncol</source>. (<year>2017</year>) <volume>7</volume>:<fpage>957</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.3892/mco.2017.1454</pub-id><?supplied-pmid 29285356?><pub-id pub-id-type="pmid">29285356</pub-id></mixed-citation></ref><ref id="B375"><label>375.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnan</surname><given-names>S</given-names></name><name><surname>Tota</surname><given-names>JE</given-names></name><name><surname>El-Zein</surname><given-names>M</given-names></name><name><surname>Burchell</surname><given-names>AN</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Ferenczy</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Study Group</article-title>. Efficacy of a carrageenan gel against transmission of cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. <source>Clin Microbiol Infect</source>. (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.cmi.2018.04.012</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B376"><label>376.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellberg</surname><given-names>D</given-names></name><name><surname>Svarrer</surname><given-names>T</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Valentin</surname><given-names>J</given-names></name></person-group>. <article-title>Self-treatment of female external genital warts with 0</article-title>.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. <source>Int J STD AIDS</source> (<year>1995</year>) <volume>6</volume>:<fpage>257</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1177/095646249500600407</pub-id><?supplied-pmid 7548288?><pub-id pub-id-type="pmid">7548288</pub-id></mixed-citation></ref><ref id="B377"><label>377.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Synergistic cytotoxic effects of a combined treatment of a <italic>Pinellia pedatisecta</italic> lipid-soluble extract and cisplatin on human cervical carcinoma <italic>in vivo</italic></article-title>. <source>Oncol Lett</source>. (<year>2017</year>) <volume>13</volume>:<fpage>4748</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2017.6091</pub-id><?supplied-pmid 28588727?><pub-id pub-id-type="pmid">28588727</pub-id></mixed-citation></ref><ref id="B378"><label>378.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lea</surname><given-names>JS</given-names></name><name><surname>Sunaga</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Kalahasti</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells</article-title>. <source>Reprod Sci</source>. (<year>2007</year>) <volume>14</volume>:<fpage>20</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1933719106298189</pub-id><?supplied-pmid 17636212?><pub-id pub-id-type="pmid">17636212</pub-id></mixed-citation></ref><ref id="B379"><label>379.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name></person-group>. <article-title>Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells</article-title>. <source>Mol Med Rep</source>. (<year>2013</year>) <volume>7</volume>:<fpage>998</fpage>&#x02013;<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2012.1246</pub-id><?supplied-pmid 23258711?><pub-id pub-id-type="pmid">23258711</pub-id></mixed-citation></ref><ref id="B380"><label>380.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>I</given-names></name></person-group>. <article-title>Oral cimetidine for the management of genital and perigenital warts in children</article-title>. <source>J Urol</source>. (<year>2000</year>) <volume>164</volume>:<fpage>1074</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5347(05)67254-0</pub-id><?supplied-pmid 10958744?><pub-id pub-id-type="pmid">10958744</pub-id></mixed-citation></ref><ref id="B381"><label>381.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amer</surname><given-names>M</given-names></name><name><surname>Tosson</surname><given-names>Z</given-names></name><name><surname>Soliman</surname><given-names>A</given-names></name><name><surname>Selim</surname><given-names>AG</given-names></name><name><surname>Salem</surname><given-names>A</given-names></name><name><surname>al-Gendy</surname><given-names>AA</given-names></name></person-group>. <article-title>Verrucae treated by levamisole</article-title>. <source>Int J Dermatol</source>. (<year>1991</year>) <volume>30</volume>, <fpage>738</fpage>&#x02013;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-4362.1991.tb02624.x</pub-id><?supplied-pmid 1955232?><pub-id pub-id-type="pmid">1955232</pub-id></mixed-citation></ref><ref id="B382"><label>382.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasser</surname><given-names>N</given-names></name></person-group>. <article-title>Treatment of common warts with the immune stimulant Propionium bacterium parvum</article-title>. <source>An Bras Dermatol</source>. (<year>2012</year>) <volume>87</volume>:<fpage>585</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1590/S0365-05962012000400011</pub-id><?supplied-pmid 22892773?><pub-id pub-id-type="pmid">22892773</pub-id></mixed-citation></ref><ref id="B383"><label>383.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadighha</surname><given-names>A</given-names></name></person-group>. <article-title>Oral zinc sulphate in recalcitrant multiple viral warts: a pilot study</article-title>. <source>J Eur Acad Dermatol Venereol.</source> (<year>2009</year>) <volume>23</volume>:<fpage>715</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-3083.2009.03169.x</pub-id><?supplied-pmid 19298490?><pub-id pub-id-type="pmid">19298490</pub-id></mixed-citation></ref><ref id="B384"><label>384.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metawea</surname><given-names>B</given-names></name><name><surname>El-Nashar</surname><given-names>AR</given-names></name><name><surname>Kamel</surname><given-names>I</given-names></name><name><surname>Kassem</surname><given-names>W</given-names></name><name><surname>Shamloul</surname><given-names>R</given-names></name></person-group>. <article-title>Application of viable bacille Calmette-Gu&#x000e9;rin topically as a potential therapeutic modality in Condylomata acuminata: a placebo-controlled study</article-title>. <source>Urology</source> (<year>2005</year>) <volume>65</volume>:<fpage>247</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.urology.2004.09.025</pub-id><?supplied-pmid 15708031?><pub-id pub-id-type="pmid">15708031</pub-id></mixed-citation></ref><ref id="B385"><label>385.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recanati</surname><given-names>MA</given-names></name><name><surname>Kramer</surname><given-names>KJ</given-names></name><name><surname>Maggio</surname><given-names>JJ</given-names></name><name><surname>Chao</surname><given-names>CR</given-names></name></person-group>. <article-title>Cantharidin is superior to trichloroacetic acid for the treatment of non-mucosal genital warts: a pilot randomized controlled trial</article-title>. <source>Clin Exp Obstet Gynecol</source>. (<year>2018</year>) <volume>45</volume>:<fpage>383</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.12891/ceog4112.2018</pub-id><?supplied-pmid 30078935?><pub-id pub-id-type="pmid">30078935</pub-id></mixed-citation></ref><ref id="B386"><label>386.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>RM</given-names></name><name><surname>Vidya</surname><given-names>K</given-names></name><name><surname>Kamath</surname><given-names>G</given-names></name></person-group>. <article-title>Topical formic acid puncture technique for the treatment of common warts</article-title>. <source>Int J Dermatol</source> (<year>2001</year>) <volume>40</volume>:<fpage>415</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-4362.2001.01242.x</pub-id><?supplied-pmid 11589750?><pub-id pub-id-type="pmid">11589750</pub-id></mixed-citation></ref><ref id="B387"><label>387.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shumer</surname><given-names>SM</given-names></name><name><surname>O'Keefe</surname><given-names>EJ</given-names></name></person-group>. <article-title>Bleomycin in the treatment of recalcitrant warts</article-title>. <source>J Am Acad Dermatol</source>. (<year>1983</year>) <volume>9</volume>:<fpage>91</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0190-9622(83)70112-X</pub-id><?supplied-pmid 6193152?><pub-id pub-id-type="pmid">6193152</pub-id></mixed-citation></ref><ref id="B388"><label>388.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>SR</given-names></name><name><surname>McNeil</surname><given-names>S</given-names></name><name><surname>Dionne</surname><given-names>M</given-names></name><name><surname>Dawar</surname><given-names>M</given-names></name><name><surname>Ogilvie</surname><given-names>G</given-names></name><name><surname>Krajden</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial</article-title>. <source>JAMA</source> (<year>2013</year>) <volume>309</volume>, <fpage>1793</fpage>&#x02013;<lpage>1802</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.1625</pub-id><?supplied-pmid 23632723?><pub-id pub-id-type="pmid">23632723</pub-id></mixed-citation></ref><ref id="B389"><label>389.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassett</surname><given-names>KJ</given-names></name><name><surname>Meinerz</surname><given-names>NM</given-names></name><name><surname>Semmelmann</surname><given-names>F</given-names></name><name><surname>Cousins</surname><given-names>MC</given-names></name><name><surname>Garcea</surname><given-names>RL</given-names></name><name><surname>Randolph</surname><given-names>TW</given-names></name></person-group>. <article-title>Development of a highly thermostable, adjuvanted human papillomavirus vaccine</article-title>. <source>Eur J Pharm Biopharm</source>. (<year>2015</year>) <volume>94</volume>:<fpage>220</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2015.05.009</pub-id><?supplied-pmid 25998700?><pub-id pub-id-type="pmid">25998700</pub-id></mixed-citation></ref></ref-list></back></article>